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ABSTRACT 
 
Angiogenesis is the formation of new blood vessels from pre-existing ones, and is 
an essential process during tissue regeneration, growth, reproduction and 
development. It is a highly regulated event that involves the interplay of multiple 
different signalling networks, and if dysregulated, can contribute to several different 
pathological conditions, including arthritis, diabetic retinopathy, heart disease and 
cancer. The signalling networks that mediate angiogenesis consist of a complex 
balance between many stimulatory or inhibitory factors. Those same key factors 
can regulate the proliferation, migration and remodelling of endothelial cells that 
form the basis of an organised vasculature. Thus, the regulation of angiogenesis 
is a common thread between seemingly unrelated diseases, like heart disease and 
cancer. My PhD acts as a bridge between the molecular regulation of cardiac and 
cancer blood vessels – learning from the latter to apply to cardiac disease. Herein 
we have investigated two questions: (1) The utility of low dose Cilengitide in the 
treatment of heart failure. (2) The role of endothelial cell focal adhesion kinase and 
angiocrine signalling in cancer. 
We demonstrate that treatment with low dose Cilengitide reduces or even reverses 
the pathogenesis of heart failure within a murine model of pressure-overload 
induced heart failure. We go on to show that low dose Cilengitide enhances 
myocardial angiogenesis and may also beneficially target the cardiomyocyte itself 
directly. Furthermore, we show that targeting the kinase domain of focal adhesion 
kinase within the endothelium is crucial for tumour cell sensitisation to the DNA-
damaging therapy, doxorubicin.   
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CHAPTER 1.0: GENERAL INTRODUCTION 
 
Endothelial cells are a pivotal feature of the vasculature and play a variety of 
critical roles in the control of its function [1]. As such, as our understanding of 
endothelial cells have grown, so has their list of functions. Indeed, endothelial 
cells have gone from being passive conduits for delivering blood, to 
multifunctional cells that can establish tissue-specific vascular niches which 
deploy specific sets of growth factors, known as angiocrine factors [2]. 
Central to their new-found responsibility, is the fact that endothelial cells form 
the interface between blood and the surrounding tissue. In this fashion, the 
endothelium connects circulating cells within the vessel lumen itself to those 
cells present in the vascular wall.  It is this feature that allows them to respond 
to changes in blood composition and blood flow and effect physiological 
changes in the surrounding tissue to achieve vascular homeostasis {Rubanyi, 
1993 #532}. As such, dysfunction of the endothelium can result in the 
development of a multitude of vascular disorders; chief amongst these, 
angiogenic disorders.  
Herein we examine the endothelium as both a tissue-specific angiocrine 
secretion factory, and also as a pivotal element of myocardial angiogenesis. 
we aim to uncover chief mechanisms that will govern these functions in order 
to achieve functional improvement in either cancer or heart failure, 
respectively.  
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2.1 Animal care and procedures 
This project has been approved by the UK Home Office and all procedures were 
carried out according to the ARRIVE guidelines (Animal Research: Reporting of In 
Vivo Experiments).  
 
Note: All surgical procedures were conducted under 2% isoflurane anaesthesia. 
Confirmation of anaesthesia was assessed using the pedal reflex. 
2.1.1 Abdominal transverse aortic constriction (TAC)  
Abdominal TAC is a common experimental procedure used to elicit pressure 
overload-induced heart failure (HF) in murine models. TAC provides a time-
dependent, reproducible model of HF characterized by a significant rise in left 
ventricular weight, deleterious myocardial dilation, and a reduction in cardiac 
inotropy, and rise in myocardial fibrosis. Physiologically this mimics many of the 
clinical features of human aortic stenosis.  
Male C57BL6 mice (Charles River) underwent TAC surgery at 4-5 weeks of age 
(body weight between 20 and 22g). Mice were anaesthetised with isoflurane 
anaesthesia, placed in a supine position on the procedure table, and an incision 
made along the ventral underbelly using scissors, extending from the xiphoid 
process of the sternum, down to the groin to reveal the abdominal muscle. The 
abdominal muscle was then cut the same distance along the linea alba to allow 
CHAPTER 2.0: MATERIALS AND METHODS 
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easy reattachment of the two halves. The two sides of the abdominal muscles were 
clipped back to reveal the abdominal gastrointestinal organs, and these were 
carefully moved to expose the underlying abdominal aorta. The aorta was cleaned 
of visceral fat using blunt dissection, and carefully separated from parallel 
vasculature, whilst avoiding any spinal nerves. The abdominal aorta was then 
constricted using a 6-0 silk suture tied to the width of a 27-gauge needle at a 
position rostral to the renal artery bifurcation. Great care was taken to ensure the 
knot remained taut after tying. This was to ensure minimal variability amongst 
aortic lumen occlusion between animals, and therefore minimize differences in the 
degree of aortic stenosis. The skin and abdominal muscles were closed with a 6-
0 silk suture thread. SHAM operated mice underwent the same operation with the 
exception of aortic constriction. In an effort to ensure reproducibility amongst TAC 
surgeries only male mice weighing between 20 and 22g (correlating to 4 – 5 weeks 
of age) were used, although it may be more pertinent to in future classify mice 
according to abdominal aortic size, rather than body weight.  Echocardiography 
was performed up to 3 days prior to surgery, 3 weeks following surgery, and then 
at 6 (and/or 12 weeks) following surgery. At the experimental end-point, mice were 
sacrificed and their lungs, kidneys and hearts excised. Hearts were halved 
longitudinally (at roughly the atrioventricular valves) and either snap frozen in liquid 
nitrogen (for immunohistochemistry) or stored in an RNAlater stabilization solution 
(for RT-qPCR).   
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2.1.2 Isoprenaline-induced heart failure 
Isoprenaline (ISO) is a synthetic catecholamine that stimulates beta-
adrenoreceptors in the heart resulting in a marked elevation of heart rate and 
cardiac contractility. Chronic administration of ISO in experimental modes causes 
cardiac hypertrophy, ECG abnormalities, myocardial apoptosis and changes to 
cardiac inotropy [3]. Chronically, this can lead to HF. These effects are both time 
and concentration dependent. Thus, isoprenaline-infusion is an excellent model of 
heart failure associated with pathological hypertrophy and contractile failure. 
 
Mini-pumps were filled with an ISO solution of 100μl in a vehicle containing saline 
and 0.05% ascorbic acid, and then left in a sterile incubator at 37°C for ~24 hours 
prior to implantation. Surgery was completed under sterile conditions and 
subcutaneous implant was made at the dorsal aspect of the scruff of the neck. 
Male C57BL6 mice (Charles River) underwent mini-pump implantation neck at 4-
5 weeks of age. All mice were infused subcutaneously with ISO at a rate of 
20mg/kg/day for 2 weeks via an Alzet osmotic minipump (model 1002, Alzet 
osmotic minipumps, Cupertino, CA, USA). Echocardiography was performed up to 
3 days prior to surgery, 7 days following surgery and then at 14 days following 
surgery. At the experimental end-point, mice were sacrificed, and their lungs, 
kidneys, hearts, and aorta excised.  
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2.1.3 Cilengitide   
Cilengitide (Bachem) was stored as a 2M solution in saline at -20°C prior to use, 
before thawing and serial diluting to an appropriate concentration with sterile saline 
for use.  
Cilengitide treatment began in mice in tandem to TAC surgery, or after heart failure 
had already been established (at 3-4 weeks post-TAC). Injections were 
administered 3 times per week at doses of 50ug/kg and 500ug/kg via the 
peritoneum (IP). The doses of Cilengitide used here were obtained from previous 
publications by the Hodivala-Dilke lab [4] [5]. Low dose Cilengitide (LDCIL) is 
classified as 50ug/kg according to these same papers. 
2.1.4 Echocardiography  
Cardiac function was assessed by transthoracic echocardiography using a 
VisualSonics Vevo 770 30-MHz transduction probe. Mice were anaesthetised with 
isoflurane anaesthesia (1.5% in O2), hair removed from their chest with hair 
removal cream, and then were placed in a supine position onto a warmed pad 
(46°C). The chest was covered in ultrasound gel, and the transduction probe was 
positioned adjacent to the mitral valve, at the tips of the papillary muscles, and 
images were taken just below this to ensure positional reproducibility. Left 
ventricular internal diameter (LVID) and LV posterior wall thicknesses at diastole 
(d) and systole (s) were measured from short-axis M-mode images. LV ejection 
fraction (EF%) was calculated as follows: LVEF% = [(LVIDd)3 − 
(LVIDs)3]/(LVIDd)3 × 100; LV fractional shortening (FS%) was calculated as 
follows: LVFS% = (LVIDd − LVIDs)/LVIDd × 100. Values were averaged between 
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3 distinct images, meaning a single mouse underwent 3 echocardiograms per 
assessment to improve reproducibility and accuracy.  
Echocardiography was completed at 0 (i.e. 1-3 days prior to surgery), 3 and 6 
(and/or 12) weeks post-TAC surgery in the majority of cases.  
All efforts were made to ensure consistency between mouse echocardiographs, 
including: pad temperature to be maintained at 46°C, isoflurane anaesthesia at 
1.5%, oxygen flow at 1.5L/M, and cardiac function to be measured in the same 
anatomical location throughout.  
2.1.5 Mean arterial blood pressure (MABP)  
Blood pressure was recorded in anaesthetised mice via intra-arterial cannulation 
of a carotid artery 6 weeks post-TAC surgery, using a Microtip pressure catheter 
(Millar instruments). Mice were placed in a supine position on a pre-warmed 
heating mat (46°C), and a midline incision made extending the length of the neck 
with surgical scissors. The large salivary glands were gently moved laterally, and 
a single carotid artery was located for cannulation. The carotid artery was blunt 
dissected to remove visceral fats, and then ligated with surgical suture at its most 
rostral and caudal ends, leaving a space of roughly 2mm in between (figure 2). A 
small incision was made between the two ties using fine dissection spring-tip 
scissors, and a microtip pressure catheter was inserted into the artery (figure 2). 
The region of the artery housing the catheter was tied in place, and the caudal tie 
loosened to allow blood flow into the pressure catheter. Mice were allowed to 
recover for 5 minutes, or until the blood pressure trace steadied. MABP was then 
averaged across a 30 second period using MATLAB analysis. All efforts were 
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made to ensure mouse body temperature, and levels of anaesthesia in particular, 
remained constant between animals.   
 
 
Figure 1: Isolation of carotid artery followed by intra-carotid cannulation to measure MABP.  
 
2.1.6 Subcutaneous tumour growth models 
B16F0 cells (derived from a C57BL6 melanoma cell line) were used to perform 
subcutaneous tumour growth experiments. Pdgfb-iCreER;R26FAKKD/KD;FAKfl/fl 
mice were anaesthetised, and 1x106 cells (B16F0) resuspended in 100l of PBS 
were injected subcutaneously into the flank. Tumours were allowed to grow for 10 
days, or until tumours reached a volume of 100mm3 (as assessed by digital 
callipers), before mice being IP injected with 100l tamoxifen (50mg/ml) for 3 
consecutive days to induce cre-recombination. After the third tamoxifen injection, 
mice were solely fed a diet consisting of tamoxifen pellets or tamoxifen mash to 
sustain cre-mediated genetic alterations. In tandem to the final tamoxifen injection, 
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mice were injected with Doxorubicin (6mgkg-1) for 3 days, or with PBS, via IP. 
Tumour volume was measured using digital callipers at pre-determined days 
throughout, and animals were culled and tumours excised 18-20 days post-
injection, or before tumours reached a volume of 1500mm3. Tumours were 
weighed, and longitudinally halved, before either being fixed in 4% formaldehyde 
or snap-frozen in liquid nitrogen in chilled isopentane.  
2.1.7 Tumour progression assessment 
Tumours were measured at defined time points using callipers. The end tumour 
volume was calculated as LxW2x0.52, where L is length and W is width.  
 
2.2 Cell culture 
 
All procedures were carried out under sterile conditions in a tissue culture hood.  
2.2.1 Cell culture media and other cell culture reagents 
2.2.1a Cardiomyocyte cell growth media 
Primary mouse cardiomyocytes (derived from C57/BL6) were grown in primary D-
MEM (Dullbeco’s Modified Eagle’s Medium) (Sigma), supplemented with 10% FBS 
(Fetal Bovine Serum) (Sigma), 1% Penicillin Streptomycin (Sigma) and 1:1000 
cardiomyocyte growth isolate (Pierce cardiomyocyte isolation kit, Thermo 
scientific). Media was stored at 4°C. Cells were incubated at 37°C and 5% CO2. 
2ml media was used per well. 
 
2.2.1b Endothelial cell growth media (MLEC – mouse lung endothelium cell 
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culture) 
Primary mouse endothelial cells (derived from C57/BL6) were cultured in low-
glucose D-MEM (Sigma) and Ham’s F12 (Gibco) medium supplemented with 
0.1mg/ml Heparin (sigma), 100μg/ml Penicillin Streptomycin, 6mM l-glutamine 
(Sigma), 20% FBS and 50μg/ml endothelial mitogen (BioRad). Media was sterile 
filtered before use and kept at 4°C. Cells were incubated at 37°C and 5% CO2. 
10ml media was used per T75 flask, and 5ml per T25 flask.  
 
2.2.1c B16F0 cell growth media 
B16F0 mouse melanoma cells (derived from C57/BL6) were cultured in high-
glucose DMEM (Sigma), supplemented with 10% FBS. Media was stored at 4°C. 
Cells were incubated at 37°C and 5% CO2. 15ml media was used per T175 flask. 
Media was changed every other day.  
2.2.1d Collagenase solution 
0.1% (w/v) collagenase solution was prepared by dissolving 0.05g type I 
collagenase (Gibco) in 25ml of PBS (plus calcium and magnesium) at 37°C for 1 
hour. A further 25ml PBS (plus calcium and magnesium) was then added, and the 
solution was sterile filtered using a 0.2mm filter (BD Falcon). Collagenase solution 
was always prepared fresh prior to use.  
 
2.2.1e Flask coating solution 
For mouse primary cardiomyocyte cell culture, a 6-well plate was pre-coated with 
0.1% gelatin (Porcine skin type A – Sigma) at 37°C for 1 hour. For primary mouse 
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endothelial cell culture, a T25 plate was pre-coated with 0.1% gelatin (Porcine skin 
type A – Sigma), 30μg/ml bovine collagen (Nutacon), and 1μg/ml fibronectin 
(Millipore) at 37°C for 1 hour. B16F0 mouse melanoma cells were cultured in 
uncoated T175 flasks. Gelatin, collagen and fibronectin were stored at 4°C.  
  
2.2.1f Antibody and magnetic bead solution for cell sorting 
For magnetic bead mediated endothelial cell sorting, 50μl bead solution 
(Invitrogen) was washed 3 – 4 times in rounds of 1ml DPBS, before overnight 
incubation with 10μl anti-CD31 (BD BioScience) at 4°C.  
2.2.2 Endothelial cell isolation (from hearts) 
Primary mouse endothelial cells were isolated from the whole hearts of C57BL6 3-
7-day old mice. Hearts were removed, mechanically minced with scissors, and 
digested in pre-heated (37°C) 10ml 0.1% collagenase type I solution (Gibco 
Invitrogen) for 1 hour. Usually 3 hearts were minced together for a single prep. The 
collagenase reaction was stopped by adding equal parts MLEC media to solution, 
and the digested tissue was homogenized in a dish by syringing up to 30 times 
with a 19 and 21-gauge needle, and then passed through a 70um pore-size cell 
strainer.  Cells were centrifuged at 1500rpm for 3 minutes, and the resulting cell-
suspension was incubated in a solution containing 1-2l magnetic beads 
conjugated to a CD31 antibody (BD BioScience) to separate cardiac endothelial 
cells from the total cell population. Sorted cells were plated in T25 flasks coated 
with 0.1% gelatin, 1μg/ml fibronectin and 30μg/ml bovine collagen, suspended in 
mouse lung endothelial cell culture (MLEC) media and incubated at 37°C, 5% CO2. 
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Cells were washed 3-4 times in PBS the next day to remove excess red blood cells 
and other cell-debris.  
2.2.3 Endothelial cell isolation (from lungs) 
Primary endothelial cells were isolated from the lungs of Pdgfb-
iCreER;R26FAKKD/KD;FAKfl/fl mice, at ages of 2 months or older (maximum 4 
months). After culling by cervical dislocation, lungs were removed from the thoracic 
cavity, and cleaned of visceral fats, clotted blood and fibrous tissue, followed by a 
10 second immersion in 70% ethanol and then in Ham’s F12 medium. Usually, the 
lungs of 3 mice were minced together using fine scissors. The minced lungs were 
then transferred to a tube with 10ml of 0.2% type 1 collagenase (Gibco Invitrogen), 
diluted in PBS, and incubated in a pre-heated water bath at 37°C. The collagenase 
reaction was stopped by adding equal parts MLEC media to solution, and the 
digested tissue was homogenized in a dish by syringing up to 30 times with a 19 
and 21-gauge needle, and then passed through a 70m pore-size cell strainer. 
Cells were centrifuged at 1500rpm for 3 minutes, and the resulting cell pellet 
resuspended in 10ml of MLEC media and plated in a T75 tissue culture flask. The 
next day, cells were washed 3-4 times in PBS to removed excess red blood cells 
and other cell-debris.  
Endothelial cell colonies were selected by magnetic immunosorting with ICAM-2 
antibodies (Abd Serotec). The antibody solution for sorting consisted of 5l anti 
ICAM-2 stock solution diluted in 3ml of PBS, and magnetic beads were prepared 
by diluting 3l stock Dynabead solution (Dyna-Invitrogen Bead separation) in 3ml 
MLEC media. Cells were first chilled at 4°C for 30 minutes in PBS, and then 
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incubated for a further 30 minutes at 4°C in antibody solution. After this, the 
antibody solution was replaced with the magnetic bead mixture and incubated for 
30 minutes at 4°C. Next, cells were trypsinised, resuspended in 10ml MLEC media 
and transferred to a 15ml falcon tube that was placed in a magnetic bead sorter. 
Here, bead-bound cells were immuno-magnetically sorted, and were resuspended 
in MLEC media and plated in pre-coated T25 flasks.  
2.2.4 Passaging endothelial cells (cardiac and lung) 
Endothelial cells from both the lungs and heart were split into new flasks when they 
reached 80% confluence. Here, media was removed and cells were washed 3-4 
times with PBS. Trypsin (25% trypsin-EDTA from Gibco, Invitrogen) was added to 
cells (2ml per T25, 4ml per T75 flask), and incubated for 3 minutes at 37°C. Cell 
detachment was confirmed and equal parts MLEC media was added to cell 
solutions, before transfer to pre-coated flasks. Mouse lung endothelial cells were 
usually split at a 1:3 ratio, whilst mouse cardiac endothelial cells were split at a 1:2 
ratio. Primary endothelial cells were passage no more than 1 (cardiac) or 2 (lung) 
times before immortalization.  
2.2.5 Transfection of mouse lung endothelial cells (for immortalization) 
Mouse lung endothelial cells were transfected with PyMT (Polyoma middle T) virus 
to induce cell immortalisation for subsequent assays.  
Sub confluent (70-80%) endothelial cells were trypsinised and plated onto pre-
coated T25 flasks at a density of 1 million cells per flask. The next day, cells were 
trypsinised, counted and spun for 10 minutes at 1200 rpm. Cells were resuspended 
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in 100ul of transfection solution (200mM HEPES, 137mM NaCl, 5mM KCl, 6mM 
D-glucose, 7mM Na2HPO4) containing PyMT, and then electroporated. Cells were 
left to recover in MLEC media for 15 minutes and finally decanted into a pre-coated 
T25 flask. Immortalised cells hereafter will be illustrated with the presence of a 
PMT suffix. 
2.2.6 Cardiomyocyte cell isolation 
Primary mouse cardiomyocyte cells were isolated from the whole hearts of 1 – 3-
day old C57BL6 wild-type mice. Hearts were dissected and removed from the 
thoracic cavity, mechanically minced with scissors and digested in cardiomyocyte 
isolation enzyme 1 (200μl per heart) and cardiomyocyte isolation enzyme 2 (10μl 
per heart) (Pierce primary cardiomyocyte isolation kit, Thermo Scientific). Digested 
hearts were then homogenized by gently pipetting up to 30 times with a 1ml pipette, 
and the resulting single cell suspension added to complete D-MEM solution (D-
MEM, 10% FBS, 1% Penicillin Streptomycin). After combination of all cell 
suspensions, the total number of viable cells were counted, and plated at 
approximately 1 million cells per well of a 6 well plate. The following day, wells 
were washed with PBS (without calcium and magnesium), and complete 
cardiomyocyte growth medium added. Complete cardiomyocyte media thereafter 
was replaced every other day.  
2.2.7 In vitro cardiomyocyte hypertrophy studies 
Following 5 days incubation at 37°C, 5% CO2, primary mouse cardiomyocytes 
were serum starved for 24 hours in a 0.5% FBS-DMEM media. Cells were then 
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washed and recoated with complete cardiomyocyte growth media. For 
cardiomyocyte hypertrophy assessment 1uM angiotensin II (Alfa Aesar) was 
added to cardiomyocyte growth media post serum starvation (i.e. day 6 post-
culture), and this was repeated the next day. Images of cardiomyocytes were 
captured using a bright field microscope at 40x magnification at 0, 24 and 48-hour 
post-angiotensin II treatment (i.e. day 6, 7 and 8 post-culture) and analysed using 
image J software. In tandem to angiotensin II treatment, cells were either treated 
with vehicle, low dose Cilengitide (20nM) (Bachem), or PI3k inhibitor (1M).  
After 8-day culture and treatment, cardiomyocytes were either lysed for RNA or 
Western-analysis (see details given below). 
2.2.8 Doxorubicin stimulation of endothelial Pdgfb-iCreER; R26FAKKD/KD; 
FAKfl/fl PMT cells 
Immortalized endothelial cells were treated with either vehicle or fresh doxorubicin 
(Tevaguard) (125M) in full MLEC media for 44 hours, before being serum starved 
in Optimem (supplemented with vehicle or doxorubicin as above) for a further 4 
hours. 
 
2.2.9 Cytokine arrays 
Pdgfb-iCreER;R26FAKKD/KD;FAKfl/fl PMT cells were grown in normal full MLEC 
media and treated with either vehicle, or fresh doxorubicin (125M) for 44 hours 
once confluent, before being serum starved in Optimem (supplemented with 
vehicle or doxorubicin as above) for a further 4 hours. Whole cell lysates were 
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extracted in high SDS buffer and mouse XL cytokine arrays (proteome profiler 
ARY028, RD systems) were performed according to the manufacturer’s 
instructions using 120g of lysates per membrane. Pixel analysis was used for 
quantification with ImageJ software.   
2.2.10 MTT assay 
Pdgfb-iCreER;R26FAKKD/KD;FAKfl/fl KD PMT cells were grown in normal full MLEC 
media until confluence. Cells were then treated with 7.5g/ml Mitomyocin C for 2 
hours at 37°C to correct for proliferative differences between samples. Next, 1 
million cells were seeded in a T25 flask, and left to recover for 24 hours. Cells were 
treated with either vehicle, or doxorubicin (125M) for 48 hours. Next, conditioned 
cell media was collected from these treated cells and passed through a 70m filter 
to remove debris. In tandem B16F0 melanoma cells were plated (500 cells per 96 
well) and grown in full media. After 2 days, B16F0 full media was removed, and 
replaced with MLEC conditioned media. After 2-3 days, MTT was added to B16F0 
wells and incubated at 37°C for an appropriate time. Media was removed, 50l 
DMSO added to each well, and samples were measured via spectrophotometry at 
an absorbance of 570nm.  
 
2.3 RNA analysis by RT-qPCR and RNA-seq 
2.3.1 RNA extraction 
Medium was removed and cells were washed 3 times in PBS. 350μl RLT lysis 
buffer (Qiagen) (plus 1:100 beta-mercaptoethanol) was added to each well to 
disrupt and lyse the cells. Cell lysate samples were then combined with an equal 
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volume of 70% ethanol, before being transferred into a RNeasy spin column, and 
centrifuged for 15 seconds at full speed in an Eppendorf Microcentrifuge. The flow 
through was discarded. Next, 350μl of Buffer RW1 was added to each column and 
spun for 15 seconds at max peed. The flow through was discarded and 80μl of 
DNase solution in Buffer RDD (70ul RDD:10ul DNase) was added directly to the 
RNeasy spin column membrane and left at room temperature for 15 minutes. 350μl 
of Buffer RW1 was then added to the RNeasy spin column and spun for 15 
seconds at max speed, and the flow through discarded. 500μl Buffer RPE was 
added to the RNeasy spin column and spun for 15 seconds at max speed, and the 
flow through discarded. This step was repeated, and then columns were spun for 
2 minutes to dry the RNeasy spin column membrane, and the flow through 
discarded. The RNeasy spin column was placed in a new 2ml collection tube and 
spun for a further 1minute at full speed without the addition of buffers to ensure 
there was no ethanol carry over. The RNeasy spin column was then carefully 
removed and placed in a fresh collection tube. Between 15μl and 30μl (depending 
on the expected yield of RNA) of RNase-free water was added directly to the 
column and spun for 1 minute at max speed to elute the RNA. The flow through 
was collected in a labelled 1.5ml collection tube and stored at -80°C until required. 
For whole hearts, less than 100mg of tissue was lysed with 700ul RLT lysis buffer 
(Qiagen) (supplemented 1:100 beta-mercaptoethanol) in a QIAshredder (Qiagen) 
for 10 minutes. Tissues were then processed as above with the RNeasy mini kit 
as above.  
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2.3.2 RNA purity assessment 
The purity and quantity of RNA was analysed using a Spectophotometer, which 
read absorbance at 260/280 and 260/230nm (NanoDrop, Wilmington, US). All 
samples were expected to exhibit a 260/280 ratio of approximately >2.0, indicating 
that the RNA was pure and free of nucleic acid contaminants, and a 260/230 ratio 
of >1.8, which was used as a secondary measure of nucleic acid purity. For RNA-
Seq, RNA integrity (RIN) was assessed using gel electrophoresis to evaluate the 
ratio of 28s to 18s rRNA.  
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Figure 2: RNA integrity (RIN) assessment of samples sent for RNA-Seq. (a) Gel 
electrophoresis of samples sent for RNA-Seq. (b) Representative RIN values of cardiac endothelial 
samples (17-22). Conducted with help from QMUL genomics centre.  
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2.3.3 Reverse transcription 
Complimentary DNA (cDNA) synthesis was carried out using the Applied 
Biosystems High Capacity cDNA Reverse Transcription (RT) Kit on a thermal 
cycler as per the manufacturer’s instructions. 
High capacity cDNA reverse transcription recipe: 
Component Volume (l) 
10x RT buffer 2.0 
25x dNTP mix 0.8 
10x RT random primers 2.0 
Multiverse reverse transcriptase 1.0 
Table 1: High capacity cDNA reverse transcription recipe.  
cDNA was made up to a total quantity of either 600 (most mouse tissue and/or 
cells), or 1000ng (human heart tissue).  
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Thermal cycle conditions:  
 Step 1 Step 2 Step 3 Step 4 
Temperature 
(°C) 
25°C  37°C 85°C 4°C 
Time 
(minutes) 
10 minutes 120 minutes 5 minutes Infinite 
Table 2: Thermal cycle conditions – cDNA synthesis.   
 
2.3.4 Quantitative PCR (qPCR) 
Analyses were performed using the ABI Prism 7500 Sequence Detection system 
Instrument and software (PE Applied Biosystems). RT-qPCR was performed using 
sample cDNA, an internal control GAPDH (VIC-tagged) and specific TaqMan 
probes (FAM-tagged). 
RT-qPCR was carried out using the TaqMan Universal PCR Master Mix (PE 
Applied Biosystems) in a 96 well plate. 160ng of cDNA from each sample was 
amplified using qPCR across 40 cycles.  
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 Step 1 Step 2 Step 3 – 4: 40x cycles 
Temperature 
(°C) 
60°C  95°C 95°C 60°C 
Time 
(minutes) 
10 minutes 10 minutes 15 seconds 60 seconds 
Table 3: Thermal cycle conditions - RTqPCR.   
Target mRNA was normalised to GAPDH (HPRT-1 if human), and the expression 
level of each gene determined relative to the initial experimental controls using 2-
ddCT method.  
The following primers were used (with associated primer codes):  
Note - All primers are Taqman unless otherwise stated. For Taqman assays, all 
housekeeping primers are VIC-tagged, and genes of interest are FAM-tagged. 
 
 
 
 
 
 
 38 
Primer Assay ID (Thermofisher Taqman) 
ANP Mm01255747_g1 
BNP Mm01255770_g1 
Myh7 Mm00600555_m1 
Myh6 Mm00440359_m1 
3 Integrin (mouse) Mm00443980_m1 
5 Integrin (mouse) Mm00439825_m1 
3 Integrin (human) Hs01001469_m1  
5 Integrin (human) Hs00174435_m1 
GAPDH (mouse) Mm99999915_g1 
HPRT-1 (human) Hs02800695_m1 
FAK (mouse) Forward: GGCGTTGCCATCAATACCA 
Probe: AAGGCATGCGGACACA 
Reverse: GGTGTATGTGTCTTCCTCATCGAT 
FAK (chicken) Forward: CAACAGCAAGAGATGGAAGAAG ATC 
Probe: ACGATTCCTGGTAATGAA 
Reverse: 5′‐CCGTCCTCCCGTTCAATG‐3′ 
Primer Primer sequence 5’-3’ (SYBR) 
RLP-19 (SYBR) Forward: GCTTGCCTCTAGTGTCCTCC  
Reverse: TTGGCGATTTCATTGGTCTCA  
 
-actin (SYBR) Forward: CACAGCTTCTTTGCAGCTCCTT  
Reverse: TCAGGATACCTCTCTTGCTCT  
CTGF (SYBR) Forward: GGGCCTCTTCTGCGATTC  
Reverse: ATCCAGGCAAGTGCATTGGT 
Table 4: Primer codes for RT-qPCR.    
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2.3.5 RNA-Seq 
Cells were harvested 48 hours after treatment and total RNA was extracted as 
above using the RNeasy Mini kit with DNase treatment (Qiagen). The quality of 
RNA was assessed and only RNAs with an RNA integrity value (RIN) of greater 
than 7 was used for sequencing, with a minimum input of 1g of RNA. Poly-A 
library preparation was performed at the Queen Mary University of London 
Genome Centre according to manufacturer’s instructions (Illumina). Briefly, first-
strand cDNA was generated using random hexamer-primed reverse transcription, 
followed by second-strand cDNA synthesis using RNase H and DNA polymerase, 
and ligation of sequencing adapters using the TruSeq RNA Sample Preparation 
Kit (Illumina). Per sample, 20 million reads were generated, with a read length of 
75 base pairs. The prepared libraries were sequenced using the Illumina 
sequencing platform NextSeq 500 high output run (150 cycles). Data was received 
in a FASTQ format and analysed by Prof. Jun Wang and Eleni Maniati of the Bart’s 
Cancer Institute.  
Human RNA-Seq and microarray data were obtained from [6], and contained 6 
RNA-Seq, and 313 microarray data sets.  
 
2.5 Protein analysis by Western Blotting 
2.5.1 Cell lysis 
For all western blot procedures, cells were grown to 70-90% confluence and lysed 
with either RIPA buffer (Millipore – 50mM Tris-HCl pH 7.4, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS, 150mM NaCl, 2mM EDTA, 50mM NaF), or high SDS 
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buffer (3% SDS, 60mM sucrose. 65mM Tris pH 6.8), both supplemented with 
protease inhibitor (1:100, CalbioChem – 100mM AEBSF hydrochloride, 60M 
Aprotinin, 5mM Bestatin, 1.5mM E-64 protease inhibitor, 2mM Leupeptin 
hemisulfate and 1mM pepstatin). 80l lysis buffer was used for 6 well plates and 
T25 flasks, and 180l for T75 flasks. Cells were scraped on ice if RIPA-lysed, or 
at room temperature if high-SDS lysed.  
For whole hearts, less than 100mg of tissue was lysed with 200-500l high-SDS 
buffer (supplemented with 1:100 protease inhibitor) (size dependent) in a 
QIAshredder (Qiagen) for 10 minutes.  
RIPA-lysed cells were transferred to an Eppendorf and centrifuged at 12000rpm 
for 10 minutes at 4°C, and the supernatant transferred to a fresh Eppendorf for 
storage. High-SDS lysed cells/tissue were transferred to an Eppendorf and 
sonicated for 10 seconds, before being vortexed at max speed for a further 10 
seconds. Aliquots were stored at -20°C in all cases.  
2.5.2 Protein quantification 
Protein concentrations were calculated using the colorimetric DC Bio-Rad assay 
(Bio-Rad laboratories). Protein standards were obtained by preparing an 
increasing gradient of bovine serum albumin (BSA) in RIPA or high-SDS buffer, 
from 0-2000μg/ml. In order to quantify protein concentrations 5μl of the protein of 
interest was sampled in triplicate in a 96 well plate, to which 25μl of Reagent A’ 
(prepared by mixing 1ml Reagent A with 20ul Reagent S), and 200μl of Reagent 
B was added. Solutions were incubated at room temperature for 15 minutes, 
before optical reading using an absorbance microplate reader set at 620nm 
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wavelength. Further analysis was completed using Magellan software.  
2.5.3 SDS-polyacrylamide gele electrophoresis  
8% (p-Akt, total Akt) or 10% (FAK, 3/5 integrin) polyacrylamide gels (1.5mm 
thick) were used for resolving protein lysates.  
10% Acrylamide gel recipe (10ml per gel):  
 
Reagent Volume 
30% Acrylamide 3.3ml 
1.5M Tris (pH 8.8) 3.8ml 
Distilled water 5.9ml 
10% SDS 0.1ml 
Ammonium persulphate (APS) 10% 0.1ml 
TEMED 0.006ml 
Table 5: 10% Acrylamide gel recipe.  
 
Resolving gel was poured into cassettes (Invitrogen), and a thin layer of water was 
added onto the gel to prevent air-gel contact, which can impair successful 
polymerization.  
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Stacking gel recipe (2ml per gel):  
 
Reagent Volume 
30% Acrylamide 0.33ml 
Distilled water 1.4ml 
1M Tris (pH 6.8) 0.25ml 
10% SDS 0.02ml 
Ammonium persulphate (APS) 10% 0.02ml 
TEMED 0.002ml 
Table 6: Stacking gel recipe.   
 
Following polymerization of the resolving gel excess water was removed and 
stacking gel was poured into the cassette. A 10-12 well comb was added, and 
stacking gel left to polymerize. Next, the gel-cassette was placed in a gel tank 
(Invitrogen) filled with running buffer (1x Tris-Glycine-SDS). Lysates were boiled 
at 100°C for 10 minutes and loaded into the gel, which was run at 110V for 30 
minutes, followed by 140V for a further 1 hour at room temperature, or until the 
desired separation was achieved.  
2.5.4 Transfer  
Resolved proteins were transferred from gels to pre-wet Hybond nitrocellulose or 
PVDF membranes (GE). A ‘sandwich’ was assembled of sponges, Whatman 
paper, membrane and gel in transfer buffer (1x Tris-Glycine, 20% Ethanol) prior to 
transfer. To remove air bubbles here, a plastic pipette was rolled over the transfer 
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‘sandwich’. The assembly was placed in a transfer apparatus and this was placed 
in a gel tank filled with transfer buffer. Transfer was performed at 4°C at 30V for 
75 minutes, and successful transfer was evaluated via the immersion of the 
membrane into a Ponceau S red (Sigma) solution for 1 minute. Membranes were 
then washed with distilled water and kept in washing buffer (PBS-0.1% Tween-20) 
prior to Western blotting.  
2.5.5 Western Blotting 
After protein transfer, membranes were blocked with 5% milk for 1 hour and probed 
with primary antibody (1:1000) overnight at 4°C in a 5% BSA blocking buffer. Blots 
were washed for 5 minutes 3 – 6 times in 0.1% PBS-Tween 20 and incubated with 
a relevant horseradish peroxidase (HRP) conjugated secondary antibody in 5% 
milk for 2 hours at room temperature. Once again, blots were washed for 5 minutes 
3-6 times in 0.1% PBS-Tween 20. Reactive bands amongst the membrane were 
visualized using an enhanced chemiluminescent kit (Millipore), and exposed using 
either auto radiographic film, or the Chemidoc.  
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The following housekeeping antibodies were used: 
Antibody Company Dilution Host Reactivity 
GAPDH Millipore 1:5000 Mouse 
(monoclonal) 
Mouse 
GAPDH Santa-cruz 1:2000 Mouse Human 
Hsc-70 Santa-cruz 1:5000 Mouse 
(monoclonal) 
Mouse 
Table 7: Housekeeping antibody list.  
 
The following primary antibodies were used: 
Antibody Company Dilution Host Reactivity 
FAK Millipore 1:1000 Mouse Mouse 
3 integrin Cell signalling 1:1000 Rabbit Human 
5 integrin Cell signalling 1:1000 Rabbit Human 
p-Akt Cell signalling 1:1000 Rabbit Mouse 
Total Akt Cell signalling 1:1000 Mouse Mouse 
Table 8: Primary antibody list.  
 
2.5.6 Enhanced chemiluminescence (ECL) 
ECL (ThermoFisher) is a light emitting and non-radioactive method used to detect 
immobilized specific antigens that are conjugated to HRP-labelled antibodies. 
Following incubation with luminescent reagents for 1 minutes, membranes were 
exposed on either autoradiographic film, or using the Chemidoc system.  
 45 
2.5.7 Densitometry 
ImageJ software was used for densitometric analysis of western blotting bands.  
 
2.6 Genotyping and PCR 
 
2.6.1 Generation of mice 
To study the effect of inducible endothelial‐specific FAK kinase deletion in vivo, we 
used a knockout/knockin system whereby endogenous mouse FAK was deleted 
and myc‐tagged chicken FAK [wild‐type (WT) or mutant] was expressed under 
control of the R26 promoter upon tamoxifen induction. To this end, we used what 
I will refer to as a Pdgfb‐iCreER; R26FAKKD/KD;FAKfl/fl; mouse (EC FAKKD). The 
mouse model has been used successfully in a recent publication [7]. The validation 
of chicken FAK, as well as its characterisation and generation were described 
elsewhere by Tavora et al. [8]. Those mice without cre were used as controls (EC 
FAKWT).  
2.6.2 Reagents 
2.6.2a Tail lysis buffer 
Tail lysis buffer consisted of 10mM Tris-HCL (pH 8.5), 10mM EDTA, 100mM NaCl 
and 0.2% SDS. 0.1mg/ml proteinase-K was thawed and added immediately before 
addition to ear clips.  
 
2.6.2b TE buffer 
TE buffer consists of 10mM Tris-HCL (pH 7.5) and 1mM EDTA.  
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2.6.3 DNA extraction from ear snips 
Tissue samples were digested over night at 56°C in 100μl tail lysis buffer (plus 
0.1mg/ml proteinase K). The following morning, 100μl isopropanol was added, 
plates were centrifuged at 2600rpm for 30 minutes, and the supernatant was 
removed by inverting the plate. The DNA pellet was dried at 56°C for 1 – 2 hours, 
and this was then re-suspended in 200μl TE buffer and left at RT for 1-2 hours 
before use.  
2.6.4 Polymerase chain reaction (PCR) 
PCR was performed to genotype all mice. I was responsible for maintaining all the 
breeding programs and genotyping of all the mice used during my PhD.  
All primers (Invitrogen) were stored as a stock solution of 100M in nuclease free 
water at 4°C.  
 
2.6.4a FAKfl/fl (LP2) PCR 
PCR for LP2 genotyping (figure 4) was performed using the following 
oligonucleotide primers: 
Primer Primer sequence 5’-3’ 
LP2as 5’-TTAATAAGACCAGAGGACTCAGC-3’ 
LP2h 5’-GGAAGAAGCTTGTATACTGTATG-3’ 
LP2s 5’-ATTGTGCTATACTCACATTTGGA-3’ 
Table 9: LP2 primer sequence.  
 
For all LP2 reactions 1.5μl DNA was added to 24μl total MasterMix (MegaMix-Blue 
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(Microzone)), and 0.3l total primer mix (LP2as, LP2h, LP2s 1:1:1).  
 
 Step 1 Step 2 – 4: 36x cycles Step 5 Step 6 
Temperature 
(°C) 
94°C  94°C 56°C 72°C 70°C 18°C 
Time 
(minutes) 
3 minutes 1 minute 45 seconds 60 seconds 5 minutes Infinite 
Table 10: LP2 PCR thermocycler cycle.  
 
Product size: LP2 697 bp and wild-type 429 bp.  
 
Figure 3: LP2 example PCR. Note: all samples here are LP2 positive where LP2 is 697bp.  
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2.6.4b Pdgfb-iCreER PCR 
PCR for Pdgfb-iCreER genotyping was performed using the following primer 
sequences:  
 
Primer Primer sequence 5’-3’ 
Cre Fwd 5’-GCCGCCGGGATCACTCTC-3’ 
Cre Bwd 5’-CCAGCCGCCGTCGCAACT-3’ 
B2M Fwd 5’-CACCGGAGAATGGGAAGCCGAA-3’ 
B2M Bwd 5’-TCCACACAGATGGAGCGTCCAG-3’ 
Table 11: Pdgfb-iCreER primer sequence.  
 
For all Pdgfb-iCreER genotyping (figure 5) 1.5μl DNA was added to 24μl total 
MasterMix (12μl DreamTaq Green PCR (2x) (LifeTechnologies), 12μl nuclease 
free water), and 0.3μl total primer mix (Cre Fwd, Cre Bwd, B2M Fwd, B2M Bwd 
1:1:1:1).  
 
 Step 1 Step 2 – 4: 34x cycles Step 5 Step 6 
Temperature 
(°C) 
94°C  94°C 65°C 72°C 70°C 18°C 
Time  4 mins 30 seconds 80 seconds 60 seconds 10 mins Infinite 
Table 12: Pdgfb-iCreER thermocycler cycle.  
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Product size: Cre 443 bp, B2M 295 bp.  
 
Figure 4: Pdgfb-iCreER example PCR. Note: Cre 443bp, B2M 295bp.  
 
2.7 Immunohistochemistry (mouse) 
 
2.7.1 Immunohistochemistry on paraffin sections 
Myocardium was fixed in 10% neutral buffered formalin for 24 hours at room 
temperature, before being transferred to 70% ethanol. Tissues were paraffin 
embedded, sectioned to 5μm and dewaxed in xylene, then rehydrated in a 
decreasing ethanol gradient for 3-5 minutes per condition (100, 100, 80, 70, 50, 
distilled water). Antigen retrieval was performed by boiling slides in 10mM citrate 
buffer (pH 6.0) for 13 minutes. Sections were left to cool for 10 minutes in PBS, 
before proceeding with the intended staining procedure.  
 
2.7.1a Picrosirius Red staining 
For collagen fibre staining, heart sections were dewaxed (as above) and then were 
incubated in phoshomolybdic acid for 2 minutes, before being transferred to 
picrosirius red for 60 minutes, and finally immersed in acidified water (5ml acetic 
acid per 1ml water) for a further 2 minutes on a shaker. For best results, sections 
were then immediately transferred to 100% ethanol without being dehydrated in 
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multiple rounds of increasing ethanol concentrations. Tissues were then immersed 
in xylene for 10 minutes before being mounted in DPX and finally cover-slipped.  
The positive fraction of percentage area of red staining of an entire section was 
quantified after setting an appropriate threshold with ImageJ.  
2.7.2 Immunohistochemistry on frozen sections 
Myocardium was snap frozen in liquid nitrogen and stored at -80°C before being 
transferred to an OCT-containing mould. Cryosections were cut to 5um and 
transferred to slides, and then fixed in 100% acetone at -20°C.  
 
2.7.2a Wheat Germ Agglutinin (WGA) staining 
To quantify cell area size (of cardiomyocytes), tissues were blocked in 5% normal 
goat serum for 1 hour and incubated with WGA Alexa Fluor 488 (Invitrogen) 
conjugate antibody (1:100) in blocking buffer (5% normal goat serum) for 2 hours 
at room temperature. Sections were washed 3 times in PBS and mounted in anti-
fade gold with DAPI (Molecular Probes). Images were taken on a Zeiss axioplan 
microscope, and the cardiomyocyte size was analysed with ImageJ (NIH). The 
cardiomyocyte size was estimated as an average of ∼100-200 cells per heart. 
 
2.7.2b Masson’s Trichrome staining 
Masson’s trichrome staining was used to detect the abundance of collagen fibers 
amongst mouse heart tissue sections. Tissues were fixed in Bouin’s solution for 1 
hour at 56°C, before being rinsed in tap water for 5-10 minutes. Tissues were then 
immersed in Weigert’s iron hematoxylin (mixed equal parts A and B) for 10 
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minutes, and rinsed in tap water, followed by staining in Beibrich scarlet-acid 
fuchsin for 15 minutes. Samples were washed in distilled water and left in 
phospolybdic-phosphotungstic acid solution for 15 minutes, and then transferred 
without washing to aniline blue solution for a further 10 minutes. Sections were 
rinsed briefly in distilled water, and immersed in 1% acetic acid for 5 minutes, 
before being washed again in water, and then transferred to 100% ethanol and 
cleared in xylene. Samples were finally mounted in DPX. The positive fraction of 
percentage area of red staining of an entire section was quantified after setting an 
appropriate threshold with ImageJ.  
 
2.7.2c CD31 staining and quantification of blood vessel density 
For anti-CD31 (BD Bioscience) stains, tissues were blocked in 5% normal goat 
serum for 1 hour, followed by incubation with anti-CD31 primary antibody (1:100) 
in blocking buffer (5% normal goat serum) for 2 hours at room temperature. Next, 
sections were incubated for 1 hour at room temperature with an appropriate 
secondary antibody, conjugated to a green (usually 488) fluorophore, before being 
washed 3 times in PBS and then mounted in anti-fade gold with DAPI.  
Images were taken with an Axioplan Zeiss microscope. To quantify cardiac blood 
vessel density, the number of CD31-positive blood vessels present across an 
entire area of transversely-orientated cardiac tissue was counted within a field of 
view taken at 40x magnification. 3 of these fields were used per heart and an 
average taken across fields.  
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2.8 Immunohistochemistry (human) 
 
Procurement of human myocardial tissue was performed under protocols 
approved by Institutional Review Boards at the University of Pennsylvania 
(Pennsylvania, USA), Johns Hopkins University (Maryland, USA) and VU 
University Medical Center, (Amsterdam, The Netherlands) and its coordinated 
affiliated centres. Thank you to Kenneth Marguiles and Ken Bedi.  Failing human 
hearts were procured at the time of orthotopic heart transplantation at the 
Hospital of University of Pennsylvania. Non-failing hearts were obtained at the 
time of organ donation from cadaveric donors. In all cases, hearts were 
arrested in situ using ice-cold cardioplegia solution, transported on wet ice, and 
flash frozen in liquid nitrogen within 4 hours of explantation. All samples were 
full-thickness biopsies obtained from the free wall of the left ventricle. Heart 
failure with preserved ejection fraction (HFPEF) patients were referred for 
cardiac catheterization and left ventricular endomyocardial biopsy because of 
clinical suspicion of restrictive cardiomyopathy. Left ventricular biopsies were 
obtained using femoral artery access and a long bioptome. Control samples for 
these studies were obtained from explanted unused donor hearts.  
Donated myocardium was pre-sectioned onto slides, and thus could be 
immediately processed. Tissues were dewaxed in xylene, then rehydrated in a 
decreasing ethanol gradient (100, 100, 80, 70, 50, distilled water). Antigen retrieval 
was performed by boiling slides in 10mM citrate buffer (pH 6.0) for 13 minutes. 
Sections were left to cool for 10 minutes in PBS, before proceeding with the 
intended staining procedure.  
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2.8.1 3 and 5 immunostaining (co-staining with Cardiac Troponin T, CD31 
or -SMA) 
For anti-3 (Invitrogen) and anti-5 (Millipore) stains, tissues were blocked in 10% 
normal goat serum and 1% BSA for 1 hour, followed by incubation with anti-3 or 
anti-5 primary antibody (1:200) in blocking buffer (10% normal goat serum, 1% 
BSA) overnight.  Sections were co-incubated with cardiac troponin T (cTnT) 
(1:200), CD31 (Santa Cruz) (1:200) or PE--SMA (Invitrogen) (1:200) also 
overnight. Next, sections were incubated for 2 hours at room temperature with an 
appropriate secondary antibody in blocking buffer (10% normal goat serum, 1% 
BSA), conjugated to a 488 (3/5) or 546 (cTnT, CD31) fluorophore, before being 
immersed in Sudan black for 15 minutes to reduce autofluorescence. -smooth 
muscle actin (-SMA) was pre-conjugated to PE (phycoerythrin). Sections were 
washed thoroughly in tap water for 5 minutes, and washed 3-6 times in PBS for 3 
minutes, and finally mounted in prolong gold with DAPI. 3 and 5 stained sections 
were imaged on either the Zeis Axioplan, or Zeis 710 confocal microscope, and 
processed using Image J software.  
 
2.9 Statistical analysis 
 
All results are presented as mean  SEM for at least 3 biological replicates, unless 
otherwise stated. Sample sizes were based upon previous power calculations 
performed by former investigators. Unless otherwise stated P values were 
calculated using one-way ANOVA with Tukey’s post-hoc analysis. P<0.05 was 
considered statistically significant.  
 54 
 
2.10 Ethical regulations 
 
All procedures were approved by our local animal ethics committee at the Queen 
Mary University of London and were executed in accordance with UK Home Office 
regulations.  
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3.1 General Introduction: Vascular System 
 
3.1.1 Organisation and function of the cardiovascular system 
The survival, reproduction and growth of living organisms rely on the delivery and 
recycling of metabolites to and from all cells in the body. Through evolution, as 
organisms grow in size and complexity, the simple diffusion of metabolites through 
cell membranes and across multiple cell layers was complemented with the 
development of specialised transport and exchange structures. As such, 
vertebrates developed highly complex and hierarchised blood vascular systems 
[9]. Additionally, these circuits co-developed as networks to facilitate movement of 
factors regulating whole organism homeostasis, including temperature regulation, 
hormonal communication, and the circulation of immune factors and cells. 
 
The blood vascular system of vertebrates is organised in a closed network of 
accumulating (veins and venules) and distributing (arteries and arterioles) vessels 
connected to a central peristaltic pump known as the heart. In tissues, the 
exchange of gases and metabolites takes place through networks of fine 
capillaries, whose organisation throughout the body ascertains sufficient 
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distribution of resources to all organs. The efficiency and adaptability of the 
vertebrate’s cardiovascular system lies in the structural specialisation and 
hierarchical organisation of the vessels within its network. Capillaries are made of 
a single layer of endothelial cells and are surrounded by a basement membrane 
and pericytes. Capillaries can locally adapt to the metabolic needs of the 
surrounding tissue, and deliver interchangeable levels of resources accordingly, 
by regulating their own permeability at various levels through fenestration, opening 
of cell junctions, partial digestion of the basement membrane, and/or detachment 
of pericytes. In contrast, larger vessels such as arteries and veins are surrounded 
by multiple layers of connective tissue and vascular smooth muscle cells (VSMCs), 
and as such can handle higher blood volumes and pressure levels and adapt their 
diameter to modulate flow between tissues [10].  
 
3.1.2 Development of the vascular system – vasculogenesis and 
angiogenesis 
Because of its critical role in nutrient and oxygen delivery, the cardiovascular 
system is the first organ system to reach a functional state during embryonic 
development [11]. In vertebrates, blood vessel formation starts soon after 
gastrulation [11]. Mice for example, will exhibit vessel formation at E7-8, whilst in 
humans, early vessels will form within 3 weeks [12, 13]. Central to early blood 
vessel formation is vasculogenesis, or the assembly of new blood vessels from 
individual precursor cells. In the embryo, blood vessels begin life as blood islands, 
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the earliest of which includes the yolk sac, connecting stalk and chorion. Blood 
islands are composed of pluripotent haemangioblasts, which are capable of 
differentiating into either angioblasts (i.e. vascular precursor cells), or 
haemocytoblasts (i.e. blood precursor cells) [14]. The differentiation of a 
haemangioblasts is determined by the spatiotemporal protein expression of 
fibroblast growth factor (FGF) – those cells on the inside of an island receive 
relatively less FGF and will form endothelial precursor cells, and those on the 
outside of an island will see relatively more FGF and form primitive haematopoietic 
cells [15].  
Angioblasts are migratory cells that will coalesce into cords and aggregate to form 
a lumen. The progressive fusion and extension of many of these primitive 
luminated vessels together forms a primordial vascular plexus, which once 
established, will itself ramify and undergo a broad remodelling of extensive growth, 
migration, sprouting and branching to further generate new vessels, in a process 
called angiogenesis [16]. Angiogenesis refers to the formation of vessels from pre-
existing vessels and occurs either through the splitting of existing vessels 
(intussusceptive angiogenesis i.e. non-sprouting), or the sprouting, and later 
fusion, of vessel branches from a parent vessel (sprouting angiogenesis). The 
overall process of angiogenesis constitutes a ‘second-wave’ of blood vessel 
formation that occurs after ‘first-wave’ developmental vasculogenesis. 
Angiogenesis generates a dense plexi of capillaries from which arteries and veins 
later develop and mature to generate a whole organism, fully functional 
vasculature [17].  
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3.1.3 Angiogenesis 
Angiogenesis is an essential process during tissue regeneration, growth, 
reproduction and development. It is a highly regulated event that involves the 
interplay of multiple different signalling networks, and if dysregulated can 
contribute to several different pathological conditions, including arthritis, diabetic 
retinopathy, heart disease and cancer [17]. There are two main types of 
angiogenesis: sprouting and non-sprouting angiogenesis [17]. Sprouting 
angiogenesis refers to the formation of new blood vessels from pre-existing 
vasculature [18]. Initiation of sprouting requires the specification of endothelial 
cells into ‘tip’ and ‘stalk’ cells bearing different morphologies and functional 
properties [18]. Endothelial tip cells are minimally proliferative, polarized and 
migratory, whereas stalk cells are highly proliferative and will form the nascent 
vascular lumen cell [19].  
 
Tip-cell selection 
Tip cells express high levels of platelet derived growth factor-b (PDGF-b), vascular 
endothelial growth factor receptor-2 (VEGFR-2), VEGFR-3, UNC-5 homolog B 
(UNC5B), delta-like 4 (Dll-4) and have low levels of Notch signalling activity [20] 
[21]. In contrast, stalk cells exhibit high levels of Notch-1, which is activated by tip-
cell Dll-4, and thus possess high Notch signalling activity [22] [21]. In this way, the 
interaction between Dll-4 and Notch-1 establishes lateral inhibition between cell 
types, leading to a positive feedback loop, which allows Notch activity to further 
determine differential cell fate [23] [20]. Consequently, pharmacologic blockade of 
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Notch signalling using γ-secretase inhibitors or inducible endothelial-specific 
deletion of the Notch-1 receptor both lead to the formation of excessive tip cell 
numbers, and a corresponding relative reduction in stalk cell number [24] [25] [26]. 
In addition, analysis of the retina of DLL4+/− mice shows that virtually every 
endothelial cell, with the exception of the main arteries, extends filopodia, and thus 
adopt a tip cell-like phenotype [26]. Previously it was thought that, once selected, 
cells will keep their fate and that the once selected tip cells will remain at the 
leading position of the sprout. However, it is now known that cells continually 
interchange their places - tip cells become stalk cells and vice versa [20].  
 
Extracellular matrix (ECM) 
Before endothelial cell migration can occur, the extracellular matrix (ECM) must be 
degraded. Tip cells do this by secreting several proteolytic enzymes, including, 
urokinase plasminogen activators (uPa), plasmin and metalloproteinases (MMPs). 
Growth factors liberated from the ECM after its degradation will further potentiate 
endothelial growth and migration [27].   
 
Migration 
Tip cells guide outgrowing capillaries across a concentration gradient of matrix-
bound vascular endothelial growth factor (VEGF). Tip cells explore their 
environment by extending motile filopodia, which express VEGFR-2 and -3, and 
transduce the migratory signal initiated by VEGF binding, thus directing vessel 
growth [21]. Consequently, VEGFR-2 blockade results in sprouting defects [28], 
and VEGFR-3 inhibition with monoclonal antibodies results in decreased 
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sprouting, vascular density, vessel branching and endothelial cell proliferation in 
mouse angiogenesis models [29].  
 
The migration of tip cell filipodia, and thus endothelial cells is a tightly regulated 
process. In theory, if all cells were to migrate, vessels should disintegrate and 
conversely, if all cells were to proliferate, vessels would likely only increase in 
diameter. When a chemotactic stimulus is present, such as VEGF, different 
signalling pathways converge to modify cytoskeletal remodelling. Firstly, 
endothelial cells polarize, resulting in the formation of a leading edge that contains 
thin, needle-like protrusions called filipodia. Cdc42 is a prerequisite for protrusion 
formation in most polarizing cells, including endothelial cells [30]. As such, the in 
vivo deletion of Cdc42 in embryonic endothelial cells results in blocked lumen 
formation and endothelial tearing, leading to lethality of mutant embryos by E9-10 
due to failed blood circulation [30]. To transform protrusion formation into forward 
movement, cells will anchor to a substrate at focal complexes. Once attached, the 
continuous addition of G-actin at the barbed ends of actin filaments will push the 
plasma membrane and the extended leading edge forward, which then stabilizes 
through the formation of new adhesion sites. Focal complexes disassemble at 
the rear, and reassemble at the leading edge, thus perpetuating forward motion 
[31].  
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Adhesion 
Focal adhesion complexes are composed of a large number of adhesion-related 
proteins including integrins and cadherins [32]. As will be discussed in further detail 
later, integrins belong to a family of heterodimeric transmembrane glycoproteins 
which mediate cell-ECM and cell-cell interactions. VEGF-induced angiogenic cell 
migration requires αvβ3, αvβ5 and β1 integrins [33]. Consequently, integrin β1-
deficient endothelial cells are defective in cell adhesion and migration [34] [35]. 
However, mice lacking αvβ3 and αvβ5 integrins are viable and fertile and blood 
vessel development in these animals is not disturbed. Importantly, loss of β3-
integrin enhances tumour angiogenesis [36]. A possible explanation for this is a 
compensatory response mediated by enhanced VEGF/VEGFR2 signalling [37].  
 
Lumen formation and vessel stabilisation 
To establish a properly patterned vascular tree, tip cells are followed by 
morphologically distinct stalk cells, which form a lumenised tube growing behind 
the tip cell. The lumen of a blood vessel is essential for providing blood to any 
given tissues, and only once it has been established can blood flow through a 
newly formed vessel. As a vessel elongates, stalk cells proliferate in response to 
VEGF and establish adherens junctions between neighbouring cells. In doing so, 
they are able to create a lumen, synthesize a basement membrane, associate 
with pericytes, and finally increase the mass and surface of the growing vessel [38] 
[17].  
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In order to be functional, the new vessels need to be stabilized. Active angiogenic 
sprouts progressively become quiescent as a result of decreased endothelial cell 
migration proliferation. Stabilisation of newly formed vessels is mainly a result of 
synthesis and deposition of new basement membrane and recruitment of 
perivascular cells, such as pericytes, if associated with capillaries and immature 
vessels, or vascular smooth muscle cells, if covering larger vessels such as 
arteries and veins. Interaction of pericytes and endothelial cells promotes a 
quiescent state by inhibiting endothelial migration and proliferation [39]. This may 
be partially controlled by pericyte-induced endothelial cell expression of 
plasminogen activator inhibitor type 1 (Pal-1), or endothelial cell Tie2 receptor 
expression [40] [41].  
 
In summary, the sprouting angiogenic process (after the release of pro-angiogenic 
growth factors) can be summarized by: (1) Endothelial cell activation and 
basement membrane degradation by the production of matrix metalloproteinases 
(MMP), (2) sprout formation involving elevated endothelial cell proliferation and 
migration, and (3) lumen formation and (4) vessel stablisation and maturation by 
the production of new basement membrane and recruitment of pericytes (Figure 
1) [17].  
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Figure 5: Schematic representation of the sprouting angiogenic process. (A) Angiogenesis 
begins from an existing vessel. (B) Tip cells are selected from quiescent endothelial cells, (C) a 
filipodia forms, and a migrating column of endothelial cells move according to a cocktail of signalling 
molecules. (D) During endothelial sprouting, vacuoles form which will eventually form the lumen of 
a blood vessel. (E) Vessels undergo stabilization mediated by intracellular adhesion, and the 
coverage of mural cells. Taken from [18].  
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Non-sprouting angiogenesis 
As an alternative to sprouting angiogenesis, internal division of pre-existing 
capillaries through the insertion of trans-capillary pillars can also form new vessels 
[42]. This type of angiogenesis, known as intussusception, or non-sprouting 
angiogenesis, is known to occur during the development of different organs but 
has not yet been implicated in pathological situations, such as tumour 
angiogenesis [43].  
 
Until recently it as thought that new blood vessels could arise only from sprouting 
and non-sprouting angiogenesis. However, in 1997 it was suggested that, for the 
first time, endothelial progenitor cells (EPCs) could also be implicated in 
angiogenesis [44]. The precise role of EPCs is still not well understood, however, 
it is generally thought EPCs may derive from a subpopulation of undifferentiated 
bone marrow peripheral mononuclear cells [45]. EPCs may be mobilized into the 
peripheral circulation, and then sites of neovascularization, in response to 
haematopoietic stimulators such as VEGF or stromal derived factor-1 (SDF-1) [46]. 
Once here, the contribution of EPCs towards neo-vessel formation may range from 
5-25%, as indicated by EPC labelling experiments [47]. Therapeutic 
transplantation of human EPCs into nude mice following hindlimb ischemia will 
reduce the rate of limb loss dramatically, and also improve blood flow and capillary 
density in affected areas [48]. Dysfunctional EPCs, as in older patients or in 
diabetics, will reduce overall tissue neovascularization, thereby indicating their 
general contribution to angiogenesis [49].  
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3.1.4 Growth factor signalling pathways in angiogenesis - VEGF 
The angiogenic process is dependent upon the fine regulation of several pro- and 
anti-angiogenic factors including FGF, angiopoietins, transforming growth factor  
(TGF-), endostatin, thrombospondin-1, Delta-Notch, Ephrin-Eph and perhaps 
most importantly, VEGF [38]. VEGF is considered to be the ‘master regulator’ of 
blood vessel formation, and as such this will be the main focus of my description 
here. VEGF is responsible for several responses in endothelial cells including: 
proliferation, migration, survival, differentiation, tube formation, permeability and 
vessel formation [50]. The VEGF family comprises seven members: VEGF-A, 
VEGF-B, VEGF-C, VEGF-D, PlGF VEGF-E and VEGF-F. With the exception of 
the latter 2 members, 5 genes of the VEGF family exist in mammalian genomes, 
including humans. All members have a common VEGF homology domain [38].  
VEGF-A is the most well characterised gene of the VEGF family and has five 
alternative splicing isoforms: 121, 165, 183, 189 and 206 amino acids [50]. 
Different splice variants may display differential functions according to their distinct 
chemotactic properties, receptor specificity and tissue specific expression [51]. 
VEGF-A is unique amongst VEGF family members in that even if only a single 
copy of the VEGF-A gene is deficient (e.g. in heterozygotic VEGF-A gene 
knockout mice), the mutant embryo dies at early embryogenesis (E10-E12) due to 
immature formation and dysfunction of the circulatory system [52]. This indicates 
that the local concentration of VEGF-A in tissue is tightly regulated during 
embryogenesis, and half the level of the VEGF-A protein is insufficient to complete 
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the formation of the body’s closed circulatory system. Homozygous VEGF-A 
knockout mice die earlier than heterozygous mice, at E9, and this is due to severe 
defects in the formation of blood islands, endothelial cells and angiogenic sprouting 
[53].  
The expression of VEGF-A is ubiquitous – it is produced by several cell types 
including macrophages, keratinocytes, pancreatic cells, hepatocytes, vascular 
smooth muscle cells, embryonic fibroblasts, tumour cells and cardiomyocytes [54]. 
To this end, cell-specific VEGF-A null models exhibit a wide array of phenotypes. 
For example, VEGF-A knockout in cardiomyocytes results in hearts with: fewer 
coronary microvessels, thinned ventricular walls, depressed basal contractile 
function, induction of hypoxia-responsive genes involved in energy metabolism, 
and an abnormal response to β-adrenergic stimulation [55]. 
Among subtypes of VEGF-A, VEGF-A165 may be the most important, both 
qualitatively and quantitatively. Maes et al. reported that VEGF-A165 is essential 
and sufficient for angiogenesis because VEGF-A164 transgenic mice in a VEGF-A–
null genetic background are alive and relatively healthy [56]. VEGF120 on the other 
hand, is insufficient for normal vessel growth by itself. Carmeliet et al. 
demonstrated that homozygous VEGF120 embryos (i.e. those lacking VEGF164/188) 
died shortly after birth and the remainder gained less weight and died before 
postnatal day 14 of heart failure. VEGF120 hearts exhibited depressed myocardial 
contractility and cardiac dilation associated with severe cardiac angiogenic defects 
[57].  More recently, another subtype of VEGF-A, VEGF-Axxxb, was reported in 
humans. VEGF-Axxxb activates VEGF-A receptors much more weakly than normal 
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VEGF-A, suggesting that VEGF-Axxxb could be a physiological competitor against 
VEGF-A [58]. 
VEGF-A binds to and activates both VEGFR-1 and VEGFR-2, promoting 
angiogenesis, vascular permeability, cell migration, and gene expression. After 
activation an autocrine loop of VEGF-A and its receptor system develops within 
vascular endothelial cells, and this can further contribute to overall endothelial cell 
function [59].  
VEGF-B and PlGF bind to and activate only VEGFR-1. VEGFR-1 will bind tightly 
to its ligands but has a weak tyrosine kinase activity, and thus generates signals 
weaker than VEGFR-2. Perhaps correspondingly, both PlGF null and VEGF-B null 
mice are alive at birth and display no significant defects related to angiogenesis, 
suggesting that these genes are dispensable at embryogenesis [60] [61]. 
However, in the adult, the knockout of PlGF impairs angiogenesis and 
arteriogenesis during pathological conditions such as tumour growth, heart, limb 
and ocular ischemia [61]. In addition, VEGF-B was recently reported to improve 
cardiac function after myocardial infarction in rats [62], and VEGF-B knockout mice 
display smaller than average hearts, atrial conduction defects, vascular 
dysfunction after coronary occlusion and impaired recovery from experimentally 
induced myocardial ischemia [63]. Other studies show that VEGF-B is required for 
efficient revascularization after myocardial infarction, but not for revascularization 
of the ischemic mouse hindlimb [64] [65]. VEGF-B is also not required for 
angiogenesis in tissues other than the myocardium, such as the skin, lung, or 
retina [65]. These results indicate that, although PlGF and VEGF-B are not 
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essential at embryogenesis, they have a variety of functions under pathological or 
stressed conditions across multiple cell types. 
Unlike other members of the VEGF family, VEGF-C and VEGF-D are produced as 
immature forms and are cleaved by proteases such as furin in both the amino- and 
carboxyl-terminal portions [66] [67]. After processing, these molecules develop a 
higher affinity for VEGFR-3, but also have a weak affinity for VEGF-2 [68]. VEGF-
C is expressed during embryogenesis, whereas VEGF-D is expressed after birth. 
VEGF-C null mice show severe accumulation of fluid in tissues due to poor 
development of lymph vessels, whereas VEGF-D null mice display no obvious 
vascular defects [69] [70] [71]. In addition, VEGF-D and VEGF-C double mutant 
mice are indistinguishable from VEGF-C mutants, suggesting that VEGF-D does 
not influence vascular development [72]. However, upregulation of VEGF-D will 
promote pathological tumour lymphangiogenesis and metastasis in mouse models 
[73] [74].  
 
VEGFRs are tyrosine kinase receptors (TKRs) containing an extracellular domain 
for ligand binding, a transmembrane domain, and a cytoplasmic domain, including 
a tyrosine kinase domain. VEGFR-1 has a much weaker kinase activity than 
VEGFR-2, and the signalling cascade is not fully understood. Ligand binding to 
VEGFR-2 induces dimerization and autophosphorylation at multiple tyrosine 
residues within its intracellular domain. Two major autophosphorylation sites 
include Y-951 and Y-1175 [75] [76].  
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Both VEGFR-1 and -2 are mainly expressed on endothelial cells. However, 
VEGFR-1 is also expressed on trophoblast cells, monocytes, and renal mesangial 
cells, whilst VEGFR-2 has been detected on megakaryocyte. At later 
developmental stages, the blood vascular expression of VEGFR-2 decreases, and 
in adults, is upregulated under pathological conditions such as tumour 
angiogenesis [77] [78].  
Deletion of VEGFR-2 in mice leads to embryonic lethality between E8.5 and E9.5 
due to a lack of blood island formation in the yolk sac, an absence of 
vasculogenesis and severe defects in the development of endothelial and 
haematopoietic cells [79], indicating an essential role in developmental 
angiogenesis and haematopoiesis.  
The primary function of VEGFR-1 appears to be that of a VEGF-trap, to fine tune 
the amount of VEGF-A acting on VEGFR-2. Evidence for this comes from VEGFR-
1 knockouts. Mice here die at E8.5 because of increased proliferation of 
endothelial cells that fill and obstruct the vessel lumen [80]. The underlying 
mechanism is believed to involve excess stimulation of VEGFR2 by the higher 
availability of VEGF-A.  
 
VEGFR-3 is almost exclusively expressed by lymphatic endothelium in the adult 
but is upregulated in blood vascular endothelium during certain pathologies, 
including chronic inflammation and tumour angiogenesis [81]. In early 
development, VEGFR-3 is expressed in both blood and lymphatic endothelial cells 
[82]. Furthermore, VEGFR-3 is expressed in non-endothelial cells, including 
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neuronal progenitors, macrophages and osteoblasts [82] [83]. After its activation 
by VEGF-C or -D, VEGFR-3 will either form homodimers or a heterodimer pair with 
VEGFR-2. The relative contribution of VEGFR-3 homodimers versus VEGFR-3/R-
2 complexes to activation of various intracellular signalling pathways and cell 
biology has not yet been established. 
Deletion of VEGFR-3 in mice results in embryonic lethality at E9.5 due to 
cardiovascular failure [84]. Vasculogenesis occurs in these embryos but 
remodelling of the primary vascular plexus is severely defective [84].  
 
3.2 The Cardiac Vasculature 
 
3.2.1 Cardiac vascular expansion during development and adulthood 
Because of its critical role in nutrient and oxygen delivery, the heart is one of the 
first organs to develop in the embryo. Heart development begins with the formation 
of an avascular, primitive tube which consists of a thin layer of cardiomyocytes and 
is lined by endothelial cells. At this early stage, oxygen is delivered to 
cardiomyocytes via simple diffusion across the endothelium, but as the 
myocardium becomes thicker (through cellular proliferation), oxygen delivery via 
diffusion becomes insufficient, and a dedicated primitive vascular plexus forms. 
Soon after, the proepicardial organ (PEO) will attach to the heart, and proepicardial 
mesothelial cells will begin to migrate and envelop the surface of the developing 
heart, giving rise to the primitive epicardium and subepicardial space [11] [85]. 
Genetic ablation of PEO results in the absence of epicardium and abnormality of 
the coronary vascular system [86]. Next, a subpopulation of epicardial cells will 
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delaminate from the epicardial epithelium and undergo epithelial-mesenchymal 
transition, generating a number of migratory mesenchymal cells, (epicardium 
derived cells – EPDCs), that populate the subepicardial space and subsequently 
the myocardium. It is thought that EPDCs give rise to cardiomyocytes and a range 
of coronary vascular cells [87] [86]. Endothelial precursor cells within the 
subepicardial space migrate over the heart and coalesce into cords to form a 
primitive vascular plexus.  This undergoes extensive remodelling, ramification and 
patterning to form a developed network that resembles the mature coronary artery 
tree. Vessel growth is then directed towards the aorta, where the two networks will 
eventually intersect and amalgamate [88]. Once perfused, these capillaries 
remodel into larger vessels, mesenchymal cells are recruited, and vessels are 
further subdivided into a more organized network of specialized vessels of varying 
size.   
 
At birth, the majority of cardiomyocytes discontinue the cell cycle and become 
quiescent [89], although some will retain a very low proliferative capacity [90]. 
Subsequent growth of the heart is achieved through cardiac hypertrophy of 
individual myocytes, meaning embryonic myocardial tissue mass possesses only 
a fraction of the thickness that it will hold in later life [89]. As a cardiomyocyte 
hypertrophies, its oxygen and nutrient demands begin to rise. This is compensated 
for by a significant expansion of the myocardial vasculature [13]. Murine capillary 
density will increase three- to fourfold in the first 3 weeks of development and the 
number of smooth muscle cell-covered coronary vessels increases tenfold over 
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the same period [91]. Additionally, increasing cardiac vessel density in the absence 
of other stimuli can solely drive cardiac tissue growth. Transgenic overexpression 
of pro-angiogenic PR39 in mice will increase myocardial hypertrophy in tandem to 
increasing cardiac endothelial cell mass and capillary number [92].  
In contrast to active vessel growth in the embryo and newborn, the adult 
myocardium remains in a quiescent state. Only when provoked by cardiac 
stressors or pathological conditions will vascular beds expand or contract. It is 
generally thought that adult vascular expansion can be generated by three 
relatively distinct, but complementary mechanisms, termed: collateral 
enlargement, angiogenesis and postnatal vasculogenesis [93].  
Collateral enlargement describes the in-situ development of large collateral 
vessels from pre-existing arteriolar anastomoses, leading to neovascularization 
between the two areas. One of the most important initiators of collateral 
enlargement is shear stress [94], and not ischemia as in angiogenesis or 
vasculogenesis. Because of this, collaterals are usually located near to 
obstructions, or occlusions of major arteries, where they act as a conduit between 
anastomoses to restore blood flow. Collaterals have been shown to preserve 
myocardial function, limit infarct size, and positively influence post-infarct 
remodelling in the heart [95].  
 
Vascular remodelling in the adult heart 
Despite previously held dogma, it is now known that active vasculogenesis and 
angiogenesis will occur in the adult heart. The primary initiator is thought to be 
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hypoxia, and many of the angiogenic processes responsible are thought to be the 
same as in development.  Although vascular beds are capable of a significant 
expansion through these mechanisms, its capacity to do so is limited, and this can 
result in relative local ischemia due to an imbalance in rates of oxygen supply and 
cellular metabolism.  If ischemia becomes too severe, over time tissue will die and 
are replaced by a less compliant fibrotic tissue, instead of contractile 
cardiomyocytes [96].  
 
3.2.2 The molecular regulation of cardiac blood vessel development 
Relatively few factors have been described as specifically important for overall 
cardiac vessel development. During coronary vessel development, one such 
essential factor is the transcription factor GATA-4 and its co-factor FOG-2. GATA-
4 is present in both the endocardium and myocardium of the developing atria and 
ventricles, and FOG-2 is expressed similarly. Both GATA-4 and FOG-2 null mice 
display an intact epicardium but lack any form of coronary vasculature or 
epicardial-derived cells [97] [98]. This suggests that FOG-2/GATA-4 interaction is 
essential for the initiation of EMT within the proepicardium, and thus the 
development of coronary vasculature. In addition, VCAM-1 and 4 integrin is also 
indispensable for coronary vessel development. VCAM-1 and 4 integrin null mice 
display very similar phenotypes. In both, the formation of the epicardium is 
severely inhibited and no subepicardial vessels develop [99] [100]. Cells from the 
PEO often fail to leave the PEO, and if they do, are unable to adhere to the heart 
or migrate out to form the epicardium. Collectively this demonstrates that VCAM-1 
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and 4 integrins are essential for migration of PEO cells and epicardial formation 
and migration thereafter.  
Both VEGF-A homozygote and heterozygote knockout embryos are unable to 
survive to term due to general impairment of blood vessel formation in the early 
embryo [50]. This makes it difficult to assess VEGF-A function during postnatal 
angiogenic processes by conventional transgene technology. However, VEGF-
A120 mice, where VEGF-A164/188 isoforms are absent, will survive to term and 
instead die postnatally due to cardiac failure associated with severe heart ischemia 
[57]. These mice almost totally lack any form of postnatal capillary or coronary 
vessel growth, and those cardiac vessels that were present were severely 
defective. Postnatal ablation of total VEGF-A function by administering soluble Flt-
1 receptor antagonist is also lethal. In the heart this leads to cardiomyocyte 
necrosis and a massive reduction in cardiac capillary density [101]. Together these 
experiments illustrate the importance of VEGF-A in postnatal cardiac vessel 
expansion, and in particular the significance of VEGF-A 164 and 188 isoforms.  
VEGF-B transcripts are expressed predominantly (but not exclusively) in the heart 
during murine embryogenesis and throughout adult life [102], thus it is likely that 
VEGF-B plays an important role in cardiac angiogenesis and vessel growth. In the 
developing heart, VEGF-B protein is first detected at E8.5 in mice [103]. This 
closely correlates to the commencement of coronary endothelial growth. 
Thereafter, it appears that capillary density follows VEGF-B expression levels, 
whereby the highest capillary density rates correlate to areas of highest VEGF-B 
expression, both before and after birth. By the time VEGF-B rates become 
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relatively even throughout the heart any regional disparities in capillary growth is 
lost.  
VEGF-B null mice overall appear relatively healthy and normal and display no 
overall defects in vasculogenesis during embryogenesis. The hearts of these mice 
appear morphologically and functionally similar after birth but are significantly 
smaller than VEGF-B+/+ littermates at all postnatal time points [63]. Since 
postnatal heart growth appears to be mainly due to increases in the coronary 
microvasculature and associated vessels, you would expect that VEGF-B null mice 
would display defects in vessel density, but this was not the case. In fact, capillary 
and coronary vessel density appeared normal. This study demonstrates that 
VEGF-B likely plays an important but redundant role in postnatal and embryonic 
cardiac vessel growth. As VEGF-B can form stable heterodimers with VEGF-A, 
and the two are generally co-expressed it is likely that VEGF-B absence is 
compensated for by functional VEGF-A, and thus VEGF-A is a more potent driver 
of cardiac vessel growth. More recent studies show that VEGF-B is required for 
efficient revascularization after myocardial infarction, but not for revascularization 
of the ischemic mouse hindlimb [65]. The cardioprotective effect of exogenous 
VEGF-B has also been documented elsewhere by multiple groups [92] [62], further 
reinforcing the notion that VEGF-B is a vital element of pathological cardiac vessel 
formation, particularly after MI.  
 
Findings obtained from mouse models and human diseases with FGF signalling 
disorders indicate that several FGFs are involved in myocardial vessel 
 76 
development during embryogenesis, adulthood and disease. Chief amongst these 
are FGF-1 and -2. FGF-2 null mice are healthy and display relatively little overt 
defects in global vasculogenesis or angiogenesis. However, after cardiac stress, 
such as during aortic banding, mice exhibit reduced cardiomyocyte hypertrophy 
and interstitial fibrosis [104]. Furthermore, deletion of FGF-2 markedly worsened 
the process of myocardial infarct repair, whilst its over expression curbed infarct 
expansion and preserved LV function also after MI [105]. In the latter experiments, 
overexpression of FGF-2 increased endothelial cell proliferation and myocardial 
revascularization, whilst vascular density was reduced significantly in FGF-2 
knockout hearts. Both FGF-1 and -2 expressions closely correlates to areas of 
myocardial revascularization after MI. Here, angiogenesis is initiated at the border 
zone between infarcted and non-infarcted myocardium and then extends into the 
infarcted myocardium. It is most evident in the first week post-MI and then begins 
to slow. Zhao et al. show that FGF-1 and -2 follow this pattern – FGF protein 
increased up until day 7 post MI and then declined, and expression moved from 
the border zone to the infract zone with time [106]. In addition, transgenic 
myocardial overexpression of FGF-1 increases coronary artery density and 
branching [107], which again reinforces the notion that FGF is an important 
mediator of cardiac vessel formation.  
Overall, the roles of FGF and VEGF during early coronary angiogenesis may be 
subtly different. This was assessed in an informative study by Tomanek et al. Here, 
inhibitory antibodies were used to determine that both VEGF and bFGF modulate 
capillary growth, but only FGF will specifically facilitate arteriolar growth. 
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Additionally, both factors need to be present in order to properly establish the 
normal hierarchy of the arteriolar tree [108]. As a caveat to all of this it should be 
noted however that the antibodies used in this study did not specifically inhibit their 
own target – for example both anti-VEGF and anti-FGF antibodies decreased 
VEGF protein, and both demonstrate differential effects on mRNA quantities – this 
should be minded when analysing this data.  
 
3.2.3 Vascular changes during cardiac disease 
Heart failure occurs when the heart is unable to provide sufficient blood flow to the 
body’s organs and is a final common pathway of various cardiovascular diseases, 
including sustained pressure overload (i.e hypertension), myocardial infarction or 
ischemia, volume overload (i.e. valvular disease), and inherited/acquired 
cardiomyopathies. Across many of these pathologies, it has been observed that 
the affected tissues may present with lower capillary number versus a healthy 
counterpart [109].  In addition, the transgenic knockout of pro-angiogenic 
molecules, in particular VEGF, can worsen cardiac pathology in animal disease 
models, including: pressure overload [110] and isoprenaline induced cardiac 
hypertrophy [55]. Similarly, the downregulation of pro-angiogenic factors (such as 
VEGF), as in old age, can itself worsen or initiation cardiac pathology [111]. By 
contrast, increasing angiogenesis has been proven to provide cardioprotective 
effects [112, 113].  
The suppression of capillary density and angiogenesis in the myocardium may be 
specifically involved in the transition from compensated, to decompensated heart 
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failure and disease. For example, in a pressure overload induced model of heart 
failure, HIF-1, a key transcription factor involved in the cellular response to hypoxia 
and therefore angiogenesis, is first up regulated within 14 days post-surgery in 
conjunction with a rise the number of cardiac microvessels. However, over the 
course of a prolonged cardiomyopathy (i.e. 28 days post-surgery), HIF-1 and 
VEGF were down regulated despite a persisting hypoxia and myocardial ischemia, 
leading to a reduction in cardiac microvessel density relative to day 14 values (i.e. 
a more acute cardiomyopathy). Day 28 hearts, or those hearts with fewer cardiac 
microvessels, proved to perform worse relative to day 14 hearts, or those with 
more cardiac microvessels [114]. The paradoxical down regulation of HIF-1 in such 
hearts despite an ongoing hypoxia may be due to accumulating levels of the 
tumour suppressor gene p53 in hypertrophied cardiomyocytes. An indication for 
this comes from observations in other cell types. One notable experiment showed 
that the homozygous deletion of murine p53 in tumour engrafted nude mice will 
lead to augmented HIF-1α activity, and therefore increased tumour 
neovascularization, and increased tumour volume [115]. In addition, the 
expression of p53 is markedly up regulated in the myocardium following pressure 
overload induced heart failure, and this is associated with an increase in cardiac 
markers of dysfunction, as well as a reduction in myocardial HIF-1α and 
angiogenesis [114]. Similarly, Shiojima L et al. show that coronary angiogenesis is 
enhanced during the acute phase of adaptive cardiac growth but reduced as hearts 
underwent pathological remodelling [116]. Enhanced angiogenesis in this study 
was associated with rapamycin-dependent induction of myocardial VEGF and 
 79 
angiopoietin-2 expression. As such, inhibition of angiogenesis with a decoy VEGF 
receptor in the acute phase of adaptive cardiac growth led to decreased capillary 
density, contractile dysfunction, and impaired cardiac growth.  
Together the experiments outlined here illustrate that both heart size and cardiac 
function are angiogenesis dependent, and disruption of coordinated tissue growth 
and angiogenesis in the heart contributes to the progression from adaptive cardiac 
hypertrophy to heart failure.  
 
In tandem to changes in total microvascular density there are also a number of 
changes to microvascular anatomy following cardiac disease. Most recently, 3D 
automated image analysis has used VE-Cadherin labelling of porcine cardiac 
sections to reconstruct a complete template of the microvasculature which has 
been used to analyse MI [117]. MI elicits intensive structural remodelling 7 days 
post MI which begins to deteriorate by 45 days post MI. In functional terms this 
led to low capacity for blood flow and long diffusion distances, leading to worse 
oxygenation in surrounding tissue. Furthermore, individual micro vessels were 
larger in diameter and had an increased number of endothelial cells per unit 
length, likely reflecting adaptation to persistent high flow in those remaining 
vessels. Interestingly, microvessels at day 3 post MI exhibit the most structural 
similarity to basal controls, whilst day 1 and 7 post MI vessels were very different 
in their densities and size to both basal, and day 3 microvessels. Vessels in the 
infarct region were most dilated at day 1, began to constrict at day 3 and then 
were pruned and arterialized by day 7. There was some increase in 
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microvasculature density at day 1 post MI, but overall the number of 
microvessels, and especially capillaries, declined by day 7 in the infarct zone. 
Finally, vessels outside the infarct and border zone remain minimally changed.  
 
The latter end of vascular remodelling after injury in the heart is indicated by the 
recruitment of pericytes. Pericytes associating with newly formed blood vessels 
thus represents the final stage in vessel maturity and establishes a functional 
blood vessel proper. Prior to this, the endothelial plexus exists as a plastic 
structure which can be pruned or added to according to available oxygen as 
previously described. Pericytes prevent this and thus stabilize the vasculature 
[118]. In aortic banding models, pericytes associate with the vasculature as early 
as day 2 post-surgery, which coincides with the start of deleterious cardiac 
remodelling in this study. This indicates that there is a physiological attempt to 
stabilize vessels during a period where the number of vessels is in decline. By 
day 7, which is coincident with the end of deleterious cardiac remodelling here, 
pericyte coverage returns to normal levels as does microvessel density [119]. 
Collectively this illustrates the importance of not only vessel density during 
cardiac recovery, but also their structure and maturity.  
3.2.4 The cardiac endothelial cell and Cilengitide 
Endothelial cells are the theme that ties our projects together. Between organs and 
vascular beds, they are a highly specialized cell type that displays marked 
diversity. A recent interesting study aimed to assess their transcriptome by RNA-
seq. Here, Lother et al. reveal that cardiac endothelial cells exhibit a distinct gene 
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expression profile versus renal, cerebral or pulmonary ECs. From a pathway 
perspective, enriched elements include: cytokine-cytokine receptor interactions, 
ECM-receptor interaction, fatty acid transport, PPAR (peroxisome proliferator-
activated receptor) signalling and haematopoietic cell lineage pathways [120]. 
Overall, this study provides salient evidence of heterogeneity between organ-
specific ECs, but what is of particular interest to me is the fact that ECM-receptor 
interactions are significantly upregulated here versus other ECs.  
 
Our hypothesis hinges upon the fact that integrins within the cardiac endothelial 
cell are present and can be therapeutically modified by Cilengitide. Cilengitide is a 
cyclic pentapeptide [cyclo(RGDf-N(Me)V)] developed initially as an anti-
angiogenic therapy. Versus (non-specific) linear peptides, cyclic RGD 
peptidomimetics show substantial specificity and activity (where RGD relates to 
the amino acid sequence - arginine, glycine, aspartame). Indeed, in comparison to 
the linear control peptide GRGDS, c(RGDfV) showed increased inhibition of A375 
cell adhesion to laminin P1 (20-fold) and to Vitronectin (100-fold), and increased 
specificity for αvβ3 (versus αIIbβ3) [291]. The tripeptide sequence Arg-Gly-Asp is 
the main pharmacophoric feature that facilitates these properties. Arg and Asp 
residues promote ionic interactions with the receptor (with the carboxylate of Asp 
coordinating divalent cations) and the Gly imposes steric restrictions [291]. The N-
methylation of c(RGDfV) to ‘make’ Cilengitide - c(RGDf-N(Me)V) increases the 
selectivity for αvβ3 versus c(RGDfV) alone and increases its affinity for αvβ5 [291]. 
More generally, N-methylation is used to enhance the biological activity and 
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selectivity profile of peptides and to overcome their pharmacokinetic limitations i.e. 
increasing their metabolic stability and bioavailability [291]. Figure 6 shows the 
chemical structure of Cilengitide (PubChem).  
Cilengitide acts as a highly potent inhibitor of angiogenesis and induces apoptosis 
of growing endothelial cells via the inhibition of the interaction between integrins 
with their ECM ligands [290] [291]. Cilengitide has been shown to influence cellular 
adhesion to αvβ3 ligands, to induce increased apoptosis after detachment of αvβ3 
and αvβ5 expressing cells in vitro and to block the growth of human xenografts in 
nude mice [291]. Additionally, at high doses Cilengitide displays anti-angiogenic 
and anti-tumour activity in various animal models through a significant reduction of 
functional vessel density and retardation of tumour growth and metastasis in vivo 
[290] [291].  
Cilengitide has entered multiple clinical trials as an anti-cancer therapy, both as a 
single agent and in in combination with radio-chemotherapy treatment. Its 
administration in humans has proven to be safe, even when co-administered with 
cytotoxic agents [291]. However, it has been removed from recent clinical trials 
(most notably the CENTRIC trial [250]) due to not meeting its clinical end point 
(usually of overall survival). Because of this, the authors of the CENTRIC trial 
recommended not pursuing further testing of Cilengitide in future anticancer clinical 
trials [250]. Some authors have refuted this claim, citing that the CENTRIC trial 
should have instead given Cilengitide twice a week, as doses of once a week would 
restrict its anti-angiogenic properties [424]. In line with this rebuttal, we postulate 
that the reason for Cilengitide’s failure to meet its clinical end points is that, in 
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contrast to a high dose Cilengitide treatment regimen, low dose Cilengitide 
paradoxically exerts a VEGF-mediated pro-angiogenic effect on the tumour 
vasculature [4]. Indeed, Reynolds et al demonstrated that, mechanistically, low 
dose Cilengitide does not act as an αvβ3-integrin antagonist and accordingly does 
not affect cell adhesion or migration, but instead alters αvβ3-signalling to enhance 
the activation and recycling of the major pro-angiogenic receptor VEGF-receptor 2 
[4]. In addition, Reynolds et al implicate the Rab4a recycling pathway as part of 
this process. They find that the suppression of Rab4A clearly opposes the effects 
that low doses of αvβ3/αvβ5 inhibitors have on VEGFR2 and αvβ3 integrin 
recycling, VEGFR2 degradation, endothelial cell migration and angiogenesis [4]. 
This suggests that low doses of RGD-mimetic αvβ3/αvβ5 inhibitors promote 
endothelial cell migration to VEGF by promoting the Rab4A-mediated recycling of 
both αvβ3 integrin and VEGFR2.  
Most recently, Wong et al. have exploited the features of low dose Cilengitide to 
improve chemotherapy efficacy in cancer models in vivo by increasing tumour 
blood vessel number and directly enhancing chemotherapy delivery and 
metabolism in malignant cells [5]. In combination with the Reynolds study this 
suggests that low dose Cilengitide treatment could be used as a strategy to affect 
αvβ3-integrin signalling without affecting cell adhesion and migration. 
One must be cautious in translating the results of mouse studies to humans 
however, as the metabolism of Cilengitide is highly specific between species [425]. 
Here, Cilengitide proved to be minimally metabolised in vivo in animals and 
humans, but there was a significant difference in the excretion of Cilengitide [C14] 
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between all species, both renally and via biliary routes [425].   
 
 
 
Figure 6: Chemical Structure of Cilengitide (PubChem).  
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3.3 Therapeutic Angiogenesis 
 
3.3.1 Angiogenesis as a potential therapy 
Therapeutic angiogenesis aims to induce, augment and regulate the host 
angiogenic response in order to re-vascularize ischemic tissues, and usually 
involves the delivery of growth factors and/or stem/progenitor cells. Growth factors 
may be delivered as whole proteins or more recently as genes encoding target 
proteins. Cells may be delivered in isolation, alongside other cells, as part of a bio-
scaffold or in conjunction with pro-angiogenic growth factors. Despite intensive 
efforts and a wealth of positive pre-clinical data, clinical trials testing the pro-
angiogenic potential of various molecules and cell-based therapies have not yet 
achieved the expected results. Although part of this failure may be attributable to 
suboptimal delivery strategies, stimulating the growth of durable and functional 
vessels is a more formidable challenge than was anticipated. Anti-angiogenic 
therapy similarly has faced problems, particularly in cancers. This may be, at 
least in part, due to acquired resistance to anti-angiogenic agents, or the 
potential for anti-angiogenics to minimize the effective delivery of co-delivered 
chemotherapies. Despite this, therapeutic angiogenesis remains a promising 
strategy. The following sections will outline current pro-vascular therapies in 
myocardial ischemia and discuss their relevance and mechanisms.  
 
3.3.2 Growth factor therapy in heart disease 
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Various growth factors have been utilized for therapeutic angiogenesis including 
FGF, VEGF, PDGF, PlGF, hepatocyte growth factor (HGF), angiopoietin-1 and 
insulin-like growth factor (IGF-1). Among these, VEGF and FGF are arguably the 
most well-studied and have reached human clinical trials [121] [122]. As the 
probable master regulator of physiological angiogenesis, one would expect that 
VEGF would be the most potent and viable choice of pro-angiogenic growth factor. 
However, when delivered alone VEGF will actually lead to the formation of leaky, 
unstable and relatively sub-functional microvessels [123]. Co-delivery with 
angiopoietin-1 [124] or PDGF-B [125] can improve this by helping to stabilize newly 
formed nascent vessels with mesenchymal cells. Similarly, the microvasculature 
of VEGF-PlGF chimeric mice was significantly denser, less leaky, contained fewer 
local inflammatory factors and were more stable than VEGF-transgene controls 
[126]. Combining growth factors as a single adjunctive therapy will in future allow 
clinicians to ‘match’ synergistic growth factors to induce maximal clinical efficacy. 
A summary of growth-factor induced cardiac regeneration mechanisms is given 
below (table 13). 
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Factor Mechanism Reference 
VEGF Angiogenesis [127] [121] [128] 
FGF Angiogenesis [129] [130] [122] 
HGF Anti-apoptosis 
Cardiac stem cell chemotaxis and 
activation 
[131] [132] 
SDF-1 Hematopoietic stem cell 
mobilization and homing 
[133] 
IGF-1 Cardiac stem cell viability and 
differentiation 
[134] 
PDGF Anti-apoptosis [135] 
G-CSF Hematopoietic stem cell 
mobilization and homing 
Anti-apoptosis 
[136] 
Angiopoietin Angiogenesis and vascular 
stabilization 
[137] 
Neuregulin Cardiomyocyte proliferation [138] 
Erythropoietin Anti-apoptosis [139] 
Table 13: A summary of growth-factor induced cardiac regeneration mechanisms.  
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To date, there have been a number of pre-clinical and clinical studies evaluating 
the safety and efficacy of growth factors for inducing angiogenesis in ischemic 
heart disease and peripheral arterial disease (PAD) [140] [141] [142]. Early phase 
I and II human clinical trials with VEGF and FGF were promising, but larger 
randomized placebo-controlled trials failed to demonstrate significant benefits in 
the approved clinical end-points. Preclinical data demonstrate that the delivery of 
FGF or VEGF eventually results in unstable vessel growth that resembles 
immature tumour vasculature. The limited clinical response to growth factor 
therapy is likely due to a number of factors. Growth factor therapy is generally 
limited by poor biostability, rapid diffusion high cost and short half-lives in vivo. 
Furthermore, such approaches often require supraphysiological doses or multiple 
injections to sustain long-term function. This could lead to excessive uncontrolled 
vascular formation in non-affected tissues, which may precipitate various 
pathologies and exacerbate existing disease conditions.  
 
The growth factors delivered during gene transfer therapy are often the same as 
in protein therapy (VEGF, FGF etc) [143] [144]. Gene therapy currently utilizes 
three distinct mechanisms of delivery – naked DNA, virus or liposome. Of these, 
delivery of naked DNA is clearly the most simplistic (and cheapest) of the three, 
but is hindered by low rates of transfection, limited protein generation in tissue of 
interest, and lack of a predictable dose response. Liposome and viral delivery on 
the other hand should theoretically induce greater levels of transfection than naked 
DNA delivery alone. Not only is the gene of interest encapsulated and protected, 
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but genes can be tagged and imaged in vivo, and also directed to their target of 
interest using tissue specific vectors. However, viral vectors may induce an 
immunogenic response in the host and may also produce only a short-term 
response. New generations of viral vectors aim to be less immunogenic and 
demonstrate longer tissue-specific expression [145].  
Gene transfer therapy in clinical trials have shown mixed results. Phase I clinical 
trials have demonstrated that VEGF gene therapy is safe in humans in both 
myocardial and peripheral ischemia [146], but its efficacy is controversial. Naked 
delivery of VEGF165 in patients with critical limb ischemia will improve wound 
healing, perfusion and increase limb salvage rates [147]. Similarly, adenoviral- and 
plasmid-VEGF165 delivery by intravascular catheter demonstrates significant 
improvement in patients experiencing peripheral vascular disease [147]. Also, 
transthoracic intramyocardial injection of adenoviral VEGF-2 delivery resulted in 
some clinical improvement in angina patients [148]. Interestingly the latter study 
was not associated with any evidence of myocardial angiogenesis which suggests 
that VEGF may have alternative beneficial effects outside of simple 
neovascularization. However, the NORTHERN trial, which assessed the 
intramyocardial delivery of adenoVEGF165, demonstrates that this provided no 
overall benefits in any of the end points measured [149]. In addition, the ‘Euroinject 
One’ phase II clinical trial, which also measured the efficacy the intramyocardial 
delivery of plasmid-VEGF165 similarly did not achieve any of its clinical end points 
[150]. 
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Human clinical trials investigating the therapeutic role of FGF gene therapy remain 
as mixed as VEGF data. In phase II clinical trials, the intramuscular injection of 
adenoFGF-1 to patients with critical limb ischemia reduces amputation rates by 
39% versus placebo alone [151]. In prospective, blinded studies, intramyocardial 
delivery of sustained-release adenoFGF-2 in non-revascularizable myocardium 
(i.e. myocardium that cannot be revascularized) at the time of coronary artery 
bypass grafting (CABG) demonstrates a significant improvement in angina and 
reduction in residual ischemic myocardium [152]. Furthermore, phase II, 
randomized clinical trials assessing the efficacy of intra-coronary infusion of 
plasmid-FGF-2 (FIRST [122]) and adenoFGF-4 (AGENT [153]) demonstrate 
symptomatic angina relief in patients but failed to show a statistically significant 
increase in either exercise tolerance or myocardial perfusion.  
Most recently, porcine models with significant endothelial dysfunction show 
dramatically decreased cardiac angiogenesis in response to FGF, suggesting 
that coronary endothelial dysfunction is limiting clinically effective angiogenesis 
[152]. Voisine et al. have demonstrated that L-arginine supplementation can 
partially restore the myocardial angiogenic response to FGF [154]. These findings 
suggest that the endothelial dysfunction present in clinical settings may limit 
efficacious therapy with FGF and other pro-angiogenics, and also highlights the 
importance of utilizing animal models with common cardiac co-morbidities. This 
may explain the marginal, and mixed, results that have been witnessed thus far in 
phase II myocardial clinical trials. Further study of synergistic cytokine delivery 
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utilizing vasodilatory adjuncts, such as L-arginine, may potentiate both myocardial 
angiogenesis and function in future clinical trials. 
3.3.3 Cell therapy 
Much research has been undertaken to more fully understand the reparative and 
regenerative potential of stem/progenitor cells in ischemic heart disease. The 
advantage of this approach is that not only will exogenous cells replace and/or 
supplement native cells, but they can also secrete paracrine factors to support 
those cells, leading to improvement in their function. Transplanted cells also 
secrete exosomes containing proteins, RNA and microRNAs which stimulate both 
receptor-mediated and genetic mechanisms that contribute significantly toward 
paracrine support of native cells [155].  The paracrine effect of stem/progenitor 
cells inhibits cell death, enhances cell proliferation, activates resident 
stem/progenitor cells in the ischemic tissue, and recruits additional stem/progenitor 
cells to the ischemic site [156]. The cells furthest along in clinical development so 
far are adult stem cells – namely endothelial progenitor cells (EPCs). EPCs 
constitute a mixed population of progenitor cells of different lineages. Within this 
population are true endothelial cells that can incorporate into the vascular network, 
and haematopoietic progenitors, which may instead contribute to vascular 
remodelling by secreting pro-angiogenic cytokines. It is thought that EPCs can be 
divided into two categories: H-EPCs and non-H-EPCs. Non-H-EPCs are the 
minority of EPCs. They are derived from non-canonical cell sources, including 
adipose tissue, blood vessel walls, spleen, kidney and the liver. They are defined 
as being CD34/CD31- but despite this can differentiate into endothelial cells and 
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promote angiogenesis. H-EPCs on the other hand fall into the canonical, and most 
well characterized EPC population [157]. They express classic CD34/CD133+ 
markers and are probably maintained in the bone marrow. Studies show H-EPCs 
are likely derived from haemangioblasts, and they will circulate in the blood at very 
low levels. Their prevalence in the blood can change according to a variety of 
stimuli including ischemia and shear stress, which alone are sufficient to mobilize 
EPCs to leave the vascular niche. Key endogenous mobilization factors include 
HIF, NO, VEGF (ischemia) and NF-kB (shear stress). It is important to note that 
the exogenous mobilization of EPCs is usually achieved using techniques such as 
granulocyte colony stimulating factor (G-CSF) or granulocyte-macrophage colony 
stimulating factor (GM-CSF), meaning that EPCs throughout may be described by 
both their method of mobilization (e.g. G-CSF) and where they were mobilized from 
(e.g. bone marrow). Regardless, after mobilization EPCs will enter the vasculature 
and hone to the site of ischemia, where they will either: a) incorporate into the pre-
existing vascular plexus and form endothelial cells, pericytes, or smooth muscle 
cells or b) potentiate local angiogenesis by releasing paracrine factors into their 
surroundings [158].  
One attractive feature of EPCs is that numerous studies show that they can be 
harvested, expanded and then re-administered to the same person they were 
isolated from [159]. Autologous transfer should in theory induce significantly less 
immunogenicity than in allogeneic implants. Since EPCs are isolated from adult 
tissues and are not derived from foetal tissues, they also face no major ethical 
concerns. Furthermore, as adult stem cells, their differentiation potential is limited 
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down a particular developmental lineage, meaning there is much lower risk for 
aberrant tissue formation and tumorigenesis. On the other hand, cell-based 
therapies still face several limitations. Upon isolation, the cell population can be 
very heterogeneous, which is worsened by the fact that there is not yet a strict 
protocol for the cell isolation of EPCs. This can lead to adverse effects, including: 
microvascular embolism, pathological neovascularization and malignancy. In 
addition, to obtain the large cell numbers needed for transplantation, ex vivo cell 
expansion is often required, which leads to regulatory concerns and increased cost 
and time, thereby increasing the barriers for clinical translation. This not only 
means that there is a delay in treatment due to the time needed to collect and 
expand cells, but ‘old’ EPCs demonstrate reduced proliferation (both ex vivo and 
in vitro), and also reduced capacity to integrate into existing capillary networks 
[160]. The patients that often require EPC therapy the most are usually older 
individuals, meaning that it is often difficult to expand their cells to the required 
amount. They often also present with multiple co-morbidities including diabetes 
(and old age itself), which itself impairs angiogenic functionality and induces EPC 
dysfunction. Interestingly, chronic insulin therapy may increase circulating levels 
of EPCs in diabetic patients [161], which suggests we may be able to enhance 
EPC therapy in these patients with synergistic co-factors. Furthermore, the cell 
engraftment efficiency is typically very low upon transplantation and may vary 
greatly between patients. Not only might this induce a supraphysiological (or 
inflammatory) response, but it also makes it very difficult for clinicians to predict a 
physiological response for a given ‘dose’ of cells.  
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Pre-clinical studies in animal models illustrate a wealth of data demonstrating the 
effectiveness of EPC transplantation after ischemic injury. In one seminal study 
Kocher et al. show that the intravenous injection of labelled human CD34+ bone 
marrow-derived cells into rats after MI surgery (LAD-ligation) significantly 
enhanced neoangiogenesis in the infarct zone and estimates that around 25-30% 
of new vessels were composed of labelled cells.  Therapy led to a 3-fold 
improvement in left ventricular ejection fraction versus controls [162]. Similarly, 
Orlic et al. observed that pre-treatment of mice with bone marrow progenitor cells 
will enhance survival from 20%-90% four weeks post-MI, with evidence that all 
components of the injured myocardium were restored, including blood vessels and 
even cardiomyocytes [163]. In parallel, multiple studies also observe that EPCs 
are able to repair large vessels after injury or atherosclerosis. Here, EPCs will 
engraft onto balloon damaged carotid arteries and rapidly re-endothelialise 
denuded areas, leading to salient improvements in vessel morphology and function 
[164]. Furthermore, lacZ labelled EPCs colonize vein grafts in the carotid arteries 
of ‘healthy’ mice. Interestingly the levels of engraftment were lower in 
atherosclerotic (ApoE-/-), hyperlipidaemic mice, which coincides with lower 
circulating levels of EPCs in those same mice [165].  Chronic treatment of elderly 
atherosclerotic mice (ApoE-/-) with young, (but not ‘old’) non-atherosclerotic bone 
marrow derived progenitor cells halts the progression of atherosclerosis despite 
persistent hypercholesteremia [166]. Following on from these early findings it was 
shown that by engineering the longevity of transplanted cells we can drastically 
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enhance their reparative capacity. Mangi et al. show that engineering rat 
mesenchymal stem cells to overexpress pro-survival Akt will regenerate ischemic 
myocardium up to four times more effectively than in controls [167]. Other groups 
report similar findings [168] [169]. This raises the question as to whether or not 
EPCs themselves can be modified to survive for longer, and if they can, will doing 
so enhance their revascularization ability over time? 
These and other studies show that EPCs can be used to enhance therapeutic 
angiogenesis and repair vascular injury in a wide variety of experimental animal 
models. The exact mechanisms of this is still not entirely understood, but cell-
therapy was quickly transferred into clinical trials after those early experiments 
described. In humans, vascular regeneration has so far been attempted using 
autologous bone marrow mononuclear cells (BMNCs), G-CSF-expanded 
peripheral blood mononuclear cells (PBMNCs), human umbilical derived adult 
stem cells and fractionated EPCs. Other cell-types have been utilized (including 
non-expanded PBMNCs, MSCs and adipose derived stem cells (ADSCs), but the 
primary purpose of these cell types is usually not to induce revascularization, so 
will be omitted from discussion. Table 2 includes a summary list of some of the 
clinical trials to date utilizing cell-therapy for revascularization in myocardial 
ischemia and PAD (adapted from [170] and [171]). Overall, meta-analysis of 
current clinical trial data indicates that cell-based therapy remains an encouraging 
treatment option but consensus dictates more extensive study is necessary before 
real world application [172] [173] [174] [175]. There remains a number of trials that 
failed to meet their hard-clinical end points and so optimisation of therapy is 
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certainly required. One interesting treatment modality that could improve cell-
therapy efficacy is to combine cells with synergistic cell types, genes or growth 
factors. Tang et al. do exactly this by transfecting MSCs to overexpress VEGF and 
SDF-1. Rats receiving those cells demonstrate significantly smaller infarct size, 
improved left ventricular function and increased capillary density after myocardial 
infarction versus either growth factor therapy, or cell-therapy alone [176].  
 
Cell-type Disease Route of 
administration 
Follow up 
duration 
Outcomes Trial author 
(including ref) 
BM-MNC PAD IM 1m Inc. ABI and 
TcPO2 
Arai et al. [177] 
BM-MNC PAD IA 120d Inc. Limb salvage Prochazka et al. [178] 
BM-MNC PAD IA 6m Inc. Ulcer healing, 
Red. Resting pain, 
No change ABI or 
limb salvage 
Walter et al. [179] 
BM-MNC PAD IM 6m Red. Amputation 
rate 
Benoit et al. [180] 
BM-MNC PAD IM 6m Red. Resting pain, 
Inc. Ucler healing 
and API 
Li et al. [181] 
BM-MNC MI IA 3m Red. Infarct 
region, Inc. SV, 
LVESV, 
contractility and 
perfusion of infarct 
region 
Strauer et al. [182] 
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BM-MNC MI IA 6m Inc. LVEF and 
myocardial 
perfusion, Red. 
LVDd 
Ge et al. [183] 
BM-MNC MI IA 6m Inc. LVEF, Red. 
Infarct area, No 
change LVEDV 
Huang et al. [184] 
BM-MNC MI IA 4m Inc. LVEF, Red. 
Infarct area, No 
change 
myocardial 
perfusion 
Janssens et al. [185] 
BM-MNC MI IA 6m Inc. LVEF, No 
change Infarct 
area or LVEDV 
Lunde et al. [186] 
G-CSF 
PBSC 
MI IA 6m Inc. LVEF, LVEDV Kang et al. [187] 
G-CSF 
PBSC 
MI IA 6m Inc. LVEF, LVEDV Li et al. [188] 
G-CSF 
PBSC 
PAD 
 
IM 3m Inc. ABI, blood 
perfusion, ulcer 
healing and angio 
score 
Huang et al. [189] 
G-CSF 
PBSC 
PAD IM 12w Inc. ABI, TcPO2, 
walking distance 
and ulcer healing. 
Red. Fontaine’s 
stage and resting 
pain 
Ozturk et al. [190] 
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G-CSF 
PBSC 
PAD IM 12m Inc. Maximal 
walking distance 
and rest pain 
Tateno et al. [191] 
G-CSF 
CD34+ 
PAD IM 12m Red. Amputation 
rate 
Losordo et al. [192] 
G-CSF 
CD34+ 
PAD IM 52w Inc. Efficacy score  Kawamoto et al. [193] 
G-CSF 
CD34+ 
PAD IM 52w Met all clinical end 
points 
Fujita et al. [194] 
G-CSF 
CD34+ 
PAD IM 6m No change in any 
clinical measures 
Perin et al. [195] 
 
Table 14: Brief summary of cell-based revascularization therapy in early clinical trials for 
PAD and MI. Key: Inc. Is increased, Red. Is reduced, ABI is ankle-brachial reflex, TcPO2 is 
transcutaneous oxygen, SV is stroke volume, LVEF is left ventricular ejection fraction, LVEDV left 
ventricular end diastolic volume, LVESV left ventricular end systolic volume, Left ventricular 
diastolic diameter. 
 
Aside from delivering exogenous EPCs, mobilizing endogenous EPCs using 
techniques such as granulocyte colony stimulating factor (G-CSF) and 
granulocyte-macrophage colony stimulating factor (GM-CSF) can also increase 
endogenous circulating EPC concentration, and consequently contribute toward 
myocardial revascularization. As such, G-CSF and GM-CSF will improve 
myocardial regeneration and accelerate cardiac healing in a number of rodent 
myocardial infarction models [163] [196]. In addition, GM-CSF displays strong pro-
angiogenic efficacy in other models of ischemia. Buschmann et al. demonstrate 
that the continuous infusion of GM-CSF for 7 days into the proximal stump of the 
acutely occluded femoral artery of rabbits produced a 2-fold increase in the number 
and size of collateral arteries and increased the maximal blood flow during 
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vasodilation 5-fold [197]. When GM-CSF and MCP-1 were simultaneously infused 
the effects on arteriogenesis were additive, and even more significant – 80% of 
normal maximal conductance of the occluded artery was restored versus 40% in 
GM-CSF alone [197]. Clinically, G-CSF and GM-CSF have been utilized in 
relatively few trials. In PAD, G-CSF and conventional therapy combined improved 
a patient’s subjective symptoms, ankle brachial pressure index (ABI), and 
transcutaneous partial oxygen pressure (TcPO2) to the same degree as with bone 
marrow mononuclear cell transplantation and conventional therapy combined. 
Such improvements were not seen in conventional therapy alone [177]. GM-CSF 
in the ‘stimulation of arteriogenesis’ (START) study however, did not improve 
walking distance (i.e. primary endpoint) in the setting of intermittent claudication in 
both small, and large-scale randomized trials [198] [199].  
 
Overall, there is no clear evidence that cell-based approaches are more preferable 
than angiogenic gene/protein therapies in clinical settings. However, theoretically, 
stem/progenitor cell therapies may be superior over protein or gene therapy due 
to not only direct vasculogenic properties but also paracrine action by secreting 
multiple growth factors besides a single angiogenic factor. It is likely that the two 
in tandem would yield the most effective therapy option.  
 
3.4 Adhesion Molecules 
 
3.4.1 Integrins 
Integrins are a family of transmembrane heterodimeric cell surface glycoprotein 
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receptors which mediate cell-extracellular matrix (ECM) interactions. They are 
expressed ubiquitously in all cellular components (including those of the 
cardiovascular system) and are essential in normal development, as well as in 
disease [200]. Integrins are composed of non-covalently associated heterodimeric 
α and β subunits, and consist of a large extracellular domain, a single 
transmembrane domain, and a short cytoplasmic tail. It is through extracellular 
domains that integrins are able to bind ECM ligands, whilst cytoplasmic tails 
determine appropriate intracellular signalling potentiation.  The ligand binding site 
of integrins is found within the head domains of the α and β subunits and will 
normally recognize short peptide motifs in their target ligands. α- subunit heads 
are characterized by a metal ion-dependent adhesion site (MIDAS), which binds 
cations such as magnesium and calcium, and is critical for integrin activation. The 
α chain is also central in determining ligand specificity, and the arginine-glycine-
aspartic acid (RGD) sequence is the most common integrin-binding sequence here 
[201]. The cytoplasmic tails of integrins are generally short (20-60kDa) and serve 
as transmembrane adaptor links between extracellular contacts and the 
intracellular cytoskeleton, through proteins such as paxillin and tallin.  
In mammals, 18α and 8β integrin subunits exist. Each associate in various 
combinations to form 24 integrins. The composition of specific heterodimers 
confers ligand specificity, and each cell type expresses a different repertoire of 
integrins. Most integrins recognize several ECM proteins, and in turn, most matrix 
proteins bind more than one integrin. There are four main groups of integrins, as 
outlined in figure 7. Of the greatest importance to my own work is the RGD-integrin 
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family, which recognizes and binds to an arginine-glycine-aspartate (RGD) 
recognition sequence on ECM ligands.  
 
 
 
 
 
Figure 7: A combination of 18α and 8β integrin subunits form 24 functional integrins. These 
are divided into arginine-glycine-aspartic acid (RGD) recognition receptors, collagen receptors, 
leukocyte-specific receptors and laminin receptors. The α4 and α9 subunits in green are restricted 
to chordates. Taken from [202].  
 
3.4.2 Integrins and growth factor signalling 
Integrins potentiate a variety of essential signal transduction pathways involved in 
the regulation of many diverse processes, including: cell proliferation, adhesion, 
migration, survival and differentiation [203]. As part of this, integrins are 
 102 
bidirectional signalling molecules that are able to transduce signals either ‘inside 
out’ or ‘outside in’ [204]. Both extracellular and intracellular portions of the integrin 
heterodimer are capable of binding to ligands. It is this ability that allows them to 
signal in both directions across the membrane. In ‘outside in signalling’, ligand 
binding to the extracellular integrin domain results in integrin clustering at the 
plasma membrane, and this leads to signal transduction to the interior of the cell. 
By contrast, ‘inside out signalling’ results from activation signals from within the 
cell and induces changes to integrin conformation. This includes straightening of 
extracellular domains from an inactive bent conformation, which exposes its 
external ligand binding site and therefore increases the affinity for extracellular 
ligands. In many cases an integrin will preferentially bind its primary ligand, 
however some integrins can also recognize other extracellular matrix components 
and bind multiple with differing affinities.  
Integrin activation results in clustering and recruitment of a wide variety of proteins 
at specialised sites named focal contacts or focal adhesions. Focal contacts 
establish a link between the ECM and the actin cytoskeleton. They are composed 
of integrins associating with a number of molecules, including: adaptor proteins 
(e.g. talin and viniculin), kinases (e.g. FAK), protein kinase C (PKC), 
phosphatidylinositol 3-kinase (PI3K), integrin linked kinase (ILK), Src-family 
kinases (e.g. Src and Fyn) and finally small GTPases (e.g. Rho and Rac). All these 
molecules work together to generate a whole signalling cascade. For example, 
integrin activation leads to the recruitment of FAK and Src-family kinases to focal 
contacts, which subsequently activates PI3K. Downstream signalling pathways of 
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PI3K in turn activates Akt and small GTPases, including Rac and Rho, which will 
regulate cytoskeletal changes, resulting in e.g. changes to cell migration, invasion 
and cell contractility.  
 
3.4.3 Endothelial integrins  
Endothelial cells are greatly influenced by the expression and activation of cell-
surface adhesion molecules like integrins. Integrin binding, and consequent 
changes in cytoskeletal organisation and thus cell shape, determine vital 
endothelial processes including migration, proliferation, differentiation, 
angiogenesis and apoptosis. As such, endothelial cells express several integrins 
that mediate interactions with a wide spectrum of ECM components and cell types, 
including collagen receptors (11 and 21), laminin receptors (31, 61 and 
64), fibronectin receptor (41and 51) and vitronectin receptors (v3 and 
v5). Different combinations of integrin subunits on the endothelial cell surface 
allow them to recognize and respond to a number of different extracellular matrix 
proteins under different physiological conditions. Accordingly, the expression level 
of integrins can also change depending upon the activity status, age and location 
of the endothelium [205]. In this way, endothelial cells are able to adapt to local 
changes in their microenvironment and respond accordingly.  
The next subsections in this chapter will discuss v- and β- integrin subunits and 
whole vβ3- vβ5- integrins themselves in the context of the endothelium and their 
respective contribution toward angiogenesis.  
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3.4.4 v-integrin subunit  
αv-integrin subunits are widely expressed on multiple cell types, including the 
endothelium. They have a wide range of potential ligands and will readily associate 
with β-integrin subunits, which themselves show distinct patterns of expression 
and activity, particularly during development or in the ‘active’ endothelium [206] 
[207]. This together implies diverse functions for αv-containing integrins, potentially 
including neovascularization. αv-null mice develop normally up until E9.5, with 
normal organogenesis, vasculogenesis and angiogenesis. Thereafter 80% die 
mid-gestation, probably due to placental defects, 20% survive up until birth and all 
of those live-born die within the first day. Live-born mice exhibit intracerebral 
haemorrhage due to defective interactions between blood vessels and brain 
parenchymal cells [208]. This implies that αv-integrin subunits are not absolutely 
necessary for normal neovascularization during development but may be 
important for mature cerebral blood vessel formation. Interestingly however, 
selective genetic ablation of αv-integrin subunit expression in the vascular 
endothelium has no detectable effect on cerebral blood vessel development, and 
at birth, mutant mice display no phenotypic defects. Instead, glial-specific αv- 
knockout leads to embryonic and neonatal cerebral haemorrhage [209]. This 
demonstrates that endothelial αv-integrin expression in the vascular endothelium 
was not responsible for cerebral haemorrhage in whole αv-null mice, perhaps 
indicating its overall redundancy toward developmental blood vessel formation. 
More recently, αv subunits have been selectively ablated in the endothelium in 
tandem to α5 integrin subunits. Van der Flier et al. show that α5 conditional 
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knockout mice were viable and lacked any immediately obvious phenotype [210]. 
Further characterization showed that this was due to compensation by αv-
containing integrin subunits, which highlights their overlapping and converging 
function. Thus, αv-α5 selective combined knockout mice develop normal 
vasculature initially, but most die mid-gestation (E11.5 onward) due to vascular 
remodelling defects in the great vessels and the heart [210]. Once again, this study 
provides salient evidence that αv (or in fact α5) is not absolutely essential for 
normal blood vessel formation during development but highlights a very important 
contribution of the two toward ‘late’ neovascularization, particularly in the heart.  
 
3.4.5 β-integrin subunit 
Unlike the αv knockout mouse, β3- and β5- null mice (and double null mice) are all 
viable and fertile and produce a vascular network without any obvious defects 
during developmental angiogenesis [211] [212] [36]. In later development 
however, those mice display enhanced tumour growth and pathological 
angiogenesis [36]. This shows that β3 and β5 integrin subunits are differentially 
involved in adult and developmental angiogenesis. Their involvement was further 
delineated by studying mutant β3 integrin receptors. Here, mutant mice (DiYF) (i.e. 
where β3 integrin subunits cannot be phosphorylated) are viable and fertile with 
normal developmental angiogenesis, but in contrast to null mice, display reduced 
pathological angiogenesis and reduced tumour growth [213]. In theory a dominant 
negative mutant integrin could be physically occupied by a ligand, but not 
functionally active, whereas a null integrin can be neither active nor occupied. 
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Thus, this difference demonstrates that β3 can differentially regulate angiogenesis 
according to these principles. This will be discussed in further detail later. 
Elsewhere, studies have also shown that β3-null mice display enhanced 
inflammatory and wound healing responses [214] [215], the latter of which is due 
to increased fibroblast infiltration and increased TGF-β1expression [215]. 
Collectively this indicates that β3-containing integrins are an active component of 
the host vasculature. 
 
β3 may be specifically important during cardiac vascular development. Weis at al. 
show that in the developing heart the mRNA expression of β3 integrin subunits 
decreases significantly as vessel maturation progresses, which was concurrent 
with the cessation of physiological angiogenesis [216]. Additionally, male, but not 
female, β3-null mice display immature coronary capillaries characterized by 
irregular endothelial thickness, endothelial protrusions into the lumen, and 
expanded cytoplasmic vacuoles [216]. The phenotype could be resolved by 
inhibiting VEGF and was recapitulated by the intravenous injection of VEGF into 
the hearts of adult wild-type mice [216]. This probably indicates that β3 containing 
integrins represents some sort of endogenous VEGF biosensor in vivo which will 
act as a ‘brake’ to dampen excessive VEGF activity and allow vessels to mature 
properly. In this model VEGF initiates angiogenesis but is ‘turned off’ by β3. 
Indeed, there is evidence in vitro that αvβ3 and VEGFR-2 will bind to one another 
and directly interact [217], and previous studies also reinforce a similar notion in 
vivo [37]. 
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In the adult, β3 is not expressed on endothelial cells of the heart or elsewhere, 
although it may be expressed in microvessels of the lung [218]. As will be 
discussed, it is however expressed in heterodimer complexes with αv- integrin 
subunits in tumours and during inflammation. Taken together this points to the fact 
that β3 is downregulated in quiescent endothelium but upregulated during active 
proliferation. To support this, endothelial cells that are grown in culture will often 
actively express β3 (own observations) and β3 mRNA has also been detected in 
cardiac vascular structures in animal models of myocardial infarction [219]. 
Interestingly, VEGF-A expression is actually relatively short lived in the adult 
myocardium after infarction [220], which might be a product of upregulated and 
transdominant β3-containing integrin expression. In this fashion, VEGF-A would 
initiate early myocardial angiogenesis post MI but is then downregulated by β3 to 
ensure vessels mature appropriately, as was postulated in the previously 
described Weis et al. study [216].  
The related integrin subunit, β5, is also present in cardiac endothelial cells. Le Gat 
et al. show that early in development, β5 gene expression was observed within 
embryonic sites of haematopoiesis and was documented in angiogenic endothelial 
cells of the lung, heart and kidneys at postnatal time points [221]. This study did 
not appear to differentiate between angiogenic or quiescent endothelial cells so it 
is unclear whether there is a difference in β5 expression between these states.  
  
 108 
3.4.6 Targeting αvβ5 and αvβ3-integrins for angiogenesis control 
Of the 24 vertebrate integrin heterodimers, the expression of 9 have been 
implicated in blood vessel formation: α1β1, α2β1, α4β1, α5β1, α6β4, αvβ1, αvβ3, 
αvβ5 and αvβ8. Of these, αvβ3 was the first endothelial cell αv- integrin to be 
shown to regulate angiogenesis. αvβ3 is most abundantly expressed on 
angiogenic endothelial cells in remodelling and pathology and is not expressed on 
quiescent endothelium [222] [223]. Antagonists of αvβ3 will block pathological 
angiogenesis in several pre-clinical animal models with little impact on pre-existing 
blood vessels, making it an attractive target for therapeutic intervention. Indeed, 
some of these inhibitors have reached human clinical trials as angiogenic inhibitors 
including Vitaxin and Cilengitide, although both of these failed to meet their hard-
clinical end points {Stupp, 2014 #199} {Gutheil, 2000 #533}. The reason for this 
failure is still open to debate, but one conceivable theory explains that genetic 
ablation experiments do not fully summarize the function of αvβ3 integrin because 
of overlapping of functions or compensation by other integrin, or non-integrin, 
partners. Integrins are well known to regulate the activation state of other integrin 
and non-integrin membrane receptors within the same cell – a phenomenon 
referred to as integrin crosstalk (or transdominance) – which is believed to play a 
role in determining how they regulate overall cell behaviour [224]. Thus, it is 
conceivable that the loss of αvβ3 integrin could result in the relief of inhibitory 
transdominance of other integrins (or non-integrins) and enhance their respective 
pro- or anti-angiogenic functions accordingly. Numerous examples detail events 
like this in the literature. With regards to non-integrins for example, the most well-
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established compensatory partnership is crosstalk between αvβ3 and VEGFR-2. 
Previous work has shown that if the expression of αvβ3 integrin is lost, both tumour 
and VEGF-induced angiogenesis is increased. This was not due to enhanced 
expression or activity of other cell-integrins but is instead a consequence of 
elevated VEGFR-2 endothelial cell expression [36]. Furthermore, β3 deficiency 
alone in β3-null mice increases the sensitivity of endothelial cells to VEGF-A by 
elevating VEGFR-2 expression, and consequently enhances VEGF-A-mediated 
endothelial permeability [225]. Both mutational and phosphorylation studies 
demonstrate that altering the cytoplasmic tail of β3 integrin subunits can prevent 
VEGFR-2-αvβ3 cross-activation, and therefore prevent successful angiogenesis 
through transdominant interaction [33] [226] [213].  
Elsewhere, other studies reveal that integrins certainly overlap in function but may 
not strictly compensate for one another, however the potential for compensation 
remains. For example, the expression of α5β1 integrin in cells inhibits αvβ3 
mediated adhesion and migration but constitutively active β3 is resistant to this 
inhibitory effect [227]. Similarly, simultaneous inhibition of both αvβ3 and α5β1 may 
be required for potent anti-angiogenic effects whereas the inhibition of either alone 
may not be sufficient in specific cases [228]. Finally, Gonzalez et al. have shown 
that in vitro there exists a crosstalk in endothelial cells between β1 and β3 integrin 
subunits, such that when αvβ3 integrin is blocked there is a concomitant inhibition 
in ligand binding of α3β1 and α6β1 integrin. Similarly, a combination of blocking 
antibodies in those same cells against α3 and α6 integrin prevent ligand binding of 
αvβ3 integrin [229]. Collectively this illustrates the importance of the 
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compensatory/overlapping involvement of other integrins (and non-integrins), and 
also indicates the potential importance of targeting multiple integrins at once to 
inhibit angiogenesis, as oppose to functionally blocking a single target as with e.g. 
Vitaxin.  
Aside from extracellular matrix molecules like vitronectin and fibronectin, αvβ3 can 
bind to any ECM molecule with an RGD motif to differentially regulate 
angiogenesis, as well as a multitude of growth factors. This means that αvβ3 can 
be both pro- or anti-angiogenic according to its current binding partner. Indeed, 
αvβ3 can bind a plethora of factors – a few of which are detailed in table 15. It is 
still unclear how αvβ3 integrin makes the decision to bind either stimulatory or 
inhibitory angiogenic factors, but an understanding of this may help us determine 
why Cilengitide and Vitaxin did not achieve their expected clinical outcome.  
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Binding partner Pro- or anti- angiogenic? Reference 
Del-1 Pro-angiogenic [230] 
Bone sialoprotein Pro-angiogenic [231] 
Proteolytically cleaved collagen 
type IV 
Pro-angiogenic [232] 
Thrombin Pro-angiogenic [233] 
ANGPTL3 Pro-angiogenic [234] 
CYR61 Pro-angiogenic [235] 
Growth factor receptors Pro-angiogenic [236] 
Thrombospondin Anti-angiogenic [237] [238] 
MMP2 Anti-angiogenic [239] [240] 
Angiostatin Anti-angiogenic [241] 
Endostatin Anti-angiogenic [242] 
Tumstatin Anti-angiogenic [243] 
Table 15: Summary of pro- and anti-angiogenic binding partners of αvβ3 integrin.  
 
Another explanation for the differences in the genetic ablation, mutation, inhibitor 
and clinical-trial data is due to the fact that integrins can regulate endothelial 
apoptosis according to their own ligation state, in a process termed integrin-
mediated death (IMD). Stupack et al. show that unligated αvβ3 negatively 
regulates cell survival and promotes apoptosis by recruiting caspase-8 to the 
plasma membrane, whereas ligated integrins do not [244]. Accordingly, 
decreasing αvβ3 integrin levels increases survival of endothelial cells, whilst αvβ3-
bearing cells undergo apoptosis [244]. This phenomenon is not specific to αvβ3, 
but also occurs with α5β1 [245], which is another important integrin regulator of 
angiogenesis [246]. Interestingly, this mechanism can be ‘hijacked’ to block 
tumorigenesis and metastasis. Hood et al. demonstrate this by using nanoparticles 
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coupled to αvβ3-targetting ligands to induce apoptosis of tumour-associated 
endothelium, which lead to tumour cell apoptosis and regression in Raf mutant 
mice [247]. In this fashion αvβ3 (or α5β1 for that matter) may function as a 
biosensor, promoting angiogenesis when ligated but preventing it by initiating 
endothelial cell apoptosis when ligands are absent or when the ligand binding site 
is antagonized. This mechanism may have developed to ensure the precise 
special regulation of vascular growth, in which endothelial cells will die if they 
spread to inappropriate environments but be left to migrate if properly coupled. It 
is plausible that genetic ablation of β3 integrin could enhance endothelial cell 
survival and thus enhance angiogenesis according to this theory, as wild-type mice 
would present with more overall unligated αvβ3 integrin, and thus see more 
endothelial apoptosis than mutant mice. This however, is unlikely as it is hard to 
believe that αvβ3 would exist primarily in its unligated form in vivo given its large 
amounts of potential binding partners. More likely is that differential endothelial cell 
apoptosis can explain the differences in phenotype between the β3 null and DiYF 
mice. Here, genetic ablation of β3 integrin could enhance endothelial cell survival 
and thus increase angiogenesis, whereas the DiFY functional mutation in β3 
integrin would have the opposite effect and thus reduce angiogenesis.  
A third reason to explain both the poor clinical-trial studies and the unreconciled 
inhibitor and genetic ablation data may involve the regulation of VEGFR-2 at the 
protein level. Given that both αvβ3 integrin and VEGFR-2 are well known to be 
internalized at the cell membrane into the endocytic pathway, from which they can 
be either degraded or recycled back to the cell surface, it is plausible that αvβ3 
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may regulate VEGFR-2 recycling or vice-versa [248]. Reynolds et al. show that 
αvβ3 RGD-inhibitors can enhance the cell-surface recycling rates of αvβ3, αvβ5 
and VEGFR-2 in endothelial cells. By doing so, the degradation of VEGFR-2 was 
prevented and αvβ3 recruitment to focal adhesions at the cell periphery was 
enhanced. This effect was mediated by the Rab4 recycling pathway as 
suppression of this clearly prevents the observed effects [4]. Collectively, this 
means that αvβ3 inhibition actually enhanced tumour growth and tumour 
angiogenesis in vivo, and also enhanced VEGF-mediated angiogenesis ex vivo, 
all of which was abrogated by inhibiting VEGFR-2 [4]. What was most interesting 
about this study was that the dose of αvβ3 RGD-inhibitor used for all assays was 
significantly lower than the effective dose used to inhibit angiogenesis in mouse 
and human studies, which means αvβ3/αvβ5 integrin inhibitors like Cilengitide may 
differentially regulate angiogenesis according to its own concentration. Reynolds 
et al. go on to say that utilizing RGD inhibitors at intermediate doses (neither high 
nor low) in an ex vivo angiogenic assay yields no overall angiogenesis – i.e. the 
expected anti-angiogenic effects (or pro-angiogenic effects for that matter) were 
compromised [4]. Based on this there are huge consequences for the design of 
clinical trials utilizing RGD-mimetic anti-angiogenic therapies like Cilengitide in 
tumours. Pharmacokinetic analysis of Cilengitide in those studies predicts that, 
based on its half-life and maximal plasma drug concentration (Cmax), 30 hours after 
delivery the plasma concentration of Cilengitide would be at angiogenesis-
promoting levels (0.2-20nM). According to this same study these plasma levels 
can persist in the plasma for several hours [4], so combining all this means that 
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Cilengitide probably exists in patients as an intermediate of ‘high’ and ‘low’ dose, 
thus achieving no overall angiogenic effect, which will compromise its efficacy in 
tumours. Theoretically you could chronically infuse patients with Cilengitide (or 
other RGD mimetics) to avoid this and ensure Cilengitide is kept at ‘high’ doses in 
vivo. Indeed, a similar method has undergone phase I clinical trials [249], but was 
unsuccessful and did not meet its primary end point. Several other groups also 
provide similar evidence that low doses of RGD-peptides yield agonistic effects, 
including Legler et al. who show enhanced adhesive function of αvβ3 to vitronectin 
after treatment [251].  
Taken together this section demonstrates that, regardless of the apparently 
conflicting data at times, αvβ3, although not required, is absolutely involved in 
angiogenesis and likely plays both pro- and anti-angiogenic roles. 
 
The related integrin αvβ5 similarly regulates angiogenesis, whereby its inhibitors 
(including Cilengitide) will block pathological angiogenesis. Interestingly, integrin 
blocking antibodies and genetic models have revealed that αvβ3 and αvβ5 integrin 
utilize two functionally distinct cytokine-dependent angiogenesis pathways. 
Integrin αvβ5-mediated angiogenesis is specifically VEGF- or transforming growth 
factor α (TGF-α)- dependent, whereas integrin αvβ3-mediated angiogenesis is 
FGF- or tumour necrosis factor α (TNF-α)- dependent [252]. The distinction 
between the two is due to the fact that β3 and β5 integrin will differentially activate 
the Ras/Raf/MEK/Erk pathway in blood vessels. Specifically, the αvβ5 integrin 
pathway downstream of VEGF leads to activation of FAK and Src kinase, whereas 
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the αvβ3 pathway potentiates p21-activated kinase (PAK) [253] [254]. In addition, 
VEGF/αvβ5 and FGF/αvβ3 differentially activate Raf, which results in differential 
endothelial protection from distinct pathways of apoptosis. The αvβ5 pathway 
activates Raf on serines 338/339 which protects against cell intrinsic-apoptosis, 
whilst αvβ3 signalling activates Raf on tyrosines 340/341 which protects from cell 
extrinsic-apoptosis [255]. These differences illustrate how local expression of 
integrins and extracellular matrix ligands can confer specificity and drive distinct 
cellular behaviours.  
More recently, αvβ5 has been shown to guide pathological angiogenesis together 
with Angiopoeitin-1 in an ischemic retinopathy model [256], and will also prevent 
vascular lung permeability if blocked either genetically or with inhibitory antibodies 
[257]. In addition, stimulating αvβ5 with low dose Cilengitide will enhance vascular 
promotion, which in turn will reduce tumour growth and metastasis [5]. On balance 
there are significantly fewer studies examining αvβ5 than αvβ3, but it is probably 
a pivotal, if dispensable, player in angiogenesis. 
 
3.4.7 Integrins in cardiomyocytes 
Integrins participate in multiple critical cellular processes including adhesion, 
extracellular matrix organization, survival, proliferation and signalling. Particularly 
important for a contracting muscle cell is the fact that integrins are 
mechanotransducers, which translate mechanical to biochemical information. 
Integrin function in the cardiomyocyte covers ubiquitous tasks such as adhesion, 
signalling and formation of cytoskeletal-ECM junctions, and also cell-specific 
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activities like modulating ion channel function, stem cell differentiation, ischemic 
protection and modification of the hypertrophic growth response.  
In the cardiomyocyte the most abundantly expressed integrin heterodimers are 
α1β1, α5β1 and α7β1, which are collagen, fibronectin and laminin binding 
receptors respectively. β1 is the dominant integrin subunit present, but β3 and β5 
also appear to be functional [258] [259] [221]. In general, integrins are most 
concentrated within cells at focal adhesion points and cell-cell borders. As such, 
within the cardiomyocyte integrins are basally expressed at those equivalent cell 
specific sites – i.e. the costameres and z-lines, respectfully [260] [261]. During cell-
signalling integrins will translocate to more specific sites. For example, β1 integrin 
will translocate to the intercalated disc in damaged areas of the myocardium after 
injury [262], whilst β3 is upregulated to the cell surface in RGD-stimulated adult 
cardiomyocytes [263]. In addition, cell-specific integrins vary temporally and during 
disease, meaning that foetal, adult, healthy and unhealthy cardiomyocytes will 
represent a very specific integrin profile. Interestingly however, adult 
cardiomyocytes can assume a foetal expression pattern when stressed and during 
disease. For instance, α5 and α7 subunits have been shown to be significantly 
increased by ischemia or post-MI and aortic constriction can increase α1, α5, α7 
and β1D subunit expression [264] [265]. Finally, all of this is further made complex 
by the fact that alternative splice forms of integrins can exist within the 
cardiomyocyte. The most common example of this are the splice variants β1A and 
β1D, which are predominantly expressed in either the embryo or the adult, 
respectfully [266].  
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Most integrin subunits have been examined in the mouse, a few of which 
demonstrate myocardium defects. Global deletion of α5 show abnormalities in 
outflow tract formation, and others lack left-right heart symmetry [267] [268]. Gain 
of function α5 in the cardiomyocyte sees mice develop a rapid deterioration of 
ventricular function, rhythm abnormalities and increased expression of calreticulin 
[269]. Elsewhere, overexpression of α7 integrin will have a protective effect in 
cardiac myocytes during ischemia/reperfusion injury and will also reduce rates of 
cardiomyopathy [270] [271]. The most well studied cardiomyocyte integrin in mice 
is β1. Global β1 knockout is embryonic lethal, so cell-specific transgenic tools are 
used here. Cardiomyocyte-specific ablation of β1 early in cardiogenesis reduced 
myocyte proliferation, and whole heart development was progressively abnormal 
[272]. Deleting β1 immediately after birth in those same cells lead to progressive 
myocardial fibrosis and development of dilated cardiomyopathy [273]. Finally, 
deleting β1 in the adult leads to a blunted hypertrophic response and defective 
hypertrophic stress signalling [273] [274].  
β3 is less well studied in murine models than other more abundant integrins, but 
there are a number of studies that implicate β3 as a pivotal member of 
cardiomyocyte signalling, particularly during disease. The first indicator of this was 
that cell culture models show that β3 is highly concentrated at focal adhesion sites 
in the cardiomyocyte, meaning that β3 is probably involved in cell 
mechanotransduction [275]. Next, it was determined that β3 null mice exhibit 
increased apoptosis during pressure overload, associated with a decreased 
ventricular mass. This was due to a reduced activity of the Ubiquitin-NF-kB 
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pathway, meaning cells undergo programmed cell death [276]. Soon after, those 
same β3 null mice were used to show that the specific loss of β3 in the 
cardiomyocyte will also lead to calpain-mediated myocyte death after pressure 
overload, which further corroborating the fundamental role of β3 during 
cardioprotection [259]. In parallel, the same lab demonstrates that β3 null mice are 
also deficient producers of interstitial fibronectin and collagen in the heart. This 
was associated with reduced levels of cardiac fibroblast proliferation, fibroblast 
function and synthesis of fibroblast-specific protein [258]. Cardiac fibrosis is a vital 
protective mechanism during cardiac disease, although if in excess it can lead to 
pathogenesis of a number of cardiac pathologies. Together with evidence showing 
that αvβ3 can control myofibroblast differentiation [277], this implicates β3 as an 
effector of multiple cardiac cell types.  
 
Collectively this demonstrates that integrins clearly play a vital role in overall heart 
health. They provide a structural, chemical and mechanical network that allows 
tissue to adapt to both physiological and pathological stimulus. Indeed, recent 
RNA-seq and microarray data of whole human hearts have identified that cellular 
adhesion-related pathway elements are upregulated pathway elements during 
disease [6].  
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3.5 Aims of the study 
 
My own study builds upon the findings of Reynolds et al. [4] and Wong et al. [5] 
and investigates the clinical efficacy of a pro-angiogenic low dose Cilengitide 
treatment regimen in a murine model of heart failure. It is my hypothesis that 
treatment with Cilengitide may not only increase the levels of cardiac 
angiogenesis, if given in nanomolar doses, but also have a direct effect upon other 
cardiac cell types such as cardiac fibroblasts and the cardiomyocytes themselves. 
It is likely that αvβ3/αvβ5 integrin heterodimers exist within many cell types of the 
heart, including cardiac fibroblasts [277], which offers multiple avenues for 
potential sites of action. Furthermore, Cilengitide appears to very safe in human 
clinical trials, which is in contrast to other pro-angiogenic based therapies such as 
VEGF, where side effects may be a cause for concern. To achieve all of this we 
have the following aims: 
 
1) Establish and optimise a model of murine heart failure.  
2) Examine the expression of αvβ3 and αvβ5 integrin heterodimers within 
human and mouse hearts, both diseased and healthy.    
3) Carry out detailed analysis of the effect of Cilengitide in murine heart failure.  
4) Investigate the molecular mechanisms underpinning these effects.  
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CHAPTER 4.0: RESULTS 
 
VASCULAR PROMOTION IN HEART FAILURE 
 
 
4.1 Optimisation of a murine model of heart failure 
 
Heart failure is a common, complex condition with a poor prognosis and increasing 
incidence. The syndrome of heart failure comprises changes in myocardial 
electrophysiology, contraction and energy metabolism, leading to an inability of the 
heart to meet circulatory demands [278]. This complexity, and the interaction of 
the clinical syndrome with frequently concurrent medical conditions like diabetes, 
means that animal modelling of heart failure is difficult [279]. As such, many 
commonly used animal models of heart failure do not entirely recapitulate many of 
the important clinical features of heart failure, but instead offer a simplified, 
indispensable tool to monitor multiple features of cardiac physiology within a 
relevant disease setting.  
Here we assessed the physiological and clinical features of two commonly utilised 
murine models of heart failure to deduce which model would enable me to most 
pertinently address – ‘Vascular promotion in heart failure’.  
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4.1a Isoprenaline-induced heart failure mouse model 
The first model we chose to investigate was chronic isoprenaline infusion, 
delivered via a minipump sewn into the scruff of a mouse’s neck. Isoprenaline is a 
synthetic catecholamine that stimulates beta-adrenoreceptors in the heart 
resulting in a marked elevation of heart rate and cardiac contractility. Chronic 
administration of isoprenaline in experimental models causes cardiac hypertrophy, 
ECG abnormalities, myocardial apoptosis and myocardial fibrosis [279]. 
Chronically, this can lead to heart failure. These effects are both time and 
concentration dependent. In addition, minipump implantation surgeries are 
technically very easy, and the physiological outcome of isoprenaline infusion is 
very reproducible between mice [280].  
 
In order to first find a suitable dose for the induction of murine heart failure via 
chronic isoprenaline infusion, we assessed several different isoprenaline doses 
(20, 30 and 40 mg/kg/day) in wild-type C57BL6 mice, and quantified end-point 
fractional shortening and cardiac hypertrophy. Isoprenaline administration 
increased cardiac fractional shortening to higher than normal physiological levels 
across doses within 1 week, and this was followed by a reduction in fractional 
shortening to baseline levels by the second week of infusion (figure 8a-b). The 
extent of change in end-point fractional shortening was relatively similar between 
isoprenaline doses and any apparent differences proved to be insignificant.  
All measured isoprenaline concentrations also proved to significantly increase left 
ventricle plus septum/body weight (a measure of cardiac hypertrophy) in mice 
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versus controls after 2 weeks (figure 8c). This effect was not associated with any 
significant changes to lung weight (data not shown). As previously, there was little 
difference in the extent of cardiac hypertrophy between doses. This led me to the 
conclusion that 20mg/kg was the most appropriate isoprenaline concentration in 
vivo, as higher doses did not especially induce further deleterious effects to the 
myocardium.  
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Figure 8: Chronic isoprenaline infusion in mice causes cardiac hypertrophy and an overall, 
time dependent change in fractional shortening. (a) Summary fractional shortening analysis, 
(b) end-point (2 week) fractional shortening and (c) Left ventricle + septum/body weight ratio in 
SHAM controls (n=12), and mice receiving 20 (n=8 hearts), 30 (n=2 hearts) or 40 (n=2 hearts) 
mg/kg/day isoprenaline infusion. Data are shown as mean ± SEM. Statistical analysis by 1-way 
ANOVA with Bonferoni’s multiple comparison test post hoc; *P<0.05 versus SHAM vehicle control. 
NS is not significant. 
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4.1b Transverse-aortic constriction (TAC) model of murine heart failure 
Transverse-aortic constriction (TAC) is a well-established surgical technique for 
inducing LV chronic pressure overload induced heart failure in rodents within 3-6 
weeks [281]. Moderate TAC imposed at an early age triggers concentric LV 
hypertrophy with compensated chamber performance, and prominent diastolic 
filling abnormalities. The transition from compensated hypertrophy to early failure 
is time-dependent and heralded by LV dilation and the impairment of systolic 
function [281]. The pathophysiology observed here may be both strain [282], and 
gender specific [283], and so all my surgeries were conducted on age-matched 
C57BL6 male mice.   
TAC (figure 9a) resulted in a sustained archetypal heart failure phenotype as 
expected, comprising reduced cardiac contractility (figure 9b) and increased 
cardiac hypertrophy (figure 9c-d) after 6 weeks. In addition, TAC hearts exhibited 
significant myocardial fibrosis after 6 weeks, as indicated by an increase in 
picrosirius red positive area in myocardial sections versus SHAM controls (figure 
9e-f). SHAM controls, where aortic banding was not completed, exhibit normal 
fractional shortening, normal heart weight, and no deleterious fibrosis, and so were 
used as controls to TAC-surgeries in all experiments (figure 9).  
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Figure 9: Transverse aortic constriction (TAC) surgery in mice causes cardiac hypertrophy, 
a reduction in cardiac contractility and an increase in myocardial fibrosis. (a) Schematic 
outline of TAC experiment, (b) End-point fractional shortening (%), (c) left ventricle + septum/body 
weight ratio, (d) heart weight: body weight (%), (e) fibrosis area of whole heart (%), (f) 
representative picrosirius red staining in SHAM control (n=8) and TAC (n=8) mice. Data are shown 
as mean ± SEM. Statistical analysis by 1-way ANOVA with Bonferoni’s multiple comparison test 
post hoc or student’s t-test if below 3 groups; *P<0.05 versus SHAM control. 
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Based on this data it is appears that chronic isoprenaline infusion results in cardiac 
hypertrophy without deleterious changes in cardiac inotropy (figure 8), whereas 
TAC surgery leads to deleterious changes to cardiac hypertrophy, inotropy, and 
fibrosis (figure 9). The two models chosen here therefore, can be broadly 
classified into two distinct heart failure categories: heart failure with preserved 
ejection fraction (ISO), and heart failure with reduced ejection fraction (TAC). 
Whilst the investigation of a murine model of heart failure with a preserved ejection 
fraction (HFpEF) would be a useful avenue of study, we believe it would be more 
beneficial for my thesis to instead study a murine model that models heart failure 
with reduced ejection fraction (HFrEF). This is due to the fact that HFpEF is 
relatively less well understood within mouse models and its mechanisms are poorly 
understood [284]. Furthermore, HFrEF offers more avenues for studying 
therapeutic intervention, like ejection fraction and fractional shortening. Aortic 
banding surgery has previously been linked to result in changes to myocardial 
angiogenesis [119], has a relatively well understood pathogenesis within the 
available literature [279], and yields consistent physiological outcomes in my own 
hands. In addition, aortic banding is also more physiologically relevant to human 
heart failure versus chronic isoprenaline infusion. Thus, for the rest of my PhD we 
decided to use the TAC model to study the control of angiogenesis in a pathological 
heart condition.  
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4.2 Integrins β3 and β5 are expressed in human cardiac endothelial cells and 
cardiomyocytes  
αvβ3 is expressed at low levels by quiescent endothelium but is significantly 
upregulated during angiogenesis, especially within the myocardium after infarction 
[285] [286]. As such, it has been postulated that αvβ3 is an important determinant 
of myocardial recovery in the endothelium, and an indispensable regulator of 
pathological myocardial angiogenesis overall. Indeed, αvβ3 is increased at sites of 
recent myocardial infarction and its expression correlates with recovering regions 
[287]. Similarly, αvβ5 is an important regulator of endothelial cell function and 
angiogenesis, although these features have not been investigated specifically in 
the cardiac endothelial cell to date [257] [256]. In the cardiomyocyte αvβ3 has 
relatively low expression, but this may also be elevated after infarction [219]. αvβ5 
on the other hand has not had its expression evaluated within the cardiomyocyte 
to my knowledge. Collectively this demonstrates that αvβ3 is an important 
regulator of cardiac endothelial cell and cardiomyocyte function, especially during 
disease. Additionally, there is sufficient evidence to postulate that αvβ5 will also 
play a role here, too. All things considered, we set out to establish the expression 
patterns and relative cell-specific levels of αvβ3 and αvβ5 integrins within the heart. 
To do this we gathered relevant human LV biopsies and stained for β3 and β5 
integrin in tandem with endothelial (CD31), mural cell (alpha-smooth muscle actin) 
or cardiomyocyte (cardiac troponin) cell-specific markers. Both β3 and β5 integrins 
were present in human cardiomyocytes (figure 10), cardiac endothelial cells 
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(figure 11) and cardiac mural cells (figure 12) as assessed by co-localisation with 
their respective cell-specific markers.  
Across cells, integrins are most concentrated at focal adhesions and cell-cell 
borders. Within the cardiomyocyte these equivalent sites are the costamere and 
z-line, respectively [288]. In longitudinal myocardium sections, β5 integrin subunits 
especially were clearly concentrated in ‘individual lines’ that represent the cardiac 
costamere (figure 10l). β3 integrin subunits were expressed in a more diffuse 
pattern across the cardiomyocyte, and at much lower levels than β5. In transverse 
myocardial sections β5- was expressed similarly diffused, probably because 
defined costamere structures are not easily visible within these regions (figure 
10m). The negative controls within myocardial sections confirm that β3 and β5 
staining was specific (figure 10n-o). Controls are particularly important for this sort 
of analysis as the myocardium is classically a very auto-fluorescent tissue-type.  
 
In contrast to this, β3 integrin subunits were more concentrated within the 
endothelium, rather than the surrounding cardiomyocytes (figure 11c). Both β3 
and β5 co-localise with the endothelium-specific marker CD31 in the vast majority 
of samples.  This was seen across multiple vessel types, including:  
 
1) Artery, or arteriole-like structures with a clearly defined vascular smooth 
muscle and collagen layer (figure 11e and j).  
2) Vein or venule-like structures without any clearly defined surrounding 
layers (figure 11k and m-n). 
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3) Relatively ‘small’ undefined vessel subtypes (figure 11l and o).  
 
Both β3 and β5 demonstrate co-localisation with alpha-smooth muscle actin (α-
SMA) in vessels, and so are probably present in human pericytes (figure 12d-e 
and i-j). We cannot say with absolute certainty that the cells outlined here are 
indeed mural cells as fibroblasts may also transiently express α-SMA [39].  
 
These experiments together constitute important preliminary evidence that 
demonstrates the presence of αvβ3 and αvβ5 integrins in cells of the myocardium. 
It is my hypothesis that not only will these integrins be differentially expressed 
across the course of human, or murine, heart disease, but that they can be 
therapeutically modulated (by e.g. Cilengitide) to reduce disease severity. Proving 
their expression in human heart cells was an important first step toward this 
overarching goal.  
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Figure 10: β3 and β5 integrin subunits are expressed in human cardiomyocytes in human 
heart sections. Immunofluorescence of human myocardial tissue demonstrating co-localisation 
between the cardiomyocyte-specific marker, cardiac troponin, and β3 and β5 integrin subunits. (a) 
DAPI, (b) cardiac troponin, (c) β3 integrin subunit and (d-e) cardiac troponin, β3 integrin subunit 
and DAPI merged. (f) DAPI, (g) cardiac troponin, (h) β5 integrin subunit, and (i-j) cardiac troponin, 
β5 integrin subunit and DAPI merged. (k-m) β5 integrin subunit and cardiac troponin. (n-o) 
Immunofluorescent negative control stain using secondary antibodies only for cardiac troponin and 
β3 (n) and β5 (o) integrin subunit (and DAPI) (scale bar 50m). Note: Images a-m taken at same 
scale as n-o. 
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Figure 11: β3 and β5 integrin subunits are expressed in human cardiac endothelial cells in 
human heart sections. Immunofluorescence of human myocardial tissue demonstrating β3 and 
β5 integrin subunits in CD31+ endothelial cells. (a) DAPI, (b) CD31, (c) β3 integrin subunit, (d-e) 
CD31, β3 integrin subunit and DAPI merged. (f) DAPI, (g) CD31, (h) β5 integrin subunit, (i-j) β5 
integrin subunit, CD31 and DAPI merged. (k-l) DAPI, CD31 and β3 integrin subunit merged. (m-o) 
β5 integrin subunit, CD31 and DAPI merged. Scale bars 10m.  
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Figure 12: β3 and β5 integrin subunits are expressed in human mural cells in human heart 
sections. Immunofluorescence of human myocardial tissue demonstrating co-localization between 
the mural cell marker, α-SMA, and β3 and β5 integrin subunits. (a) DAPI, (b) α-SMA, (c) β3 integrin 
subunit, (d-e) α-SMA, β3 integrin subunit and DAPI merged. (f) DAPI, (g) α-SMA, (h) β5 integrin 
subunit, (i-j) α-SMA, β5 integrin subunit, and DAPI merged. Scale bars 30m.  
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4.3 β3 and β5 integrin subunit receptor expression does not change in 
human cardiac disease  
Trans-membrane receptors such as integrins are important for the dynamic 
interaction between intracellular processes and the extracellular environment. 
They are critical to cellular form and function and are essential in regulating cellular 
processes such as differentiation, proliferation and cell death [203].  
In the adult heart, cellular-ECM interactions provide a structural, chemical, and 
mechanical substrate that is essential for normal homeostasis and adaptations to 
pathophysiologic signals. Because integrins are the principal receptors for the 
ECM, their appropriate expression and function is likely to be necessary for normal 
cardiovascular function in the adult [289]. To investigate the relative expression of 
β3 and β5 in the heart, both in healthy and diseased tissue, we gathered 4 different 
human cardiac biopsy variants (non-failing (NF), non-failing with hypertrophy (NH), 
dilated (Dil.), and ischemic (Isc.)) and quantified β3 and β5 expression across 
samples.  
β3 protein expression did not change amongst the hearts of heart failure patients 
(dilated or ischemic groups) or healthy controls (non-failing and non-failing with 
hypertrophy groups), as shown by immunoblot (figure 13a-b) and 
immunofluorescent assays (figure 14a-d and k). β3 expression did not change at 
the RNA level between samples (figure 13d).  
Similarly, β5 protein expression did not change amongst the hearts of heart failure 
patients (dilated or ischemic groups) or healthy controls (non-failing and non-failing 
with hypertrophy groups), as shown by immunoblot (figure 13a-b) and 
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immunofluorescent assays (figure 14a-d and k). β5 expression did not change at 
the RNA level between samples (figure 13d).  
It has been noted that GAPDH may not be an appropriate control for the western 
blots in this instance, as GAPDH may actually increase in heart failure. If I had 
more time therefore, I would repeat these studies with other controls like actin or 
hsc-70. However, it is worth noting that other similar studies have used GAPDH as 
a control like Lee et al [403], which is why these studies were constructed in such 
a manner.  
Overall, these data were important to show that the targets of Cilengitide is 
expressed in the diseased heart.  
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Figure 13: β3 and β5 integrin subunit protein and mRNA levels do not change in human 
heart disease. (a) β3 and β5 integrin subunit western blots of human non-failing (NF), non-failing 
with hypertrophy (NH), Dilated (Dil.) and Ischemic (Isc.) whole heart tissue lysates with (b-c) 
associated densitometry analysis (n=6 separate hearts per group). (d-e) β3 and β5 integrin RT-
qPCR of human NF, NH, Dilated and Ischemic hearts (n=3 separate hearts per group). Data are 
shown as mean ± SEM. Statistical analysis by 1-way ANOVA with Tukey’s multiple comparison 
test post hoc; NS is not statistically significant. 
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Figure 14: Integrin β3 and β5 cardiac expression does not change in human heart disease. 
Immunofluorescence of human heart tissue across four different cardiac phenotypes demonstrating 
relative β3 and β5 integrin subunit expression. (a) non-failing (NF), (b) non-failing with hypertrophy 
(NH), (c) Dilated (Dil.) and (d) Ischemic (Isc.) hearts stained with DAPI and β3 integrin. (e) NF, (f) 
NH, (g) Dilated and (h) Ischemic hearts stained with DAPI and β5 integrin. (i-j) Immunofluorescent 
negative control stain using secondary antibodies only for cardiac troponin and β3 (i) and β5 (j) 
integrin (and DAPI). Scale bars 50m – note: images a-h taken at same scale. (k-l) Mean intensity 
of β3 and β5 immunofluorescence (assessed via image J) (n=4 heart samples per group). Data are 
shown as mean ± SEM. Statistical analysis by 1-way ANOVA with Tukey’s multiple comparison 
test post hoc; NS is not significant.  
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4.4 β3 and β5 integrin subunit receptor cardiac protein expression is not 
differentially expressed after TAC surgery 
Now we have established that β3 and β5 integrin subunit expression is present 
within human heart failure samples, but their expression does not change with 
disease, we sought to investigate whether those same integrins were differentially 
expressed in a TAC model of heart failure after 6 weeks.  Neither β3 nor β5 was 
significantly upregulated in the myocardium of TAC surgical mice versus SHAM 
controls as assessed by immunofluorescence (figure 15a-h). However, although 
immunofluorescence signals were greater than that of the negative antibody 
controls, we are not convinced that this is bonafide integrin staining, partially 
because it is very different to that in the human heart. Similarly, both β3 and β5 
integrin subunit protein levels did not change after TAC surgery as assessed by 
western blot (figure 15i-k). Interestingly, β3 RNA was upregulated in the whole 
hearts of mice that had undergone TAC surgery (figure 15l). This could indicate 
that the rate of β3 protein breakdown is higher in those mice, or its translation is 
slower.  
Collectively these results demonstrate that β3 and β5 integrin expression does not 
change in ‘late-stage’ stage heart failure tissue (in humans or murine models). This 
is perhaps unsurprising and may reflect the fact that the tissue sampled here has 
already undergone cardiac remodelling, and so the molecules involved during this 
process are now mostly downregulated to normal levels. Several studies 
previously have implicated integrin β3 especially as an important mediator of 
cardiac remodelling. The majority also show that its levels return to normal after 
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cardiac remodelling is over [219] [286] [285]. With that said, we do not actually 
have any evidence to say that my human heart tissue actually represents ‘late-
stage’ disease, nor can we ascertain that the tissue itself was taken after recovery 
from e.g. ischemic insult.  
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Figure 15: β3 and β5 integrin subunit protein is not differentially expressed in whole mouse 
heart tissue after TAC surgery. Immunofluorescence, immunoblot and RT-qPCR demonstrating 
β3 and β5 integrin expression and mRNA levels in whole heart tissue of 6-week TAC mice versus 
SHAM controls. (a) SHAM and (b) TAC heart tissue stained with β3 integrin and DAPI antibodies. 
(c) SHAM and (d) TAC heart tissue stained with β5 integrin and DAPI antibodies. (e-f) 
Immunofluorescent negative control stain using secondary antibodies for β3 (e) and β5 (f) integrin 
(and DAPI). (g-h) Mean intensity of β3 and β5 immunofluorescence (assessed via image J) (n=3 
heart samples per group). (i-k) Western blot assessing β3 and β5 protein expression (n=3 hearts 
per group). (l) β3 and (m) β5 whole heart RNA expression in mice undergoing either SHAM or TAC 
surgery (age-matched) (n=4 hearts per group). Data are shown as mean ± SEM. Statistical analysis 
by student’s t-test; *P<0.05 versus control. NS is not significant. Scale bars 20m.  
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4.5 Cilengitide functions as a dose dependent regulator of cardiac inotropy 
in pressure-overload-induced heart failure 
Now we have established the expression of αvβ3 and αvβ5 integrin in both a 
murine model of heart failure, and human heart failure itself, we sought to 
investigate the utility of Cilengitide in the TAC model of heart failure. Cilengitide is 
an αvβ3/αvβ5 integrin-specific RGD-peptidomimetic (i.e. antagonist) developed 
initially as an anti-angiogenic therapy. In vivo, high dose Cilengitide acts as a highly 
potent inhibitor of angiogenesis, and will also induce the apoptosis of growing 
endothelial cells [290] [291]. Cilengitide has entered multiple clinical trials as an 
anti-cancer therapy, but has been withdrawn from many, including a phase III 
clinical trial for the treatment of glioblastoma, mostly due to failure to meet its 
clinical endpoints [250]. Most recently, Cilengitide has been discontinued as an 
anti-cancer therapeutic. In a bid to repurpose this drug the Hodivala-Dilke lab has 
shown that, in contrast to a high dose Cilengitide treatment regimen, low dose 
Cilengitide paradoxically exerts a VEGF-mediated pro-angiogenic effect on the 
tumour vasculature, most likely through altered vascular endothelial growth factor 
receptor-2 trafficking and recycling [4]. My own study builds upon this finding and 
investigates the clinical efficacy of a pro-angiogenic low dose Cilengitide treatment 
regimen in a murine model of heart failure. Efficient blood supply to 
cardiomyocytes is necessary to meet their high metabolic demand and oxygen 
requirements. Pathological cardiac stressors such as hypertension or myocardial 
ischemia can upset the balance between the volume of myocardial tissue mass 
and adequate blood supply, leading to a relative impairment in local tissue 
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oxygenation [292] [293]. Thus, revascularizing and reperfusing damaged, or non-
functional heart tissue, may potentially restore cardiac function, vastly improve the 
symptoms of heart failure, and/or halt the progression of heart failure entirely [294] 
[295]. 
It is my hypothesis that treatment with Cilengitide may not only increase levels of 
cardiac angiogenesis (and therefore myocardial perfusion) if given in nanomolar 
doses, but also have a direct effect upon other cardiac cell types, such as 
cardiomyocytes. To this end, Cilengitide was administered to mice either in tandem 
to, or after TAC surgery and the clinical outcome measured. As this was a 
preliminary experiment only one indices of disease severity was measured – 
cardiac contractility, which was quantified by fractional shortening.  
Cilengitide was administered intraperitoneally 3 times per week in tandem to the 
onset of surgery as a ‘low dose’ (50μg/kg), or ‘high dose’ (500μg/kg) therapy. As 
expected, TAC surgery itself brought about a sustained decline in fractional 
shortening across the 7-week period, which as mentioned, is an archetypal feature 
of heart failure (figure 16a-d). In contrast, SHAM-surgery control mice exhibit 
normal fractional shortening across the 7 weeks (figure 16a-d). Of the Cilengitide 
doses used, 50μg/kg (i.e. ‘low dose Cilengitide’) proved to be cardioprotective 
against TAC surgery, whilst 500μg/kg Cilengitide (i.e. ‘high dose Cilengitide’) was 
ineffective as a cardioprotectant. Here, administration of ‘low dose Cilengitide’ 
prevented measured aspects of deleterious cardiac remodelling, and so the 
fractional shortening of those mice receiving this therapy regime remained normal 
(46.5%) (i.e. similar to SHAM controls – 47.4%), and did not decline, as in 
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untreated TAC-surgery mice (29.8%) (figure 16a-d). In contrast, the fractional 
shortening of those mice receiving ‘high dose Cilengitide’ in tandem with TAC 
surgery fell to 34% within 7 weeks, which was significantly lower than SHAM 
controls (47.4%) and low dose Cilengitide treated TAC surgery-mice (46.5%) 
(figure 16a-d). 
Henceforth, we classify a Cilengitide dose of 50μg/kg to be ‘low dose Cilengitide’ 
(LdCil). Perhaps fortuitously, this is the same concentration that was demonstrated 
to exhibit tumour angiogenic properties by previous lab members [4] [5].  
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Figure 16: Cilengitide functions as a dose dependent regulator of cardiac inotropy in 
pressure-overload-induced heart failure. Wild-type, male, C57BL6 mice underwent either 
SHAM, or TAC surgery and were treated with prophylactic Cilengitide or used as vehicle controls. 
(a) Representative echocardiographic images in SHAM (n=10), TAC (n=6) and Cilengitide treated 
(SHAM n=8, TAC 50 n=9, TAC 500 n=7) mice. (b-c) Summary fractional shortening (%FS) analysis 
and (d) End point fractional shortening analysis. Statistical analysis by 1-way ANOVA with Tukey’s 
multiple comparison test post hoc; *P<0.05 versus control. NS is not statistically significant.  
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4.6 Pressure-overload-induced cardiac pathobiology is suppressed with 
delayed low dose Cilengitide treatment 
Since human heart failure patients will not report symptoms until after 
cardiovascular disease has already developed, it would be remiss of us to solely 
report beneficial data from a treatment that was given in tandem with TAC surgery. 
Thus, in order to recapitulate the circumstances seen in the clinic mice were left to 
develop cardiac dysfunction after TAC surgery before commencing low dose 
Cilengitide treatment. 
 
Based upon previous observations we chose to investigate whether or not cardiac 
dysfunction had developed by 3 weeks post-TAC surgery. This constitutes a time-
point that was early enough in the TAC-experimental protocol to allow for therapy 
with Cilengitide, but also late enough that cardiac dysfunction should be 
established. By 3 weeks post-surgery those mice that had undergone TAC 
displayed significantly lower fractional shortening and ejection fraction than at 
baseline, and also their hearts were hypertrophied, and the left ventricle displayed 
some minor dilatation (figure 17a-d). Together this shows that some cardiac 
dysfunction had already been established, and for this reason we classified 3 
weeks post-TAC surgery as the time point by which heart failure had been 
established, and so treatment could begin here. Thus, after 3 weeks low dose 
Cilengitide (LDCIL) was administered 3 times per week for a further 3 weeks. 
TAC surgery without associated treatment brought about an archetypal heart 
failure phenotype as previously shown, which comprised of significantly reduced 
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cardiac contractility (as measured by fractional shortening and ejection fraction), 
and also LV dilatation, which here was quantified by measuring LV internal 
diameter at systole (LVID;s) and diastole (LVID;d) (figure 18a-f). Within 3 weeks 
of LDCIL treatment, there was a significant reversal in each of the measured 
indices of disease severity, including cardiac contractility and LV dilatation. Indeed, 
the fractional shortening and ejection fraction of mice that had undergone TAC 
surgery improved significantly after low dose Cilengitide treatment, and their 
LVID;s was also reduced versus untreated controls (TAC) (figure 18b-f). These 
effects were independent to changes in mean arterial blood pressure (MABP) 
(figure 18h), which excludes the possibility that low dose Cilengitide may lead to 
peripheral dilatation and a reduction in the cardiac overload, which could in theory 
indirectly dampen any heart failure phenotype. 
 
Low dose Cilengitide also prevented maladaptive changes in cardiac hypertrophy, 
which is another salient feature of heart failure. Indeed, mice that have undergone 
TAC surgery exhibit significantly ‘heavier’ hearts (relative to body weight), which is 
due to extensive cardiomyocyte hypertrophy (figure 19a-c). Treatment with low 
dose Cilengitide 3 weeks after TAC surgery will ostensibly return cardiomyocytes 
back to normal size, which manifests as significantly lower heart weight (relative 
to body weight) (figure 19a) and smaller myocytes (figure 19b-c) versus untreated 
surgical controls (TAC) (as assessed by wheat germ agglutinin staining (WGA)).  
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A hallmark feature of the heart during pathophysiological situations is the 
suppression of the post-natal gene program and return to a predominant foetal-
like gene program [296]. This is an adaptive mechanism which facilitates extensive 
cardiac remodelling and includes: a decrease in the rate of aerobic metabolism, 
an increased in cell survivability, increased cardiomyocyte size and also a change 
in cardiac contractility, amongst others [297]. Overall, these features exist to 
maintain overall cardiac output whilst also increasing the rate of cardiac efficiency 
during the pathogenesis of disease. As part of this foetal-like gene program, the 
pathological hypertrophy markers Myh7, Myh6, ANP and BNP will be re-
expressed. Multiple investigators have demonstrated that many of these genes will 
be upregulated after TAC surgery in murine models [298] [299] [300] [301], and so 
we sought to investigate whether or not low dose Cilengitide treatment could 
prevent the deleterious cardiac transition which is heralded by the re-expression 
of fetal-like genes.  
Across the markers sampled (Myh7, Myh6, ANP and BNP), TAC surgery 
surprisingly did not induce a significant increase in Myh7, ANP and BNP or Myh6, 
although the results did tend toward an increase (figure 20a-d). The administration 
of Cilengitide 3 weeks after TAC surgery did appear to reduce the expression of 
those ANP, BNP and MYH7 markers, although this was insignificant (figure 20a-
d).  
 
Collectively this indicates that the salutary effects of low dose Cilengitide are 
sufficient to significantly reverse many of the disease features of pressure-overload 
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induced heart failure, including: reduced cardiac contractility, LV dilatation, 
deleterious cardiac hypertrophy, and finally a return to a foetal-like gene 
expression pattern (figure 18-20). We have previously been able to assess cardiac 
fibrosis in my TAC models of heart failure, but unfortunately was not able to do this 
in any of the studies we conducted with low dose Cilengitide. This was because 
the majority of the hearts from experimental mice were snap-frozen for further 
investigation. We found it impossible to properly stain frozen myocardium sections 
with picrosirius red, as the stain itself is optimised for paraffin-embedded sections. 
We attempted multiple other stains for cardiac fibrosis, including Masson’s 
trichrome and Collagen type 1 (data not shown) (Collagen type 1 has specifically 
been shown to be the primary collagen type within cardiac fibrosis [302] [303]), but 
these did not capture extensive fibrosis following TAC surgery, as was seen with 
picrosirius red stains. Sarrazy et al. show that integrins αvβ5 and αvβ3 are 
upregulated in myofibroblast-enriched fibrotic lesions, and will together activate 
latent TGF-β1 activation, which will itself trigger myofibroblast differentiation [277]. 
They show that by blocking those integrins you could theoretically block the 
progression of fibrosis in the heart, and so modulating their expression with 
Cilengitide could be either detrimental or beneficial. Perhaps Cilengitide worked so 
well in these experiments precisely because there was so little fibrosis in mouse 
models of TAC. By contrast, fibrosis is itself an early adaptive mechanism to 
cardiac injury, and so by potentiating early fibrosis αvβ5 and αvβ3 may actually 
facilitate repair. 
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Figure 17: Transverse aortic constriction (TAC) surgery in mice causes a reduction in 
cardiac contractility and an increase in left ventricular dilatation by 3 weeks. (a) Fractional 
shortening (FS%), (b) ejection fraction (EF%), (c) left ventricle internal diameter (at systole) 
(LVID;s) and (d) left ventricle internal diameter (at diastole) (LVID;d) for SHAM (n=3) and 3w TAC 
(n=3) surgical mice. Data are shown as mean ± SEM. Statistical analysis by student’s t-test; 
*P<0.05 versus control. 
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Figure 18: Pressure overload induced cardiac pathobiology is suppressed with delayed low 
dose Cilengitide treatment. Wild type, male, C57BL6 mice underwent either SHAM, or TAC 
surgery and were treated with ‘low dose Cilengitide’ (LDCIL) 3 weeks after surgery or used as 
vehicle controls. (a-b) Summary fractional shortening (%FS) analysis and (c) representative 
echocardiographic images in SHAM (n=6), TAC (n=7) and delayed low dose Cilengitide treatment 
(SHAM LD n=7) (TAC LD n=7) mice. (d) End point fractional shortening, (e) ejection fraction (%EF), 
(f) left ventricular internal diameter (during systole) (LVID;s), (g) left ventricular internal diameter 
(during diastole) (LVID;d), (h) and mean arterial blood pressure (MABP) across treatment groups. 
Data are shown as mean ± SEM. Statistical analysis by 1-way ANOVA with Tukey’s multiple 
comparison test post hoc; *P<0.05 versus control. NS is not statistically significant.  
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Figure 19: Pressure overload induced cardiac hypertrophy is ameliorated with delayed low 
dose Cilengitide treatment. Wild type, male, C57BL6 mice underwent either SHAM, or TAC 
surgery and were treated with ‘low dose Cilengitide’ (LDCIL) 3 weeks after surgery or used as 
vehicle controls. (a) Heart weight normalized to body weight (Hw:Bw %) in SHAM (n=6), TAC (n=7) 
and delayed low dose Cilengitide treatment (SHAM LD n=7) (TAC LD n=7) mice. (b) Quantitation 
of wheat germ agglutinin stained myocardium, with (c) representative image (n=3 hearts per 
group). Data are shown as mean ± SEM. Statistical analysis by 1-way ANOVA with Tukey’s multiple 
comparison test post hoc; *P<0.05 versus controls. Scale bar 20µm.  
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Figure 20: Pressure overload induced cardiac gene changes are ameliorated with delayed 
low dose Cilengitide treatment. Wild type, male, C57BL6 mice underwent either SHAM, or TAC 
surgery and were treated with ‘low dose Cilengitide’ (LDCIL) 3 weeks after surgery or used as 
vehicle controls. (a-d) ANP, BNP, MYH7 and MYH6 whole heart RNA expression levels 
(normalised to GAPDH) (n=6 hearts per group). Data are shown as mean ± SEM. Statistical 
analysis by 1-way ANOVA with Tukey’s multiple comparison test post hoc; NS is not significant.  
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4.7 Low dose Cilengitide’s cardioprotective effects continue, even after 
cessation of treatment 
It has been reported that the beneficial effects of Cilengitide may continue even 
after its cessation [5]. For this reason, we performed TAC surgery, allowed heart 
failure to develop for 3 weeks, and then treated mice with low dose Cilengitide for 
3 weeks. At 6 weeks, treatment with Cilengitide was stopped, and mice were left 
for a further 6 weeks before culling and post-mortem analysis.  
Abdominal TAC surgery here brought about a significant change in fractional 
shortening within 3 weeks (average 25 FS%) (figure 21a) but did not induce any 
further deleterious changes beyond 3 weeks (average 27 FS%) (figure 21a). By 
12 weeks the majority of the indices of disease severity, including: cardiac 
contractility (fractional shortening and ejection fraction), LV dilatation (LVID;s and 
LVID;d) and cardiac hypertrophy (heart weight relative to body weight) were not 
significantly different from SHAM controls (figure 21a-g). It is likely that cardiac 
contractility did not change beyond 3 weeks because by this time point it was 
already as low as 25% on average, which reflects a value whereby abdominal TAC 
surgery will rarely induce further deleterious change. In addition, by 6 weeks post-
surgery one mouse from a cohort of 6 total had already died (probably due to heart 
failure – Hw:Bw % = 1.3, FS% = 12%), and by 12 weeks post-surgery 2 more had 
died (also probably due to heart failure – Hw:Bw % = 1.23, 1.18, FS% Unknown), 
which left only 3 mice alive from a total cohort of 6 by 12 weeks (figure 21h). It is 
thought that TAC surgery produces a variable cardiac phenotype in which only a 
subset of mice will develop heart failure ‘proper’, and others will develop 
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compensated LV hypertrophy, or no deleterious phenotype whatsoever [304]. 
Thus, it is my hypothesis that the 3 mice (from 6) that had died over the course of 
the experiment constituted the majority, if not all, of the heart failure developing 
group within the cohort. The other 3 mice will represent either those mice with 
compensated LV hypertrophy or those mice where TAC-surgery was relatively 
ineffective. Figures 21c-g contain only data from mice that had survived the entire 
12 weeks as they represent ‘end point data’, meaning that within the TAC surgery 
group this only contains the sample of 3 that do not represent models of heart 
failure. A sample of 3 itself is difficult to draw meaningful conclusions from, 
especially considering these circumstances, and so this may be why all indices of 
severity within TAC-surgical groups prove to be non-significant whereas previously 
they have been significantly different from SHAM-surgical controls. Overall this 
does constitute a major caveat to the model we have chosen to use, and we will 
discuss this in later sections.  
Despite all this, we can draw meaningful conclusion from mice undergoing TAC 
surgery that were treated with low dose Cilengitide. As previously, low dose 
Cilengitide will reverse the decline in cardiac contractility observed 3 weeks after 
TAC surgery (figure 21b). Interestingly, once treatment with Cilengitide has been 
stopped (i.e. at 6 weeks post-TAC), both fractional shortening and ejection fraction 
do not decline by the 12-week measured end-point (figure 21b-d). Furthermore, 
LV dilatation and cardiac size were ‘normal’ (i.e. not significantly different from 
control groups) in those same mice (figure 21e-g). Finally, treatment with low dose 
Cilengitide improved the survival of those mice undergoing TAC surgery – 3 
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‘naïve’, or untreated, mice that had undergone surgery died across the 12-week 
experiment from a total of 6, whereas only 1 mouse from a cohort of 6 died within 
the low dose Cilengitide treated surgical group (figure 21h). Whilst this experiment 
clearly had its setbacks, we think it represents some interesting preliminary 
evidence that low dose Cilengitide confers benefits even after its cessation in the 
TAC model of murine heart failure.  
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Figure 21: Low dose Cilengitide’s cardioprotective effects may continue, even after 
cessation of treatment. Wild type, male, C57BL6 mice underwent either SHAM (n=6), or TAC 
(n=3) surgery and were treated with ‘low dose Cilengitide’ (LDCIL) 3 weeks after surgery or used 
as vehicle controls (SHAM treated n=6, TAC treated n=5). After 3 weeks treatment was stopped, 
and mice were monitored for a further 6 weeks. (a-b) Summary fractional shortening (%FS) 
analysis, (c) end point fractional shortening, (d) end point ejection fraction (EF%) and end point left 
ventricular internal diameter at (e) systole (LVID;s) and (f) diastole (LVID;d). (g) Heart weight 
normalized to body weight and (h) percentage survival. Data are shown as mean ± SEM. NS is not 
significant.  
 
 
 156 
4.8 Treatment with low dose Cilengitide enhances cardiac angiogenesis in 
vivo 
Pressure-overload induced heart failure (TAC) will modulate cardiac angiogenesis 
in the heart by modifying both the capillary density itself and the total number of 
pericytes present overall [119]. Souders et al. used a thoracic TAC model to detail 
these observations, so first we sought to investigate whether not abdominal TAC, 
which is a milder and slower onset model of heart failure, would yield similar 
results. To this end, we performed TAC surgery and culled mice at either 2, 3 or 6-
weeks post-surgery and measured their blood vessel number against age-
matched hearts from SHAM-surgical control mice. In order to count blood vessel 
number, we took 5 fields of view at 40x magnification per heart and counted the 
number of CD31+ blood vessels. From 2-6 weeks post-TAC surgery the number 
of blood vessels within the heart did not change significantly (figure 22a-b). 
However, TAC surgery will induce cardiac hypertrophy by 6 weeks, which means 
that the blood vessel density, or the number of blood vessels per cardiomyocyte, 
may actually be higher between controls and those hearts 6 weeks post-TAC 
surgery. To measure this, we stained serial sections of myocardium with CD31 and 
then WGA and counted both the number of CD31+ blood vessels and the number 
of WGA+ cells across 5 fields of view at 40x magnification per heart. CD31 is a 
marker of endothelial cells, and thus blood vessels, whilst WGA will mark cell 
borders but has previously been used by myself and other lab members to also 
determine cardiomyocyte size [298]. The number of CD31+ blood vessels per 
WGA+ cell was not significantly increased between those mice receiving SHAM, 
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or TAC surgery after 6 weeks, but the result did tend toward significance (figure 
22c). Potentially a reduction in capillary density in those mice undergoing TAC 
surgery may generate an imbalance in the amount of oxygen delivered to 
cardiomyocytes, and thus potentiate a relative local ischemia, which in turn could 
lead toward the transition from compensated to uncompensated heart failure. A 
higher sample size may yield more powerful observations in this study and is worth 
pursuing, especially considering the data generated by Souders et al [119]. 
Furthermore, we did not assess the number of vessels relative to cell size in mice 
2 or 3-weeks post-TAC surgery. This time point may represent a view of when 
hearts initially develop failure in the TAC model, and so is worthy of study. Because 
the hearts of those mice do not display an increase in actual vessel number, and 
it is unlikely that the cardiomyocytes of those mice are any larger than at 6 weeks 
post-TAC surgery, it is unlikely we would receive more positive data if we were to 
analyse it as blood vessel number per cardiomyocyte as previously. However, the 
structure of vessels may change at this time point, or their association with 
pericytes and other mural cells, so this is worth investigating.  
 
Low dose Cilengitide increases angiogenesis across various murine tumour 
models [4]. It is my hypothesis that any functional improvements observed in 
cardiac disease indices following treatment with low dose Cilengitide may be partly 
due to an increase in cardiac angiogenesis. In order to study this, we double 
stained myocardium for CD31 and α-smooth muscle actin (α-SMA), which has 
been used by lab members to successfully mark mural cells in the past [305, 306]. 
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CD31 will identify most, if not all, vessels in the heart, including much of the small 
capillary microvasculature. α-SMA on the other hand will label only those vessels 
supported by mural cells, which constitutes most vessels larger than capillaries.  
 
The number of blood vessels in the hearts of those mice 6 weeks post-TAC surgery 
increased modestly (but not significantly) versus SHAM controls (figure 23a-b), 
which is in line with previous observations made in figure 22. Interestingly, low 
dose Cilengitide increased cardiac angiogenesis significantly in those mice that 
underwent TAC surgery, but not in those mice that underwent SHAM-surgical 
control (figure 23a-b).  
In order to determine whether or not the number of ‘mature’, or mural cell covered, 
vessels changed between groups we analysed data from α-SMA and CD31 
stained myocardium. In general, α-SMA+ vessels constitute a very small fraction 
of overall vessels in the heart. For a given 40x field of view they represent around 
1-4% of total vessels (figure 23c-d). This did not change between samples, and 
the total number of α-SMA+ vessels totalled across 10 fields of view was the same 
across groups (figure 23c-d). In order to more accurately sample the number of 
α-SMA+ vessels in the myocardium between hearts, we attempted to measure this 
figure in the entire heart and then match this against the overall size of the heart 
itself, but we were not able to do this within the available time.    
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Overall this shows that low dose Cilengitide will enhance cardiac angiogenesis in 
a murine model of heart failure. The exact disposition and physiology of these 
vessels is unknown but would be a useful avenue of study if we had more time.  
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Figure 22: Cardiac blood vessel number does not differ temporally after TAC surgery. (a) 
CD31+ blood vessel number per field of view (at 40x magnification) with (b) representative CD31 
stained mouse myocardium. (c) CD31+ blood vessel number per wheat germ agglutinin positive 
(WGA +) cell number. Data are shown as mean ± SEM. Statistical analysis by 1-way ANOVA with 
Tukey’s multiple comparison post hoc (if greater than 2 groups) or student’s t-test (if less than 3); 
NS is not significant. Scale bars 20m. 
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Figure 23: Treatment with low dose Cilengitide enhances cardiac angiogenesis in vivo. Wild 
type, male, C57BL6 mice underwent either SHAM, or TAC surgery and were treated with ‘low dose 
Cilengitide’ (LDCIL) 3 weeks after surgery or used as vehicle controls. (a) CD31+ blood vessel 
number per field of view (at 40x magnification) with (b) representative CD31 stained mouse 
myocardium. (c) α-smooth muscle actin (SMA) positive blood vessel number across 10 fields of 
view (at 40x magnification) with (d) representative images of α-SMA and CD31 stained 
myocardium. Data are shown as mean ± SEM. Statistical analysis by 1-way ANOVA with Tukey’s 
multiple comparison test post hoc; *P<0.05 versus control, NS is not significant. Scale bars 30m. 
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4.9 Low dose Cilengitide as a dual function therapy for the treatment of heart 
failure (effect on cardiac endothelial cells) 
The next question we sought to investigate was whether or not mouse cardiac 
endothelial cells and cardiomyocytes will express β3 and β5 integrin receptor 
subunits, and if so in what relative quantities. This serves the dual purpose of 
corroborating the evidence we have already accumulated in human hearts, whilst 
also being the first in a set of experiments that aims to uncover why low dose 
Cilengitide demonstrates efficacy in a murine model of heart failure. To this end, 
we isolated cardiac endothelial cells and cardiomyocytes from mouse hearts, 
cultured cells for a period of time and then quantified the relative β3 and β5 mRNA 
and protein expression levels within isolates by RT-qPCR and western blot 
analysis. At the RNA level, endothelial cells express significantly more β3- integrin 
than corresponding cardiomyocytes, whereas cardiomyocytes express 
significantly more β5- integrin (figure 24a-d). Both integrins are expressed 
relatively abundantly in cells despite overall apparent differences (qPCR threshold 
cycle 22-28 – figure 24c-d). Western blot analysis reveals diverging results. Here, 
β3- integrin is upregulated in endothelial cells, as is β5- integrin versus 
cardiomyocytes. This may indicate that there is less overall translation in the 
cardiomyocytes of β5- integrin than endothelial cells, despite their being relatively 
more transcription of β5- integrin in those same cardiomyocytes. Interestingly, we 
have observed in both human and mouse myocardium sections that β5- integrin 
appears to be relatively more present in the cardiomyocytes and β3- integrin in the 
endothelial cells. These results may reflect the fact that we are using isolated foetal 
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cardiomyocytes to assess β5- integrin in figure 24, which may not perfectly 
recapitulate the same protein expression pattern that is observed in adult 
cardiomyocytes. In addition, cardiomyocytes will certainly behave differently in 
culture than in vivo, and so may differentially express integrins according to their 
culture period and strategy.  
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Figure 24: Isolated cardiomyocytes and cardiac endothelial cells express 3 and 5 integrin 
receptor subunits in differing relative quantities. Mouse cardiac endothelial cells and 
cardiomyocytes were isolated as described and 3 and 5 integrin expression quantified using (a-
d) RT-qPCR or (e-g) western blots. Data are shown as mean ± SEM. Statistical analysis by 
student’s t-test; *P<0.05 versus control.  
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After having established that mouse cardiomyocytes and cardiac endothelial cells 
did in fact express β3- and β5- integrin, we next investigated the mechanism of 
action underpinning Cilengitide’s cardioprotective effects in vivo. To do this we 
isolated cardiac endothelial cells and cardiomyocytes in vitro and extracted RNA 
for RNA-Seq analysis. This allowed me to sample the entire genome for potential 
genetic targets of interest in cells both treated and untreated.  
 
500,000 endothelial cells were seeded in a T25 flask, serum starved for 24 hours, 
treated with either vehicle or low dose Cilengitide for 24 or 48 hours and then lysed 
for RNA-seq analysis. Briefly, raw reads were first aligned to the reference genome 
GRCm38/mm10 using HISAT2, at which point the number of uniquely aligned 
reads (q>10) which aligned to the exonic region of each gene was counted using 
HTseq. Only those genes that achieved at least one read per million reads (CPM) 
in at least 2 samples were kept, which gave us 13,459 filtered genes in total. Reads 
were further normalised using the ‘cqn’ method, accounting for gene length and 
GC content. Those filtered genes were analysed using initial principle component 
analysis (PCA), which revealed that between samples of the same group, the 
differential gene profile was wholly similar, indicating that within treatment groups 
different samples display an overall similar response to either vehicle or Cilengitide 
(figure 25a). As the separation was clear between groups, this means that 
differentially expressed genes in the future section were identified based upon 
FDR q < 0.05 and an absolution value of log2FC > 1. Differential expression (DE) 
analysis was performed using the ‘limma’ R package. 
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Under the microscope low dose Cilengitide treated endothelial cells appeared 
modestly more confluent than vehicle controls within 48 hours, and similarly 
elongated within the available flask space. Morphologically they were very similar, 
and if allowed to reach confluence, both treated and untreated cardiac endothelial 
cells exhibit a classic endothelial cobblestone morphology. After 24-hours of low 
dose Cilengitide treatment cardiac endothelial cells exhibit 146 differentially 
expressed genes versus vehicle controls (FDR q < 0.05 and absolute log2FC >1) 
of a total 13,459 filtered genes sampled. Of these, 36 transcripts are upregulated 
and 116 downregulated. For the top 10 most differentially regulated genes see 
table 16. Genes of interest which have previously been implicated as important or 
novel players during angiogenesis are highlighted and will be discussed later. 
These include: Mt2, Csf2rb, Nov, and Bcl6.  
 
At a whole pathway level, the most upregulated pathways include: cell-cycle 
mitosis, DNA-replication, cell-cycle transition and DNA-strand elongation (figure 
26a). Angiogenesis relies upon a complex balance of stimuli which will balance 
and modulate endothelial cell migration and proliferation [38]. In theory, active 
DNA-replication, mitosis and cell-cycle transition could point to the fact that cells 
are in an ‘active’ state of turnover or proliferation. Thus, for perhaps the first time 
these pathways combined appear to point to the fact that low dose Cilengitide will 
promote cardiac endothelial cell proliferation in vitro, which is a major driving force 
underpinning angiogenesis [307]. However, this conclusion needs to be tested 
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and/or verified with e.g. a cell-counting in vitro assay. In addition, the small sample 
size used in these preparations may have had an impact on results and need to 
be increased in future.  
 
After 48-hour treatment, many of those genes differentially expressed were similar 
to that which were differentially expressed after 24 hours of treatment. Versus 
vehicle controls, 107 genes are differentially expressed, of which 30 are 
upregulated and 77 downregulated, (FDR q < 0.05 and absolute log2FC >1) (of a 
total 13,459 filtered genes sampled). For the most differentially regulated genes 
see table 17. At a pathway level, the most enriched pathways correlate to: cell 
cycle mitosis reactome, cell cycle transition and DNA-replication (figure 27a). 
Between 24 and 48-hour treatments, only 54 genes were differentially expressed 
between groups, but none of these genes passed an FDR q <0.05 threshold, 
indicating the two group’s overall similarity.  
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Figure 25: Principle component analysis (PCA) demonstrates good clustering between 
cardiac endothelial cells treated with low dose Cilengitide.  Cardiac endothelial cells were 
plated, treated for 0, 24 or 48 hours with low dose Cilengitide (n=2 per group) and then isolated, 
sequenced via RNA-Seq, and clustered with PCA analysis. (a) Principle component analysis of 
treated cells.  
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Table 16: Top 10 most differentially expressed genes in cardiac endothelial cells after 24-
hour low dose Cilengitide treatment. Bold denotes angiogenesis-related genes that will be 
discussed later.  
  
Gene Name Log Fold Change (FC) 
24h LDCIL vs Control 
Description 
Mt2 4.60717235 metallothionein 2 [Source:MGI Symbol;Acc:MGI:97172] 
Fgf23 4.3769134 fibroblast growth factor 23 [Source:MGI Symbol;Acc:MGI:1891427] 
Mt1 2.88623252 metallothionein 1 [Source:MGI Symbol;Acc:MGI:97171] 
Csf2rb 1.93229863 
colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) 
[Source:MGI Symbol;Acc:MGI:1339759] 
Nov 1.90298234 nephroblastoma overexpressed gene [Source:MGI Symbol;Acc:MGI:109185] 
Hey2 -2.1800461 
hairy/enhancer-of-split related with YRPW motif 2 [Source:MGI 
Symbol;Acc:MGI:1341884] 
Lmntd2 -2.1884053 lamin tail domain containing 2 [Source:MGI Symbol;Acc:MGI:1919250] 
Bcl6 -2.7046606 B cell leukemia/lymphoma 6 [Source:MGI Symbol;Acc:MGI:107187] 
Mpl -2.9459403 
myeloproliferative leukemia virus oncogene [Source:MGI 
Symbol;Acc:MGI:97076] 
Ankrd55 -3.1127775 ankyrin repeat domain 55 [Source:MGI Symbol;Acc:MGI:1924568] 
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Gene Name Log Fold Change (FC) 
48h LDCIL vs Control 
Description 
Mt2 5.37494602 metallothionein 2 [Source:MGI Symbol;Acc:MGI:97172] 
Fgf23 4.71331743 fibroblast growth factor 23 [Source:MGI Symbol;Acc:MGI:1891427] 
Mt1 3.182225 metallothionein 1 [Source:MGI Symbol;Acc:MGI:97171] 
Csf2rb 2.88230495 
colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-
macrophage) [Source:MGI Symbol;Acc:MGI:1339759] 
Csf2rb2 2.59823504 
colony stimulating factor 2 receptor, beta 2, low-affinity (granulocyte-
macrophage) [Source:MGI Symbol;Acc:MGI:1339760] 
Nov 2.49984628 nephroblastoma overexpressed gene [Source:MGI Symbol;Acc:MGI:109185] 
Ankrd55 -2.4914517 ankyrin repeat domain 55 [Source:MGI Symbol;Acc:MGI:1924568] 
Bcl6 -2.5118543 B cell leukemia/lymphoma 6 [Source:MGI Symbol;Acc:MGI:107187] 
Gm567 -2.5485162 predicted gene 567 [Source:MGI Symbol;Acc:MGI:2685413] 
Mpl -2.7282001 
myeloproliferative leukemia virus oncogene [Source:MGI 
Symbol;Acc:MGI:97076] 
 
Table 17: Top 10 most differentially expressed genes in cardiac endothelial cells after 48-
hour low dose Cilengitide treatment.  
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Figure 26: Low dose Cilengitide stimulates DNA-replication, mitosis and cell-cycle transition 
in cardiac endothelial cells in vitro within 24 hours. (a) Enrichment plot analysis for those whole 
pathways enriched in 24 hour treated cells (n=2), versus untreated controls (n=2).  
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Figure 27: Low dose Cilengitide stimulates DNA-replication, mitosis and cell-cycle transition 
in cardiac endothelial cells in vitro within 48 hours. (a) Enrichment plot analysis for those whole 
pathways enriched in 48 hour treated cells (n=2), versus untreated controls (n=2).  
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4.10 Low dose Cilengitide as a dual function therapy for the treatment of 
heart failure (effect on cardiomyocytes) 
We have previously shown that both mouse and human cardiomyocytes express 
β3 and β5 integrin receptor subunits. This means that low dose Cilengitide could 
potentially be an effector of these cells to modify their underlying behaviour. 
Indeed, integrin-based modulation by external reagents can play a pivotal role in 
determining the health and biological activity of cardiomyocytes [308], but is not 
currently a well understood area of research. Because of this, we believe it is 
reasonable to postulate that Cilengitide may serve a dual purpose by potentiating 
effects in both cardiac endothelial cells and cardiomyocytes after administration. 
To study the mechanism underpinning the function, if any, of low dose Cilengitide 
in cardiomyocytes, we isolated cells from 1-3-day old pups, seeded cells at a 
density of 1 million cells per 6 well dish, and left them for 3 days before performing 
assays. The extraction of cardiomyocytes from pups did not involve any cell-
specific isolation techniques, and so cells must be left for 3 days (if not longer) to 
ensure media selection and enrichment of a cardiomyocyte population. Cultured 
cardiomyocytes proved to be very difficult to assay – they are not proliferative, 
begin to die within 6-7 days and the overall yield between preparations can vary 
drastically. The assay we eventually decided to use was to add angiotensin II (1µm 
for 48 hours) to cardiomyocyte media, which will generate cardiomyocyte 
hypertrophy within 24 hours. This same phenotype could then be assessed with or 
without low dose Cilengitide. Angiotensin II induces cardiomyocyte hypertrophy in 
vitro through the activation of protein kinase cascades, initiation of a foetal-like 
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gene program, impairment of calcium handling, and increasing the production of 
reactive oxygen species [309] [310] [311] [312]. In my hands, angiotensin II 
induced significant cardiac hypertrophy in treated cells within 24-hours (figure 
28a-b).  
 
Having established that angiotensin II will induce hypertrophy amongst 
cardiomyocytes, we investigated the effects of low dose Cilengitide in the 
cardiomyocyte using RNA-seq analysis. Here, we investigated vehicle control 
cardiomyocytes (n=3), angiotensin II (n=4), low dose Cilengitide (n=4) and 
angiotensin II and low dose Cilengitide combined treated cardiomyocytes (n=4). 
The analysis of these samples was made difficult due to the fact that low dose 
Cilengitide and low dose Cilengitide-angiotensin II treated cells exhibit large intra-
sample variation, as demonstrated by poor sample clustering in PCA (figure 29a). 
It was evident that, especially in low dose Cilengitide (alone) treated samples, that 
there were 2 samples that were similar to control cardiomyocytes, and two samples 
similar to angiotensin II treated cells (figure 29a). The method we used to isolate 
cardiomyocytes does not guarantee that preparations will be 100% ‘pure’ (i.e. 
consist of solely cardiomyocytes). Indeed, we estimate that a single well will 
consist of an average of 70% cardiomyocytes, with the rest appearing to be a 
mixture of endothelial cells and fibroblasts. This estimate is based upon the ratio 
of ‘beating’ to ‘non-beating’ cell-types. Between samples, and certainly between 
different preparations, there can be a large amount of variation in the purity of 
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cardiomyocytes, and this may explain the large intra-sample variation exhibited by 
some groups.  
 
To examine whether or not low dose Cilengitide will ameliorate the deleterious 
effects of angiotensin II in cardiomyocytes we compared RNA-seq pathway and 
gene analysis data from vehicle control, angiotensin II treated and angiotensin II-
low dose Cilengitide treated cells. This allowed us to highlight first specific genes, 
and next whole pathways, that were enriched in cardiomyocytes after the addition 
of Cilengitide. Table 18 shows those genes that are most enriched concordantly 
between control samples and angiotensin II-low dose Cilengitide treated 
cardiomyocytes, that have already been published in the cardiovascular field. 
Comparing control to Cilengitide-angiotensin II treated cardiomyocytes allowed us 
to establish a ‘healthy’ genetic baseline profile. For instance, both Irs2 and Glul are 
upregulated within control and angiotensin II-low dose Cilengitide treated 
cardiomyocytes, whilst they are downregulated in samples treated only with 
angiotensin II. Thus, they represent genes that may restore cardiomyocytes to a 
‘healthier’ phenotype after the addition of Cilengitide. In addition, we identified 
several whole signalling pathways that became differentially regulated by treating 
cardiomyocytes with Cilengitide in tandem to angiotensin II (figure 30a).  Of these, 
the most interesting was the fact that that angiotensin II alone will downregulate 
the PI3K-Akt pathway, but this pathway is moderately upregulated in those same 
cardiomyocytes also treated low dose Cilengitide (figure 30a). This may suggest 
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that low dose Cilengitide may upregulated PI3k-Akt signalling in cardiomyocytes. 
This will be discussed in further detail later.  
 
Next, we aimed to add human relevance to the in vitro observations and data we 
had already accumulated. To do this, we took available human microarray and 
RNA-seq data from Liu et al. [313] and compared this to my own in vitro RNA-Seq 
data. The human dataset included data from 6 RNA-seq and 313 microarray data 
sets - and included information from two subsets of heart failure: ischemic heart 
disease and dilated cardiomyopathy. The first question we asked was whether 
treating cardiomyocytes with angiotensin II results in changes to similar genes, or 
whole pathways, to that which were differentially expressed amongst heart failure 
patients. Interestingly, angiotensin II treated cardiomyocytes expressed a 
surprisingly similar number of differentially expressed whole pathways to that of 
ischemic and idiopathic dilated heart failure (figure 31a-b). Indeed, many of these 
enriched pathways were concordantly dysregulated between angiotensin II treated 
cardiomyocytes and human heart failure patients (figure 31c-d). This analysis 
provides novel evidence that angiotensin II will recapitulate many of the whole 
pathway features of human heart failure, which adds increasing validity to the 
model we have chosen to use. Having taken this into account, we sought to 
measure what whole pathways were most enriched across control 
cardiomyocytes, non-failing human heart patients and angiotensin II-low dose 
Cilengitide treated cardiomyocytes (figure 32 and 33). This was used to establish 
a ‘normal’ or ‘healthy’ pathway expression signature, which can point to a pathway 
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which underpins the effect of low dose Cilengitide in cardiomyocytes. Between 
pathways we found that a commonly upregulated ‘healthy’ signalling effector was 
PI3K-Akt, and a downregulated ‘healthy’ signalling effector was the TCA cycle. 
PI3K-Akt is relatively upregulated with low dose Cilengitide treatment, whereas 
TCA cycle metabolism is downregulated across all pathway analysis. The PI3K-
Akt pathway will be discussed in more detail later.    
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Figure 28: Angiotensin II induces cardiac hypertrophy in vitro. (a) Cardiomyocyte area in 
control and angiotensin II treated cardiomyocytes (n=50 cells) and (b) representative images. Data 
are shown as mean ± SEM. Statistical analysis by student’s t-test; *P<0.05 versus control.  
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Figure 29: Principle component analysis (PCA) demonstrates poor clustering between 
cardiomyocytes treated with vehicle, low dose Cilengitide, angiotensin II or angiotensin II-
low dose Cilengitide combined.  Cardiomyocytes were plated and left to expand for 3 days, 
before being serum starved for 24 hours and then treated with vehicle (n=3), low dose Cilengitide 
(n=4), angiotensin II (n=4) or angiotensin II-low dose Cilengitide (n=4) combined for 48 hours. 
Samples were sequenced via RNA-seq and clustered with PCA analysis. (a) Principle component 
analysis of treated cells.  
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Gene Log Fold Change (FC) 
AngII-LDCIL vs AngII 
Log Fold Change (FC) 
Control vs Ang II 
Log Fold Change (FC) 
Ang II vs Control 
Reference 
Sprr1a -1.7651457 -1.51252528 +1.51252528 [314] 
Irs2 0.65326632 0.4872927 -0.4872927 [315] 
Akap6 0.60451254 0.4761421 -0.4761421 [316] 
Lrrc10 0.69439078 0.6152291 -0.6152291 [317] 
Glul 0.98877967 0.8555815 -0.8555815 [318] 
 
Table 18: Candidate genes have previously been published as important factors in the heart. 
All represent a ‘healthy’ gene expression pattern – i.e. are concordantly enriched between 
control and angiotensin II-low dose Cilengitide treated cardiomyocytes.  
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Figure 30: Low dose Cilengitide dysregulates several enriched pathways in angiotensin II 
treated cardiomyocytes. (a) Whole pathway analysis of differentially expressed pathways 
between angiotensin II and angiotensin II-low dose Cilengitide treated cells. All those pathways 
selected P<0.05.  
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Figure 31: Gene set enrichment analysis (GSEA) reveals that there is a high concordance 
between those pathways enriched in angiotensin II treated cardiomyocytes and human heart 
failure. (a) Venn diagram illustrating overlap of GSEA pathways between angiotensin II treated 
cardiomyocytes and dilated human heart failure. (b) Venn diagram illustrating overlap of GSEA 
pathways between angiotensin II treated cardiomyocytes and ischemic human heart failure. (c) 
Scatterplot of the normalised enrichment scores (NES) of the 88 overlapping pathways identified 
by GSEA between angiotensin II treated cardiomyocytes and dilated cardiomyopathic heart failure 
patients. (d) Scatterplot of the normalised enrichment scores (NES) of the 83 overlapping pathways 
identified by GSEA between angiotensin II treated cardiomyocytes and ischemic heart failure 
patients. Only those pathways selected P<0.05.  
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Figure 32: Low dose Cilengitide will restore several enriched pathways back to ‘heathy’ 
levels in angiotensin II treated cells. (a) Heat map illustrating concordant gene expression 
pathways between vehicle and angiotensin II-low dose Cilengitide treated cardiomyocytes, and 
non-failing human tissue (versus dilated). Only those pathways selected P<0.05.  
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Figure 33: Low dose Cilengitide will restore several enriched pathways back to ‘heathy’ 
levels in angiotensin II treated cells. (a) Heat map illustrating concordant gene expression 
pathways between vehicle and angiotensin II-low dose Cilengitide treated cardiomyocytes, and 
non-failing human tissue (versus ischemia). Only those pathways selected P<0.05.  
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By this point we have established common pathways and genes that may indicate 
that low dose Cilengitide is a dual effector of cardiomyocytes and endothelial cells. 
My next priority was to functionally validate the information we had received from 
RNA-seq. RNA-seq appears to indicate that low dose Cilengitide will have some 
effect on isolated cardiomyocytes, and so we investigated whether Cilengitide will 
ameliorate cardiac hypertrophy in angiotensin II treated cardiomyocytes. As a 
readout of cardiomyocyte hypertrophy, we examined the RNA expression of 3 
hypertrophy-related genes used previously, that are also re-expressed as part of 
a deleterious cardiac foetal-like gene pattern: Myh7, ANP and BNP. Here, the 
addition of angiotensin II alone modestly increased the expression of Myh7, ANP 
and BNP, and this was somewhat reversed, especially for Myh7 (significantly), 
after the concordant addition of low dose Cilengitide (figure 34a). In contrast, low 
dose Cilengitide alone had no effect on cardiomyocyte hypertrophy (figure 34a). 
This provides tentative proof of principle evidence that low dose Cilengitide will 
restore a healthy phenotype within disease cardiomyocytes, although much more 
work needs to be done here.  
To functionally validate the pathways teased out by RNA-seq we performed 
preliminary westerns in cardiomyocytes treated with either: vehicle control (n=1), 
angiotensin II (n=1) and angiotensin II-low dose Cilengitide combined (n=1). This 
was a small sample size (n=1), but we saw no significant difference between 
groups (data not shown).  
Finally, because endothelial cells are important paracrine regulators of cell 
behaviour [306] (i.e. angiocrine signalling) we attempted to study the effect of 
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endothelial cell conditioned media on cardiomyocytes. Unfortunately, 
cardiomyocytes did not survive for an extended period of time in this media, and 
so we were unable to conduct the experiments we had hoped.  
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Figure 34: Low dose Cilengitide may reverse cardiac hypertrophy in cardiomyocytes. (a) 
Relative ANP, BNP and Myh7 expression in cardiomyocytes treated with: vehicle control, low dose 
Cilengitide, angiotensin II and low dose Cilengitide-angiotensin II combined (n=1 preparation).  
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4.11 Summary of chapter results 
 
The results presented during this chapter show that: 
 
1) Both human cardiac endothelial cells and cardiomyocytes express β3 and 
β5 integrin receptor subunits. 
2) The relative expression of β3 and β5 integrin receptor subunits does not 
differ in heart failure in both humans and mice. 
3) Treatment with low dose Cilengitide will reduce or even reverse disease 
severity in a murine model of pressure-overload induce heart failure. 
4)  Low dose Cilengitide will enhance cardiac angiogenesis.  
5) Low dose Cilengitide may enhance endothelial cell proliferation in vitro.  
6) Low dose Cilengitide may potentiate a number of cellular signaling 
cascades within cardiomyocytes in vitro, which themselves may restore a 
healthy cardiomyocyte phenotype after injury. 
7) Low dose Cilengitide may be an effector of cardiomyocytes in vitro to 
ameliorate cardiac hypertrophy.  
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CHAPTER 5.0: DISCUSSION 
 
VASCULAR PROMOTION IN HEART FAILURE 
 
 
In the previous chapter we optimised a murine model of heart failure (TAC) and 
used it to determine the utility of low dose Cilengitide in a murine model of heart 
failure. To this end, we first establish that the targets of Cilengitide, v3 and v5 
integrin, are expressed in cardiac endothelial cells and cardiomyocytes in both 
mice and humans. The relative whole expression levels of those 3 and 5 integrin 
receptor subunits are not differentially expressed, either in two subtypes of human 
heart failure, or in a pressure-overload induced murine model of heart failure, as 
compared to controls. Both prevention and intervention studies show that 
treatment with low dose Cilengitide will suppress many of the deleterious features 
of cardiac pathobiology which are induced following pressure-overload induced 
heart failure, including: cardiac contractility, LV dilatation, cardiac hypertrophy and 
foetal-gene expression pathways. Those improvements in cardiac disease severity 
are concordant to an increase in myocardial angiogenesis. Specifically, low dose 
Cilengitide will significantly increase the number of microvessels in the left 
ventricles of ‘diseased’ hearts, but has no effect on the number of mature, -SMA 
covered vessels in those same sections. Finally, we include preliminary evidence 
that show low dose Cilengitide will potentiate a number of intracellular signalling 
cascades in vitro to propagate cardiac endothelial cell proliferation, and which may 
also restore cardiomyocytes to a healthier phenotype after their injury. These 
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results together provide rudimentary proof of principle evidence that low dose 
Cilengitide may function as a dual function effector of both cardiac endothelial cells 
and cardiomyocytes to modify their underlying behaviour, which may be effective 
in the treatment of heart failure.  
 
5.1 Caveats to the TAC model of murine heart failure 
 
Heart failure is a common, complex condition that is often concurrently associated 
with multiple secondary conditions, like diabetes and pulmonary disease. This 
ensures that the animal modelling of heart failure is very difficult. The majority, if 
not all, of the models available to us will not recapitulate many of the features of 
human heart failure, but instead offer us a reductionist setting to model more 
specific features. The TAC model herein offers an excellent system to model 
pressure-overload induce heart failure but is attached to a few caveats. The most 
major of these is the fact that TAC may be variably characterized as a model of 
either pressure overload induced hypertrophy of pressure overload induced heart 
failure.  Mohammed et al. [304] show that TAC surgery will only induce heart failure 
in a subset (28% of mice). Importantly, their classification of heart failure was that 
mice develop pulmonary congestion. Those mice that did not develop pulmonary 
congestion, which itself was classified according to lung weight, were instead 
categorized as mice with compensated LV hypertrophy. The mean ejection fraction 
of the mice within these groups differed significantly. We did not measure lung 
weight in my own study, and instead classified heart failure according to more 
fundamental cardiac parameters, like cardiac hypertrophy, contractility and LV 
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dilatation. We do see some variability amongst cardiac contractility changes in my 
own study, but this itself has not been an overt issue, as the vast majority of those 
mice develop at least modest cardiac pathobiology. Variability amongst mice 
undergoing TAC surgery most obviously manifested as a problem during the 12-
week study in figure 21.  Here, only 50% of mice developed significantly reduced 
cardiac contractility, and those that did had to be culled by the experimental end 
point due to their symptoms (ejection fraction less than 10% in one measured 
case). This left me with 3 mice that clearly did not develop significant heart failure, 
which made it more difficult to properly interpret the results of this study as we have 
previously. If we were to use the TAC model in future, we would put more stringent 
roadblocks in place to minimize the variability amongst mice and to maximise the 
efficacy of the surgery. The first of these would be to assess the dimensions of the 
aorta before surgery. Mice would then be stratified not by their weight, but by their 
aortic size. This should ensure that the pressure gradient generated by the aortic 
band is more similar between mice, which should in turn generate cardiac 
pathobiology with less variability. In addition, it may be necessary to stratify mice 
according to their LV ejection fraction by 3 weeks and remove those mice did not 
meet a specific criterion. This could further ensure that we only choose those mice 
that have absolutely developed heart failure with reduced ejection fraction for later 
study. Of course, minimizing groups according to these selection criteria generates 
its own problems, in that any future conclusions we draw from those groups will 
only reflect a very small subset of heart failure cases, whereas previously we may 
have been utilizing models that more accurately reflect a wider group of patients. 
 192 
Aside from also classifying heart failure differently, Mohammed et al. also used a 
subtly different model than my own to generate their data. Investigators modelled 
aortic constriction at the thoracic level in the aortic arc, whereas we used a model 
of abdominal aortic constriction. Thoracic TAC will generate a significantly higher 
early mortality rate (32% survival by 3 weeks) as compared to our own study (90% 
survival by 3 weeks) and will also induce more significant cardiac hypertrophy and 
inotropy changes [304]. The fact that thoracic TAC induces higher early mortality 
may mean that there is actually a significantly higher subset of mice that actually 
develop heart failure within this study, but they were not accurately depicted 
because they were not sufficiently investigated before their death. This may 
explain why most studies choose to only investigate thoracic TAC across a 2-week 
period [319].  Overall, we think it is reasonable to suggest that the variability 
amongst TAC surgeries is a caveat to the model, but we think they can certainly 
be minimized with effective checks in place and probably did not overtly influence 
my own study negatively.  
 
5.2 v3 and v5 integrins are not differentially expressed during cardiac 
disease 
3 and 5 integrin receptor subunits are not differentially expressed in either a 
mouse model of heart failure or subtypes of human heart failure itself. This may be 
due to the type of hearts we investigated, or rather the stage of disease that they 
reflect. The tissue used here could represents ‘late-stage’ disease, although as 
discussed earlier we do not have the evidence to ascertain this, especially in the 
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human myocardium. We use this term to describe myocardium that has already 
transitioned from compensated to uncompensated heart failure, and so manifests 
as deleterious, symptomatic, cardiac pathobiology. Increasing evidence suggests 
that integrins play a pivotal role in cardiovascular remodelling [320] [321]; and so, 
by strictly investigating late-stage heart failure tissue, we may have missed 
significant integrin expression changes that occur during acute cardiac 
remodelling. The integrins involved may then be downregulated to normal levels 
after this phase has ended, to be replaced by other proteins (including integrins) 
whose function instead serves to potentiate chronic remodelling. Cardiac 
remodelling constitutes changes in the size, shape, structure and function of the 
heart. Those changes are characterized by rearrangement of the architecture of 
the cardiac ventricular wall, which involves (among others) myocyte hypertrophy, 
fibroblast proliferation, increased deposition of ECM proteins and altered 
expression of miRNAs [322] [323] [324].  
Because integrins are the principle anchoring proteins of myocardial cells to one 
another and to the ECM, it is probable that their expression will change temporally 
as the structures they anchor themselves change. Indeed, a variety of integrin 
heterodimers are altered concomitantly with the initiation of both acute and chronic 
cardiac remodelling. In rodents, increased expression of 1A, 1D, 1, 3 and 5 
(among others) have been detected after aortic constriction, whilst 1, 3 and 5 
integrin subunits will also change temporally after MI [325] [265] [264]. MI involves 
both an acute healing phase and also a chronic remodelling phase. Work has been 
performed to evaluate the changes in several integrin subunits across these 
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stages. Early work saw that by 7 days post MI 1 was expressed in both the normal 
myocytes of the peri-infarct zone and also the myocytes of the remodelled tissue 
within the infarct zone itself. The peri-infarct expression of 1 remained elevated 
at 6 weeks post MI, but its expression within remodelled tissue was downregulated. 
By contrast,  5 integrin expression was increased in peri-infarct regions by day 7 
but returned to normal levels within 2 weeks [264].  
More recently, myocardial v3 integrin expression was shown to be upregulated 
within 2 weeks of MI in infarct regions [287]. Interestingly its expression here is 
thought to activate latent myofibroblast differentiation and also induce myocardial 
salvage by increasing angiogenesis [277] [287]. By 10 weeks post-MI v3 integrin 
expression persisted in infarct regions but was reduced in comparison with 2 week-
assessment [287]. In addition, multiple other studies have also demonstrated that 
v3 integrin will accumulate at early sites of infarction. Those same studies 
collectively demonstrate its levels will peak between 1 and 3 weeks, and will then 
begin to decline [285] [326] [327]. 
Furthermore, the subcellular localisation of integrins may also change during 
remodelling. For instance, pulmonary artery banding will result in mobilization of 
3 integrin to the cytoskeleton of lysed myocardial fractions within 4 hours, but by 
48 hours its expression was found in both cytoskeletal and membrane-bound 
fractions. Thereafter its levels returned to baseline within 1 week [328]. We saw 
that v5 especially was concentrated within focal contact costameres of the 
cardiomyocytes (as expected) but did not analyse its subcellular localisation or 
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concentration within costameres, and so did not observe any changes in its 
localisation after disease.  
Certainly, these studies together demonstrate the importance of  v3 integrin 
especially during cardiac remodelling. Indeed, other studies reinforce the notion 
that 3 integrin subunits play an important role in the stressed myocardium [276] 
[275] [259].  For example, Johnston et al. show that when aortic constriction is 
performed on 3-null mice they will exhibit reduced compensatory hypertrophy and 
depressed ventricular function, which results in increased mortality [276]. Similarly, 
3-null mice in a secondary study show increased myocardial cell death after 
pressure-overload, demonstrating that 3 integrin contributes toward 
cardioprotective signalling [259].  
Collectively this indicates that the expression of 3 and 5 integrins may only be 
differentially expressed early on in the cardiac remodelling process, which is why 
we didn’t see any expression changes in late disease tissue. In order to more 
accurately reflect their localisation, expression and function we may need to in 
future analyse tissue taken from hearts early after surgery, such as within 1-2 
weeks of TAC. With that said, it is important to note that the studies discussed here 
will often use different imaging modalities to quantify temporal integrin changes. 
Those techniques may differ in sensitivity, and so two different imaging modalities 
for the same event may yield different results.  we have used immunofluorescence, 
western blotting and RT-qPCR to investigate the expression changes of 3 and 
5-integrin receptor subunits, and so a different imaging modality may give 
different quantitative results.  
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5.3 Cilengitide functions as a dose dependent regulator of cardiac 
pathobiology in pressure-overload-induced heart failure 
In this present report we show that low dose Cilengitide will ameliorate many of the 
cardiac disease features of pressure overload induced murine heart failure. These 
effects are dose-dependent and may even be continued after Cilengitide’s 
cessation. To my knowledge this is the first time Cilengitide has been used for this 
treatment purpose. Cilengitide has previously undergone clinical study trialling its 
anti-tumour efficacy but has not achieved its expected clinical outcome [250]. 
Considering the wealth of clinical data available, and the fact that chemotherapy 
may often induce concomitant cardiotoxicity in patients [329], one might expect 
that there is human data available that might indicate that Cilengitide will improve 
cardiac function if my findings were to be true. Unfortunately, we have not been 
able to find any data supporting this theory however, probably because patients 
with serious heart disease are often excluded from clinical trials, and also because 
the dose of Cilengitide used in human trials does not constitute sustained ‘low 
dose’ therapy.  
Despite displaying efficacy in the model used here, it is important that the utility of 
Cilengitide is studied in other murine heart failure models. These investigations 
could also be extended to models of peripheral artery disease (PAD) and cerebral 
ischemia, where Cilengitide also may yield benefit.  
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5.4 Low dose Cilengitide enhances cardiac angiogenesis 
 
Low dose Cilengitide enhanced myocardial angiogenesis in a murine model of 
heart failure, but not in SHAM surgical controls. This suggests that Cilengitide will 
only potentiate angiogenesis in challenged but not quiescent or unchallenged 
organs. It would be interesting to investigate whether angiogenesis was 
upregulated in other organs, such as the skin or in the eye, as this would give us 
a readout of how Cilengitide will affect ‘unchallenged’ organs. However, previous 
work from our lab indicates low dose Cilengitide has no effect on blood vessels 
density in non-stressed or non-damaged tissue {Reynolds, 2009 #78}. Overall, 
Cilengitide probably had no, or only minimal angiogenic effects in ‘offsite’ tissue. 
We saw no deleterious side effects of therapy, as might be seen if there was 
excessive angiogenesis in the retina, for example. In this fashion, we expect that 
tissue needs to be ‘primed’ before low dose Cilengitide will enhance angiogenesis. 
Reynolds et al. demonstrate that low dose Cilengitide will enhance angiogenesis 
in tumour models [4], which themselves are tissues that are already undergoing 
extensive vascular remodelling once a specific volume is reached. Similarly, the 
TAC model used here will undergo changes in capillary density without the 
administration of pro-angiogenic therapy, and so the tissue may be equally ‘primed’ 
for Cilengitide function [119]. This raises the question of what primes a tissue-type 
for later Cilengitide activity. In this case it may be endogenous pro-angiogenic 
factors like VEGF, or even an upregulation of  v3 itself. Both factors are notably 
upregulated in the early phases of myocardial angiogenesis, and also in tumours 
[220] [287] [330] [331].  
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The mechanism underlying the pro-angiogenic effects of low dose Cilengitide are 
that therapy will promote recycling of both v3 and VEGFR-2, which in turn will 
attenuate the degradation of VEGFR-2 and also enhance the recruitment of v3 
to focal contacts [4]. Indeed, there is evidence elsewhere that v3 and VEGFR-
2 are able to directly interact, which reinforces the notion that the two are able to 
modulate one another’s function [217]. 
VEGFR-2 appears to mediate almost all known cellular responses to VEGF [332], 
so conceivably almost all subtypes of VEGF could be responsible for increasing 
myocardial angiogenesis after low dose Cilengitide. The most obvious candidate 
for enhancing myocardial angiogenesis is VEGF-A, but this might not necessarily 
be the case. VEGF-A is persistently downregulated in the infarcted myocardium 
post MI. Its expression was only significantly increased at the border zone 1 day 
after MI, but not in later stages, which may indicate that VEGF-A may initiate 
angiogenesis but is not necessary for its later stages [220]. In contrast to this, 
VEGF-A isoforms have been detected in myocardial infarct regions at points as 
late as 40 days post MI in other MI models, which seems to suggest its continual 
angiogenic involvement [333]. This may reflect the fact that the two studies used 
different methods to evaluate the expression of VEGF-A.  
It may be that VEGF-A is downregulated at later time points to ensure proper 
vascular stabilization. Indeed, the transgenic over expression of VEGF in 
cardiomyocytes will result in the production of abnormal vascular trees, which 
consist of irregular, sac-like vessels, which ultimately lead to ‘leakiness’, and a 
highly disruptive oedema in the adult heart [334]. This highlights the fact that VEGF 
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must be downregulated to facilitate vascular maturation. Indeed, recent studies 
have shown that v3 can exert phosphorylation dependent transdominant effects 
over VEGFR-2 [226]. In this fashion, v3 may potentiate or dysregulate VEGF 
signalling according to its own phosphorylation status.  
If Cilengitide does indeed potentiate VEGFR-2 activity, and VEGF must be 
downregulated to achieve vascular maturity, then Cilengitide may actually 
generate immature, ‘leaky’ blood vessels. We saw no obvious vascular oedema, 
and the microvessel morphology in low dose Cilengitide treated myocardium 
appeared to be similar to that of controls. Unfortunately, we were unable to 
properly assess the maturity of the microvessels however, as, unlike in tumours, 
-SMA did not mark pericytes that associate with myocardial capillaries. Instead 
-SMA only appeared to mark vessels that were much larger than what we have 
classified as microvessel capillaries.  Overall the number of -SMA positive 
vessels were similar between all groups, which is unsurprising given the type of 
vessels that -SMA marks in my samples. More work certainly needs to be 
conducted to investigate the type of vessels generated after the administration of 
Cilengitide. One possible method could be to intravenously inject PE 
(phycoerythrin) labelled CD31 into mice before culling, which will then mark ‘active’ 
vasculature. These could then be measured against unlabelled CD31+ (488) 
vessels in sections to determine the ratio of inactive to active microvessels.   
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5.5 Low dose Cilengitide as a dual action therapy 
 
Herein we provide preliminary evidence that low dose Cilengitide may potentiate 
cardiac endothelial cell proliferation, as well as restore cardiomyocytes to a 
healthier phenotype after their injury. Thus, Cilengitide at nanomolar 
concentrations will function as a dual function effector of both cardiac endothelial 
and cardiomyocyte cell types in vitro. Furthermore, we show that both cardiac 
endothelial cells and cardiomyocytes express the necessary v3 and v5 
receptors for Cilengitide function, which reinforces this notion.  
Notably, we show that low dose Cilengitide will upregulate the expression of Mt2, 
Csf2rb and Nov, and also downregulate Bcl6 in isolated cardiac endothelial cells. 
All have been shown to be pivotal players during angiogenesis.  
Mt1 and 2 are more classically categorized as regulators of metal detoxification as 
part of cellular homeostasis. However, more recently Mt2 is demonstrably required 
for endothelial cell migration, proliferation and angiogenic sprouting upstream of 
VEGF-C in zebrafish [335]. Similarly, CCN3 (Nov) will support endothelial 
adhesion, migration and survival. It will bind directly to v3, which will determine 
CCN3-induced endothelial cell migration. In addition, CCN3 will induce 
neovascularization in rat corneas and its expression is also altered in a variety of 
tumours, whereby it may be a novel mediator of tumour angiogenesis [336]. 
Finally, the inhibition of Bcl6 will induce endothelial sprouting, and will also control 
Notch target genes like Hey2, which is another downregulated protein highlighted 
by RNA-seq analysis in treated endothelial cells [337]. We need to functionally 
validate these targets with proteomic analysis to be certain that their expression is 
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differentially regulated. In addition, we also need to perform function assays to 
demonstrate that low dose Cilengitide will indeed induce cardiac endothelial cell 
proliferation. Low dose Cilengitide will induce migration, but not proliferation, in 
lung endothelial cells [4], so it is perhaps surprising that RNA-seq seems to point 
to the fact that low dose Cilengitide will potentiate proliferation in the cardiac 
endothelium.  However, cardiac endothelial cells do exhibit a distinct gene 
expression profile when compared to pulmonary endothelial cells so there is 
certainly evidence to indicate it is feasible for the two cell types to differentially 
respond to a given therapy [120].  
 
The major pathway that was highlighted as an important feature of cardiomyocyte 
signalling after low dose Cilengitide administration was the PI3K-Akt pathway. This 
signalling cascade was ostensibly highlighted as a signature of cardiomyocyte 
health, in that it was upregulated in low dose Cilengitide and vehicle treated 
cardiomyocytes and also in non-failing human hearts. The PI3K-Akt pathway will 
promote cardiomyocyte proliferation, survival and physiological hypertrophy, and 
so low dose Cilengitide may perpetuate those functions in the cardiomyocyte [338]. 
RGD stimulation in adult cardiomyocytes will activate 3 integrin, which is 
accompanied by c-Src sarcolemmal localisation, and also p130Cas binding and 
FAK phosphorylation [275]. FAK is thought to be upstream of NF-kB in 
cardiomyocytes and will regulate their survival following ischemia reperfusion 
injury through NF-kB [339]. The NF-kB survival pathway also has the ability to 
crosstalk with PI3k-Akt pathways in some cell types [340], so this same interaction 
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may be present in the cardiomyocytes also.  Similarly, studies show that RGD 
stimulation will activate pro-survival ubiquitination and NF-kB pathways in 
cardiomyocytes in vitro [276]. Finally, the in vivo ablation of 3 can lead to calpain 
mediated myocardial cell loss [259]. Importantly, calpain activation will inhibit Akt 
signalling in rat diaphragm muscle [341], highlighting that  v3 could indeed 
potentiate Akt signalling by downregulating calpain activity. Collectively these 
studies show that RGD mimetics can regulate cardiomyocyte behaviour, possibly 
through modulation of the NF-kB and PI3K-Akt signalling. We certainly need to 
functionally validate those same pathways in my own cardiomyocyte preparations 
after treatment with low dose Cilengitide to ascertain the data we obtained by RNA-
seq. 
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5.6 Future work 
 
The main objective of any future work should first aim to clarify the mechanism of 
low dose Cilengitide function in vitro. To do so, we would continue to perform 
western blot analysis for phosphorylated Akt in Cilengitide and angiotensin II 
treated cardiomyocytes. We have isolated the PI3K-Akt pathway as a potentially 
important target signalling target of low dose Cilengitide, and we require functional 
validation of the RNA-seq data that initially highlighted this. In parallel we would 
perform MTT and cell counting assays on low dose Cilengitide treated cardiac 
endothelial cells to functionally validate the hypothesis that low dose Cilengitide 
will induce proliferation in those cells. In addition, we would investigate how 
conditioned media from low dose Cilengitide treated and untreated cardiac 
endothelial cells effects cardiomyocyte viability, hypertrophy and survival after their 
injury with angiotensin II.  
In the long term, we think it would be interesting to examine functional and genetic 
differences between cardiac endothelial cells isolated from mice that had 
undergone TAC surgery, and those that had undergone TAC surgery, both 
untreated and treated with low dose Cilengitide. The experiments themselves here 
would be tricky, as the initial isolation of cardiac endothelial cells yields a very small 
number of cells which may be insufficient for investigation but plating them to 
expand colonies for assessment could minimize any differences in phenotype 
between the cells. Similarly, we would have liked to focus on isolating adult 
cardiomyocytes, and in an ideal would examine them over the foetal 
cardiomyocytes we have used previously. Adult and foetal cardiomyocytes display 
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significantly different functional features, including cell morphology, 
electrophysiological characteristics, sarcomere organization and contractile force, 
which means that the two cell-types may yield different results under investigation 
[342] [343]. Examining cardiomyocytes from adult mice would also mean that we 
could determine the functional effects of TAC surgery on those myocytes, both 
with and without Cilengitide. we would have liked to perform functional siRNA 
knockouts of targets on those mice, to more properly ascertain the functional 
mechanism of low dose Cilengitide on those cells.  
Furthermore, it would be interesting to observe the effects of low dose Cilengitide 
therapy in other mouse models, including after myocardial infarction. Pro-
angiogenic therapy appears to be a promising strategy to treat MI, as the formation 
of microvessels could salvage ischemic myocytes, especially in its early stages 
[295].  
In addition, we would have liked to further delineate how low dose Cilengitide will 
enhance cardiac angiogenesis. We have so far been able to postulate using RNA-
seq data and the information from the Reynolds et al. paper, but this is no 
substitute for actually measuring the activity of e.g. VEGFR/VEGF activity within 
those treated hearts. Similarly, it would have been interesting to observe how v3 
and v5 expression and activity changes a) temporally after TAC surgery and b) 
temporally after low dose Cilengitide therapy. To do this we could sacrifice mice at 
various time points and examine protein/RNA levels with western blots and RT-
qPCR respectively. It may be that those integrin expression does not change 
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temporally within the whole heart itself, and so we may more specifically need to 
classify changes within particular areas, such as the wall of the LV itself. 
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6.1 Focal adhesion kinase (FAK) 
Focal adhesion kinase (FAK) is a cytoplasmic, non-receptor tyrosine kinase that 
plays a vital role in integrin and growth factor mediated signalling, extending to 
functions in a variety of cellular processes including: motility, focal adhesion 
turnover, survival, growth and invasion [344]. FAK is ubiquitously expressed 
across most cell types and is overexpressed within many types of solid and non-
solid tumours [345] [346]. FAK is concentrated within specialized intracellular 
structures called focal contacts. Focal contacts are the interface site between 
integrins and the cytoskeleton, which together mediate adhesion to the 
extracellular matrix (ECM). In general, they are composed of dynamic groups of 
structural, adaptor and regulatory proteins which transduce both extracellular, and 
intracellular, activity [347].  The subsequent sections will outline FAK expression, 
function, structure and activity, with particular emphasis upon its pivotal role in the 
endothelium.   
  
CHAPTER 6.0: INTRODUCTION 
 
FOCAL ADHESION KINASE AND ANGIOCRINE SIGNALLING IN CANCER 
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6.1.1 FAK domains, associated proteins and downstream signalling 
pathways 
Structurally, FAK is composed of a central catalytic kinase domain, a carboxyl-
terminal focal adhesion targeting (FAT) domain and an N-terminal regulatory 
FERM domain (see figure 1). Historically, FAK function has more generally been 
attributed to its central kinase domain kinase activity, but this has more recently 
been challenged by its interrelated scaffold function [345].  The FAT domain of 
FAK is necessary and sufficient to direct FAK to focal adhesion complexes. Its 
integrity is absolutely vital for FAK signalling as cells displaying FAK isoforms with 
a truncated FAT domain do not spread or migrate as normal [348]. Structural 
studies reveal that the FAT domain of FAK is composed of a four-helix bundle that 
resembles alpha-catenin and vinculin, two other cellular adhesion proteins [349]. 
Paxillin binding to the FAT domain requires the integrity of the four helical bundle, 
but binding to other proteins, like talin for instance, does not [349]. Together, 
paxillin and talin appear to mediate focal adhesion targeting [350] [351].  
The C-terminal of FAK also contains FRNK (FAK-related non-kinase) in certain 
cells. FRNK is thought to be a negative regulatory of kinase activity [352]. FRNK 
is upregulated in vascular smooth muscle cells and may be upregulated in vascular 
injury [353]. The forced overexpression of FRNK in FAK inhibits cell spreading, cell 
migration and growth factor-mediated signals to MAP kinase [353] [354] [355].  
The FERM domain of FAK on the other hand is thought to be the majority binding 
site linking the plasma membrane to cytoskeletal structures at specific cellular 
locations [356]. To this end, integrins, PDGF receptors and c-Met will bind to the 
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FERM domain, amongst others [357] [358]. The FERM domain also contains a 
nuclear localisation signal (NLS) which indicates that FAK can shuffle between the 
nucleus and membrane. Indeed, in the nucleus FAK promotes cell survival and 
proliferation whilst at the membrane FAK regulates integrin-dependent cell 
interactions with the ECM [356]. In addition, the FERM domain has also been 
implicated in FAK auto-inhibition. We know this because deleting the first 375 
amino acids of FAK at its N-terminal will increase its catalytic activity and also 
directly inhibit cell-cycle progression in CHO cells in vitro [359] [360]. In addition, 
the analysis of several point mutations in the FERM domain of FAK revealed that 
some of those mutations increased FAK phosphorylation whilst others decreased 
it, which reinforces the notion that the FERM domain is an important regulator of 
FAK activity [361]. The precise molecular and structural basis for FERM auto-
inhibition describes a model whereby the FERM domain will bind directly to the 
kinase C-lobe, which impedes access to the active cleft that contains Tyr 397 and 
the Src recognition site [362].  
The central portion of FAK is thought to be the catalytic, or kinase, domain (figure 
35). The activation of FAK and its downstream signalling via this domain is a 
complex process [363]. A model has been proposed to describe this from 
accumulating from crystallography studies [359] [361] [364]. Briefly, prior to 
activation FAK is maintained in an inactive conformation in which the FERM 
domain impedes access to the active site of the FAK kinase domain. This prevents 
phosphorylation of the Tyr 397 residue of FAK, which leads to FAK auto-inhibition. 
Integrin clustering at focal contacts of the cell membrane initiates a signal that 
 209 
releases the auto-inhibitory interaction between the FERM and kinase domains, 
leading to kinase activation and subsequent autophosphorylation of Tyr 397. There 
is evidence that Tyr 397 can also be transphosphorylated to activate FAK 
signalling, but it is unclear how much non-canonical activity like this contributes to 
overall FAK function [365]. Phosphorylation of Tyr 397 provides a high-affinity 
SH2-binding site which allows Src, or other SH2-binding proteins like 
phospholipase C (PLC), to functionally interact with FAK. Next, Src 
transphosphorylates FAK on a number of key tyrosine residues, including Tyr 576, 
Tyr 577, Tyr 861 and Tyr 925. It is thought that Tyr 576 and Tyr 577 in particular 
are required for maximal catalytic activity [366]. The phosphorylation of Tyr 861and 
Tyr 925 together increases the binding of proteins like p130Cas, paxillin and GRB2 
to FAK. In this instance, p130Cas binding will go on to potentiate the PI3-kinase 
signalling pathway, GRB2 will activate the MAPK signalling pathway. Both are 
thought to differentially mediate focal adhesion dynamics, proliferation and survival 
[367]. On top of all this, Tyr 861 phosphorylation may itself result in further auto-
phosphorylation of Tyr 397, which adds multiple layers of complexity to FAK 
signalling [368].  
FAK also contains four serine residues that can be phosphorylated: serines 722, 
732, 843 and 910. Serine phosphorylation is thought to modulate binding and 
stability of downstream signalling proteins [369]. Ma et al. show that of these, Ser 
722 may play a role in regulating FAK binding to the SH3 domain of p130Cas. This 
did not manifest as any functional changes in this study during mitosis however. 
Instead, Ser 843 and 91 exhibit increased phosphorylation during mitosis [370]. In 
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addition, it was shown that the phosphorylation of Ser 843 inhibits Tyr 397 
phosphorylation, which inhibited cell migration and spreading [371].  
Aside from phosphorylation there are other events governing FAK kinase activity. 
Perhaps the most well studied mechanism of this demonstrates that 
autophosphorylation of Tyr 397 will differ significantly between FAK isoforms.   The 
functional effects of this were not established in this particular study however [365].  
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Figure 35: FAK structure and function. Canonical FAK signalling involves a number of events: 
(1) ligand-bound growth factors or clustered integrins initiate signals that release the auto-inhibitory 
interaction between the FERM and kinase domains, leading to FAK kinase activation by facilitating 
ATP binding. (2) FAK autophosphorylates Tyr 397. (3) phosphorylation creates a high affinity 
binding site for Src. (4) Src transphosphorylates FAK at key FAK residues including Tyr 861 and 
925. (5) p130cas binds proline-rich domains of phosphorylated FAK and is phosphorylated itself.  
(6) downstream signalling of activated FAK elicits changes in cellular morphology and behaviour, 
including changes in motility, focal adhesion turnover, survival, growth and invasion. Taken from 
[344].  
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6.1.2 FAK in tumour cells 
FAK lies at the intersection between several important signalling pathways in 
cancer growth and metastasis, including cell motility, invasion and epithelial-
mesenchymal-transition (EMT) [372]. Conditional tissue-specific mouse models 
and chemical FAK inhibitors combined with the study of human cancers have 
together allowed investigators to delineate the involvement of FAK in several solid 
and non-solid cancers. Early examples of this include Weiner et al. who saw that 
FAK mRNA was upregulated in a number of human cancer tissue samples which 
covered a range of neoplasms and malignancies [373]. Similar findings were seen 
across colon and breast tumour samples [374], and more recently thyroid, 
prostate, cervix, colon, rectum, oral epithelium and ovary cancers [375]. Indeed, 
increased FAK expression and activity frequently correlates with poor prognosis, 
malignancy or metastasis which could indicate that FAK protein levels are a 
valuable prognosis indicator [376] [377] [378].  The mechanisms that underpin the 
fact that FAK is increased in tumour cells are not well understood, but one study 
postulates that the amplification of FAK gene copy numbers may be a contributing 
factor, especially in head and neck cancer [379].  
More direct involvement for the involvement of FAK in both tumour formation and 
malignancy progression comes from an early mouse skin carcinogen model. Here 
Quintanilla et al. show that FAK expression was increased in a stepwise fashion in 
cell lines derived from progressive stages of the mouse skin cancer [380]. When 
global FAK heterozygote knockouts are analysed in this same skin assay ‘half 
FAK’ is sufficient impair papilloma formation [381]. In addition, the conditional 
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deletion of FAK in epidermal cells substantially reduces both the formation and 
progression of skin carcinomas in mouse models, probably through enhanced 
apoptosis of those cells harbouring deletion [381].  
The success of these observations has led to FAK kinase inhibitors progressing to 
clinical trial. As is often the case, the initial positive results observed in mice with 
these same inhibitors have not yet translated to efficacy in humans however.  This 
may be due to the fact that FAK inhibitors will not only affect tumour cells, but also 
other cells of the tumour microenvironment, including pericytes, endothelial cells 
and fibroblasts. For example, PF-573,228 produces a defect in platelet 
aggregation in vitro so could consequently induce similar, if not deleterious, 
aggregation defects in vivo [382].  
Additionally, tumour growth and malignancy may not strictly be characterized by 
an overexpression of FAK protein. It has been reported that in some cancers, such 
as cervical or liver metastasis, low FAK expression actually correlates to a much 
poorer prognosis [383] [384]. Furthermore, inhibiting FAK correlates with increases 
in tumour cell migration, invasion and metastasis in some human carcinoma lines 
[385]. Together this implies regulating global FAK may not strictly yield the most 
effective anti-cancer efficacy across all variants.  In fact, recent evidence from 
colleagues indicates that the endothelial cells themselves may be a promising 
FAK-related target in the fight against cancer [305, 306].  
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6.1.3 Endothelial cell FAK - Angiogenesis  
Tumours, like any other organs, require a system of blood vessels to ensure that 
their oxygen and nutrient requirements are met. This is achieved primarily through 
angiogenesis. Early stage, pre-malignant tumours will typically display little or no 
intra-tumour vascularization. In contrast, malignant tumours exhibit robust intra-
tumoural angiogenesis. The progression of tumours from a benign to a malignant 
state involves the activation of the so-called ‘angiogenic switch’ [386]. It is this 
switch that triggers the development of a vascular network that will facilitate the 
active growth and invasiveness of tumours. Hypoxia is a key instigator of this 
tumour angiogenesis. Hypoxic cancer cells secrete VEGFA, which stimulates 
tumour angiogenesis by activating VEGFR2, expressed on neighbouring 
endothelial cells. Gradients of soluble VEGFA induce the formation of motile 
endothelium, called tip cells, which break down the surrounding extracellular 
matrix (ECM) and lead the growth of new vascular sprouts towards VEGFA 
[387].  
FAK is an important regulator of endothelial cell (EC) function, especially during 
angiogenesis [305]. Indeed, VEGF stimulation increases endothelial FAK kinase 
activity, FAK Tyr 397 is phosphorylated in tumour endothelium (which will in turn 
potentiates EC migration and cell-cycle inhibition) and finally, FAK inhibits p53 
mediated apoptosis and controls EC survival [388] [389] [390] [391] [392]. 
Furthermore, FAK is thought to be essential during Angiopoietin-1 mediated 
porcine pulmonary EC migration and also differentially regulates EC 
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proliferation/cell-cycle transition in culture dependent upon their particular growth 
strategy [393] [394].  
EC migration and proliferation are essential aspects of angiogenesis so 
extrapolating this evidence certainly implicates FAK as a vital mediator of 
angiogenesis. To this end, mouse models have been employed to further address 
this hypothesis. In general, global FAK ablation results in embryonic death at E8.5 
due to multiple defects, including those in the cardiovascular system [395]. 
Deleting specific domains of FAK yields similar results, as knock-in mutations 
which impede FAK catalytic domain activity lead to embryonic death at E9.5, 
associated with haemorrhage and disruption of the blood vascular network [396]. 
More specifically, targeted deletion of Tyr 397 within the FAK kinase domain 
causes mice to develop an abnormal vasculature by E12.5, which is later than in 
kinase dead global knockouts, indicating that the role of FAK in early development 
is independent of its autophosphorylation [397]. On further investigation it was 
noted that the vascular defects exhibited in FAK-null mice were due to defects in 
endothelial migration, and not the impairment of EC differentiation [398]. The 
relatively early embryonic death of global FAK knockouts limits their use in 
analysing FAK’s role in angiogenesis, so tissue specific, conditional models have 
been employed to circumvent this.  
In endothelial cells FAK has been both over and under expressed. FAK 
overexpression was achieved in mouse models using a Tie2 promoter and 
enhancer to overexpress wild-type chicken FAK. As might be expected, FAK 
overexpression did not induce any defects in vascular development in those mice, 
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but instead increased wound healing angiogenesis and microvessel density in 
hindlimb ischemia models [399]. In contrast, the constitutive deletion of FAK in 
mouse ECs results in embryonic lethality by E11.5, associated with severe 
vascular defects [400] [401]. Of the two groups that measured this, they each 
reached differing conclusions regarding why FAK ablation lead to vascular 
dysfunction. Shen at al. [400] showed that deleting FAK will reduce EC migration 
and proliferation in response to VEGF or fibronectin, whilst Braren et al. [401] 
reveal that ECs exhibit spreading and lamellipodia defects. Surprisingly, the 
deletion of FAK in adult endothelial cells has no effect on angiogenesis. It has been 
shown that this is due to compensation by PYK2 [402]. PYK2 will not however 
compensate for global or developmental EC FAK deletion, as described above. It 
remains unclear why this is the case but may indicate that PYK2 is dispensable 
during embryonic development but is required post-development.  As such, it may 
be necessary to inhibit both FAK and PYK2 in the adult to achieve maximal 
efficacy. Indeed, Weis et al. show in the same study that the FAK inhibitor PF-
573,228 will not decrease sprout length in aortic ring assays alone, but the 
synergistic inhibition of FAK and PYK2 will decrease sprout length [402].  
 
Studies also demonstrate that there are elevated levels of FAK (and 
phosphorylated FAK) in ECs isolated from astrocytomas, which specifically 
demonstrates the potential importance of EC-FAK in cancer progression and/or 
growth [390]. In contrast to the previous report by Weis et al. it is thought that this 
may be due to the involvement of adult EC-FAK in angiogenesis. Tavora et al. 
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show that the deletion of FAK in the endothelium will inhibit tumour growth and 
reduce tumour angiogenesis. Furthermore, FAK deletion will significantly impair 
both FGF and VEGF-induced neovascularization in aortic ring assays [305]. 
Similarly, Lee et al. demonstrate that EC-FAK deletion will reduce the volume of 
gliomas and reduce the diameter of the associated vasculature. Interestingly, there 
were actually more tumour-related blood vessels in these gliomas, and the vessels 
were less permeable and more ‘normalized’ (i.e. less tortuous and branched) than 
controls [403]. In both studies there was no compensation by PYK2 which may 
reflect the fact that the studies used different promoter sets, which may target 
different subpopulations of the endothelium.  
In addition, global FAK heterozygote mice actually display enhanced tumour 
angiogenesis [404]. Interestingly, low doses of FAK inhibitor will phenocopy this as 
it will also enhance angiogenesis ex vivo and tumour growth in vivo [404]. This 
same study showed that FAK-heterozygous endothelial cells demonstrate 
increased proliferation and microvessel sprouting, but not migration. PYK2 levels 
did not change across assays, however ECs did display increased Akt expression 
[404]. Sustained Akt expression in ECs results in enhanced blood vessel size and 
permeability [405], so increased Akt in ECs may be the causative molecule behind 
these results. Collectively these data indicate the importance of FAK in both 
developmental and tumour angiogenesis, and also indicates that PYK2 will not 
always compensate for the loss of FAK. Furthermore, the latter studies show that 
FAK may be a non-linear, dose-dependent regulator of angiogenesis.  
More recent studies have sought to establish the relative contribution of kinase-
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dependent and kinase-independent FAK function. The most recent study by Sun 
et al. used a kinase dead FAK mutant to explore the role of FAK kinase activity in 
the endothelium of adult mice during angiogenesis.  They show here that the 
inactivation of the FAK kinase domain results in suppressed angiogenesis during 
wound healing and in the retina. Consistent with this, they also show that loss of 
FAK kinase activity decreased endothelial cell proliferation and migration, which 
suggests that kinase-dependent function is vital for this. Central to this was the fact 
that FAK kinase activity, and its movement to the nucleus, is an essential regulator 
of VEGFR2, which is crucially involved in angiogenesis, as described later [406]. 
In addition, colleagues show similar findings indicating that the loss of FAK kinase 
in the endothelium will reduce tumour size, associated with reduced tumour blood 
vessel density, increased tumour hypoxia, and also reduced vascular leakage [7]. 
Together this indicates the probable predominant role of FAK kinase activity over 
its non-kinase (e.g. scaffolding function) in tumour angiogenesis and also adult 
pathogenesis. During developmental angiogenesis the relative contribution of FAK 
kinase-independent and dependent function may differ. Zhao et al. show that the 
majority of endothelial FAK-null mice will die during development by E13.5, 
whereas knock-in models displaying defective FAK kinase activity were relatively 
normal here. Those mice lacking FAK kinase activity display reduced EC apoptosis 
versus total FAK null mice but exhibit similar levels of dysregulated angiogenesis 
and vessel dilation. Furthermore, both groups exhibit similar vascular permeability, 
VE-cadherin expression abnormalities and reduced VE-cadherin Tyr 658 
phosphorylation [407]. In contrast to adult data this shows that FAK kinase activity 
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is dispensable during early vascular development (prior to E13.5), but kinase-
independent activity alone is insufficient to maintain EC function to allow for 
completion of embryogenesis. More specifically, they show that FAK non-kinase 
activity alone can modulate EC survival but not other aspects of EC behaviour 
during development  [407].  
 
6.1.4 Endothelial cell FAK - Chemosensitivity and angiocrine signalling 
Chemotherapy is often used as a main stead of therapy in the overall treatment of 
most cancers. However, despite encouraging initial responses to DNA-damaging 
chemotherapies, many tumours become resistant to treatment (chemoresistance), 
which presents a major hurdle in cancer therapy.  Therefore, there is an urgent 
need to identify a strategy that can overcome chemoresistance and sensitize 
tumour cells to chemotherapeutic agents. Previous work has concentrated on 
understanding resistance by focusing on mechanisms within tumour cells. More 
recently, colleagues have identified endothelial cells as an important regulator of 
chemoresistance [306]. 
 
Endothelial cells are now known to secrete organ-specific sets of molecules, 
known as angiocrine factors, which will actively modify whole organ patterning, 
regeneration and repair by e.g. progenitor cells [2]. There are increasing lines of 
evidence that show factors within the endothelium can determine their angiocrine 
signalling profile and thus differentially regulate both the efficacy of existing 
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chemotherapy treatments, and also the basal invasiveness and malignancy of 
tumours. For example, endothelial-derived IL6 will help to generate a ‘chemo-
resistant niche’ in lymphoma mouse models that moderately protects a subset of 
tumour cells from senescence after DNA damage [408]. In addition, tumour ECs 
will upregulate Jag1 in response to FGFR1 activation by B cell lymphoma cells, 
which induces a crosstalk between cells which manifests as a more aggressive 
lymphoma cell phenotype. Consequently, deleting FGFR1 or Jag1 in ECs 
diminishes the aggressiveness of lymphomas and prolongs mouse survival [409]. 
In line with this, EC-FAK may also play a pivotal role in establishing 
chemoresistance. Tavora et al. first show that the genetic ablation of EC-FAK will 
not reduce tumour angiogenesis or tumour growth if FAK is conditionally deleted 
after tumour growth has already begun. Next, they treated EC-FAK null mice with 
various DNA damaging therapies and showed that this is sufficient to sensitize 
malignant cells to these therapies, which resulted in significant tumour growth 
control without affecting tumour angiogenesis. The survival of EC-FAK knockout 
mice was significantly extended in doxorubicin-treated melanoma and lymphoma 
models, and their perivascular niches show increased apoptosis and reduced 
tumour cell proliferation. Mechanistically, FAK deficiency inhibited the NF-kB-
dependent production of tumour protective endothelial cell-derived cytokines [306]. 
It is unclear whether or not EC-FAK can regulate other molecules previously 
implicated in tumour-related angiocrine signalling or whether we can 
therapeutically harness angiocrine signalling to modify chemoresistance itself. We 
do however know that EC Akt deletion will lead to the gradual loss of Jag1/Notch 
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signalling within vascular smooth muscle cells [410], and FAK heterozygote mice 
exhibit increased EC FAK [404], so it is a logical step to assume that EC FAK can 
a) regulate EC Akt levels, and b) Akt in turn can modify Notch signalling within the 
EC compartment, and thus could modify the angiocrine output of the endothelium.  
 
6.2 Aims of the study 
 
My own study builds upon the findings of Tavora et al. [306] and investigates 
whether the kinase domain of EC-FAK is required for EC-FAK mediated 
chemosensitisation. It is my hypothesis that the FAK kinase domain is an important 
mediator of this process, and that it is likely that the mechanism underlying this is 
the same as previously described [306].  To achieve this, we have the following 
aims: 
 
1) Follow on from the work of previous lab members to assess tumour growth 
rate in a melanoma model of cancer in EC-FAK Kinase Dead (EC FAKKD) 
mice. 
2) Should there prove to be chemosensitisation in EC FAKKD mice, what is the 
mechanism underlying tumour cell sensitisation to DNA damaging therapy?  
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CHAPTER 7.0: RESULTS 
  
FOCAL ADHESION KINASE AND ANGIOCRINE SIGNALLING IN CANCER 
 
7.1 The kinase domain of endothelial cell FAK is a pivotal mediator of FAK-
dependent tumour cell sensitisation 
Chemotherapy is often used as a main stead of therapy in the overall treatment of 
most cancers. However, despite encouraging initial responses to DNA-damaging 
chemotherapies, many tumours become resistant to treatment (chemoresistance), 
which presents a major hurdle in successful cancer therapy.  Therefore, there is 
an urgent need to identify a strategy that can overcome chemoresistance and 
sensitise tumour cells to chemotherapeutic agents. Previous work has 
concentrated on understanding resistance by focusing on mechanisms within 
tumour cells. More recently, colleagues have identified endothelial cells as an 
important regulator of chemoresistance [306]. Tavora et al. show that targeting 
endothelial-cell FAK in established tumours is sufficient to sensitise tumour cells 
to DNA-damaging therapies. They go on to show that deletion of FAK in endothelial 
cells has no apparent effect on blood vessel function per se but induces increased 
apoptosis and decreased proliferation within perivascular tumour-cell 
compartments of doxorubicin- and radiotherapy-treated mice. In addition, they 
demonstrate that the mechanism underlying this phenomenon is that DNA-
damage will induce NF-kB activation, which leads to the production of 
cytoprotective cytokines from the endothelium. Loss of endothelial-cell FAK will 
reduce DNA-damage-induced cytokine production, and so enhance 
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chemosensitisation of tumour cells to DNA-damaging therapies in vitro and in vivo 
[306]. 
FAK is a cytoplasmic, non-receptor tyrosine kinase that plays a vital role in integrin 
and growth factor mediated signalling, extending to functions in a variety of cellular 
processes including: motility, focal adhesion turnover, survival, growth and 
invasion [344]. FAK is ubiquitously expressed across most cell types and is 
overexpressed within many types of solid and non-sold tumours [345] [346]. More 
recently, FAK activity in the endothelium has been shown to govern tumour 
angiogenesis [404] [305] and chemosensitisation [306]. Historically, FAK function 
has more generally been attributed to its central kinase domain kinase activity, but 
this has more recently been challenged by its interrelated scaffold function.   
 
Herein, we follow on work from previous lab members to investigate tumour growth 
in mice whose FAK kinase function has been abrogated specifically in the 
endothelium. These mice are engineered using a knockout/knockin cre-
recombinase system to simultaneously knockout mouse FAK and knockin chicken 
FAK (with a disabled kinase domain) specifically in the endothelium. The kinase 
domain is disabled in constructs by mutating the ATP binding site in lysine (AAA) 
position 454 to arginine (AGA) (K454R) {Tavora, 2014 #430}.  
 
Pdgfb-iCreER;R26FAKKD/KD;FAKfl/fl (Cre+) mice were injected subcutaneously with 
mouse melanoma (B16F0) cell line. 11 days after tumour-cell inoculation 
endothelial-cell FAK was deleted and the kinase dead mutation (K454R) was 
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introduced with three consecutive IP tamoxifen injections, to generate EC-FAKKD 
mice. Mice were then treated with doxorubicin on days 13, 15 and 17 post tumour-
cell inoculation. Similarly treated Pdgfb-iCreER;R26FAKKD/KD;FAKfl/fl (Cre-) were 
used as controls (EC-FAKWT). The loss of kinase activity in endothelial FAK did not 
affect B16 tumour growth in placebo-treated mice (figure 36a). Similarly, the 
abrogation of kinase activity in endothelial FAK did not affect B16F0 tumour growth 
in doxorubicin-treated mice (figure 36b). In comparison to tumour growth assays 
that had been conducted previously in the lab, we saw that B16F0 tumours grew 
faster than they had in other studies, and so potentially there was not enough time 
after the last dose of doxorubicin for there to be a differential response to 
chemotherapy. The data from Tavora et al. show that it took 3-4 days for the 
tumours from EC-FAKKO mice to be differentially sensitised to doxorubicin, and we 
were forced to cull mice 1-2 days after doxorubicin was administered in my own 
study. The experiment here took place in C57BL6/129SVJ mice of a ‘mixed’ 
background. Prior lab members had observed that B16F0 tumours may grow at 
different rates amongst mice of different backgrounds, and so we investigated 
B16F0 tumour growth in mice of a C57BL6 ‘pure’ background as compared to mice 
of a C57BL6/129SVJ ‘mixed’ background.   
Pdgfb-iCreER;R26FAKKD/KD;FAKfl/fl (‘pure’) and Pdgfb-iCreER;R26FAKKD/KD;FAKfl/fl 
(C57BL6/129SVJ) background mice were injected subcutaneously with 1 million 
B16F0 cells. The time taken for the average tumour to reach the legal limit of 
1500mm3 was investigated.  It took 18 days for those tumours in mice of a mixed 
background to reach 1500mm3, whereas it took 23 days in mice of a ‘pure’ 
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background (figure 37). On average, tumours in ‘mixed’ background mice took 12 
days to reach a volume of 100mm3 and 13 days in tumours on a ‘pure’ background. 
Ideally, 100mm3 is the size when we aim to begin tamoxifen treatment. Activating 
cre recombinase with tamoxifen in tumours smaller than this volume will potentially 
affect their size by differentially regulating tumour angiogenesis [305]. Thus, 
investigating tumours on a ‘pure’ background could extend the time over which we 
can observe tumour growth. Of course, this is a preliminary experiment and tumour 
growth rates in general can vary dramatically between mice, even those of the 
same background. This did however give us some rudimentary early evidence to 
indicate that we might have more success in this particular experiment by 
observing mice on a ‘pure’ background.  
 
Having established that B16 tumours may grow more slowly on a ‘pure’ 
background, we performed the same study as in figure 36, but on Pdgfb-
iCreER;R26FAKKD/KD;FAKfl/fl from a ‘pure’ C57BL6 background. To this end, Pdgfb-
iCreER;R26FAKKD/KD;FAKfl/fl (Cre+) mice were injected subcutaneously with 1 
million B16F0 mouse melanoma cells. At 11 days after tumour-cell inoculation, the 
kinase domain of endothelial-cell FAK was deleted with three consecutive 
intraperitoneal tamoxifen injections, to generate EC-FAKKD mice. Mice were then 
treated with doxorubicin on days 13, 15 and 17 post tumour-cell inoculation. 
Similarly treated Pdgfb-iCreER;R26FAKKD/KD;FAKfl/fl (Cre-) mice were used as 
controls (EC-FAKWT). Herein, the loss of kinase activity in endothelial FAK did not 
affect B16F0 tumour growth in placebo-treated mice (figure 38a). However, the 
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loss of kinase activity in endothelial FAK may affect B16 tumour growth in 
doxorubicin-treated mice (figure 38b). The difference in tumour volume between 
doxorubicin treated EC-FAKWT and EC-FAKKD mice was not significant but did tend 
toward significance.  
Previous reports suggest that chemotherapy may generate chemoresistant niches 
in the perivascular space that will protect tumour cells from apoptosis [306] [408] 
[411]. In addition, EC FAK has also been shown to regulate tumour angiogenesis 
accompanied by changes in tumour growth [305]. 48 hours after doxorubicin 
treatment cessation, the number of endomucin positive blood vessels did not 
increase in either untreated or treated mice (figure 39a-b). This indicates that any 
potential changes in tumour volume between EC FAKWT and EC FAKKD 
doxorubicin treated mice were independent to changes in tumour angiogenesis. 
The number of blood vessels within apoptotic perivascular tumour-cell niches, 
detected by cleaved caspase 3 staining, was enhanced significantly in doxorubicin-
treated ECFAKKD mice when compared with similarly treated ECFAKWT or 
placebo-treated control mice (figure 39c). This suggests that, upon doxorubicin 
treatment, endothelial cells will secrete factors that will protect tumour cells from 
apoptosis. The kinase domain of FAK is a pivotal element upstream of these 
factors, as when it is abrogated in the endothelium, the peri-vascular tumour cell 
niche in doxorubicin treated EC FAKKD mice is itself is significantly more apoptotic.  
 
Together these experiments constitute preliminary evidence that demonstrate the 
kinase domain of EC FAK is required during tumour-cell sensitisation to 
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doxorubicin therapy. Certainly more in vivo work needs to be done to ascertain this 
however.  
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Figure 36: Deleting the kinase domain of endothelial cell FAK (EC FAKKD) will not sensitise 
cancer cells to doxorubicin in vivo in mice from a ‘mixed’ C57BL6/129SVJ background. 
Pdgfb-iCreER;R26FAKKD/KD;FAKfl/fl (n=12) and control mice (n=12) were injected subcutaneously 
with B16 tumour cells (day 0), given tamoxifen (Tam.; from day 11 for 3 consecutive days) to 
generate EC FAKKD and EC FAKWT mice, respectively, and subsequently treated with either 
doxorubicin or PBS (Dox/PBS; day 13,15 and 17).  (a) B16 tumour volume in PBS treated and (b) 
doxorubicin treated EC FAKKD and EC FAKWT mice (C57BL6/129SVJ). Data are shown as mean ± 
SEM.  
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Figure 37: The background of C57BL6 mice can determine B16 tumour growth rate. 1 million 
B16 tumour cells were injected subcutaneously into mice from either a pure C57BL6 or 
C57BL6/129SVJ background (n=10 mice per group). The time taken to reach a tumour volume of 
1500mm3 was investigated. Data are shown as mean ± SEM.  
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Figure 38: Deleting the kinase domain of endothelial cell FAK (EC FAKKD) will potentially 
sensitise cancer cells to doxorubicin in vivo. Pdgfb-iCreER;R26FAKKD/KD;FAKfl/fl (n=12) and 
control mice (n=12) were injected subcutaneously with B16 tumour cells (day 0), given tamoxifen 
(Tam; from day 11 for 3 consecutive days) to generate EC FAKKD and EC FAKWT mice, respectively, 
and subsequently treated with either doxorubicin or PBS (Dox/PBS; day 13,15 and 17).  (a) B16 
tumour volume in PBS treated and (b) doxorubicin treated EC FAKKD and EC FAKWT mice (C57BL6 
pure background) (p=0.1138). Data are shown as mean ± SEM. Statistical analysis by 1-way 
ANOVA with Tukey’s multiple comparison test post hoc; NS is not significant.  
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Figure 39: Loss of the kinase domain of endothelial-cell FAK (EC FAKKD) sensitizes tumour 
cells to doxorubicin but will not affect tumour blood vessel density. Tumour sections from 
mice treated with either doxorubicin or PBS were stained for the endothelial cell marker (a-b) 
endomucin or the apoptotic marker (b) cleaved caspase 3 (CC3). Data are shown as mean ± SEM. 
Statistical analysis by 1-way ANOVA with Tukey’s multiple comparison test post hoc; NS is not 
significant, *P<0.05. Work done in tandem with Dr. Delphine Lees.  
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7.2 Abrogating the kinase domain of endothelial cell FAK can modify the 
angiocrine output of endothelial cells after doxorubicin therapy 
 
Endothelial cells are now known to secrete organ-specific sets of molecules, 
known as angiocrine factors, which will actively modify whole organ patterning, 
regeneration and repair by e.g. progenitor cells [2]. There are increasing lines of 
evidence that show factors within the endothelium can determine their angiocrine 
signalling profile and thus differentially regulate both the efficacy of existing 
chemotherapy treatments, and also the basal invasiveness and malignancy of 
tumours. To confirm that the production of cytoprotective factors from the 
endothelium is dependent on the kinase domain of FAK after doxorubicin therapy, 
we performed conditioned media assays and cytokine arrays.  
 
To first validate the cell lines that we will use in subsequent assays, we performed 
RT-qPCR and western blot analysis to confirm the knockout of mouse FAK and 
the re-expression of chicken FAK in those EC FAKKD cells. Control cells (EC 
FAKWT) do not express Cre, and so will express normal mouse FAK and no chicken 
FAK (figure 40).  
 
To determine whether endothelial cells will continue to secrete protective paracrine 
factors after the kinase domain of FAK is abrogated, we performed MTT assays to 
investigate B16F0 survival in conditioned media. Here, conditioned media from 
untreated EC FAKKD or wild type control endothelial cells did not affect B16F0 
tumour cell survival (figure 41a-b). Similarly, conditioned media from doxorubicin 
 233 
treated EC FAKKD or wild type control endothelial cells will not protect B16F0 
tumour cells from doxorubicin therapy (figure 41c-d). Since doxorubicin therapy 
alone will significantly decrease the survival of tumour cells, we chose to 
investigate whether using a suboptimal dose of doxorubicin would achieve a 
differential experimental outcome. To this end, we investigated the effects of 
varying doses of doxorubicin on B16 tumour cell survival (figure 42). We used 
125nM doxorubicin in the previous MTT assay, which based on this evidence, will 
almost entirely kill my tumour cell population. It may therefore be more appropriate 
to use a suboptimal dose like 40-50nM in future experiments.  
 
We next examined whether abrogating kinase activity in EC FAK will affect 
doxorubicin-induced cytokine production. Cytokine protein array analysis revealed 
that doxorubicin stimulation induced an increase in production of several cytokines 
in wild-type endothelial cells (EC FAKWT) as compared with untreated controls 
(figure 43). In contrast, doxorubicin did not induce an increase in cytokine 
production with EC FAKKD endothelial cells (figure 43). This data shows that 
abrogating the kinase domain of EC FAK will reduce cytokine secretion by the 
endothelium after doxorubicin induction.  
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Figure 40: Confirmation of kinase deletion in endothelial-cell FAK. RT-qPCR demonstrating 
effective knockout of mouse FAK and re-expression of kinase dead chicken FAK in EC FAKKD 
immortalised endothelial cells.  
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Figure 41: Conditioned media from endothelial cells will not protect B16F0 tumour cells from 
doxorubicin. (a-d) Conditioned media from untreated (−) and doxorubicin-treated (+) endothelial 
cells were applied to B16 cell cultures 3 (a-b) or 4 (c-d) days after seeding, and tumour-cell survival 
was measured (A550nm). n = 2 technical repeats. Data are shown as mean ± SEM. Statistical 
analysis by 1-way ANOVA with Tukey’s multiple comparison test post hoc; NS is not significant. 
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Figure 42: A suboptimal dose of doxorubicin may allow us to more accurately examine 
tumour-cell survival in MTT assays. (a-b) Conditioned media from range of doxorubicin-treated 
endothelial cells were applied to B16 cell cultures 3 (a) or 4 (b) days after seeding, and tumour-cell 
survival was measured (A550nm). 
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Figure 43: Loss of the kinase domain of endothelial-cell FAK inhibits doxorubicin-induced 
production of endothelial cytokines. Quantitation of fold difference in cytokine expression 
between doxorubicin-treated and non-treated wild-type (WT) and kinase dead (KD) FAK 
endothelial cells. n = 1 experimental array. Work done in tandem with Dr. Delphine Lees. 
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7.3 Summary of chapter results 
We have previously shown that specific deletion of focal adhesion kinase (FAK) in 
endothelial cells is sufficient to induce tumour-cell sensitization to DNA-damaging 
therapies and thus significantly inhibit tumour growth in mouse models. Here we 
present novel in vitro and in vivo evidence that indicates FAK kinase activity may 
be crucial for tumour cell sensitization to the DNA-damaging therapy Doxorubicin. 
Mechanistically, we demonstrate that the kinase domain of endothelial FAK is 
required for doxorubicin induced cytokine production – a so called ‘angiocrine 
response’ – leading to enhanced chemosensitisation. We anticipate that this data 
will be useful in determining new chemotherapy strategies, particularly with the 
clinical availability of FAK kinase domain inhibitors for this purpose.   
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CHAPTER 8.0: DISCUSSION 
 
 FOCAL ADHESION KINASE AND ANGIOCRINE SIGNALLING IN CANCER 
 
The primary objective of this chapter was to determine whether the kinase domain 
of FAK is an essential feature of endothelial-cell mediated tumour-cell 
chemosensitisation to DNA-damaging doxorubicin therapy. Indeed, we show 
preliminary data that indicates that abrogating the kinase domain of FAK (EC 
FAKKD) in the endothelium will sensitise B16F0 tumour-cells to doxorubicin 
therapy, versus controls (EC FAKWT). These effects may be mouse background 
specific, as deleting kinase activity in mice of a C57BL6/129SVJ background will 
not generate differences in tumour responsiveness. In parallel, we show that 
tumour angiogenesis within EC FAKKD mice is not different from controls, and 
instead the perivascular apoptosis of tumour cells within doxorubicin-treated EC 
FAKKD tumours is significantly upregulated. The mechanism underlying these 
effects may potentially be that endothelial cells which lack the kinase domain of 
FAK will secrete significantly fewer cytokines after doxorubicin treatment, as 
compared to controls. MTT assays could provide functional evidence that the 
angiocrine factors of endothelial cells could either protect or sensitise B16F0 
tumour cells to doxorubicin therapy, but those that we attempted here were 
unsuccessful, possibly because the dose of doxorubicin used was too high. We 
propose that with a suboptimal dose of doxorubicin we may see a different 
experimental outcome.  
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8.1 The effect of genetic background on tumour-growth rate assays 
 
Genetically engineered mouse models of tumourigenesis have significantly 
improved our understanding of the molecular mechanisms which propagate 
cancer. However, this comes with a caveat. The models themselves may display 
strain-specific phenotypic variation for a given cancer, which will arise due to the 
influence of their genetic background [412] [413]. This phenomenon has been 
observed in a variety of strains, across multiple tumour-types. For example, the 
tumour susceptibility of p53-null and Atm-null mice was increased in mice on a 
129SVJ background as compared to mice that were backcrossed onto a C57BL6 
background [414] [415]. Consistent with these observations, B16F0 tumours grew 
at different rates on mice on a C57BL6/129SVJ background as compared to a 
‘pure’ C57BL6 background. In addition, the chemosensitivity of tumours within 
these mice also differed for a given targeted mutagenesis strategy. In all 
experiments, mice were kept in the same conditions, treated with the same drugs 
and to the same diet, and were injected in the same position with the same number 
of tumour cells, so we can assume that differences in environmental factors did 
not influence these phenotypic characteristics.  
Phenotypic changes in mice of different strains and genetic backgrounds arise due 
to the differential activity and expression of modifier genes [416]. Modifier genes 
are genes that have small qualitative effects on the level of expression of another 
gene [416]. This may manifest for instance, in the coat colour of mice, where 
instead of a particular gene masking the effects of another gene, it will instead 
modify its phenotypic expression. It is thought that the background that will present 
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with the widest variety of phenotypic differences is a ‘mixed’ ground [413].  In 
theory then, using mice of a ‘pure’ background could limit the inherent variation 
between models for a given assay that exists for a particular set of experimental 
mice. ‘Mixed’ mice may give a result that is less consistent, and more variable, 
than ‘pure’ mice therefore. On the basis of this it could be important to conduct all 
future experiments on mice of a pure background to reduce phenotypic variability 
amongst different experimental sets. Of course, this itself presents problems in that 
mice of a ‘pure’ background are probably less representative of wider human 
populations, which themselves are an amalgamation of many different genetic 
heritages. 
Aside from this we have also found that the B16F0 tumour cells that we have used 
will themselves grow at very different rates, both in vitro and in vivo. This has meant 
that some experiments have had to be finished much earlier than others since 
tumour volumes have reached their legal limit before we could properly begin 
therapy. To minimise these events, we propose that B16F0 tumours should be 
used from a particular known ‘stock’ vial. The act of culturing cells multiple times, 
re-freezing those cells, and then recycling this same process can introduce intra-
sample genetic drift and selection pressures, which could manifest as differences 
in e.g. proliferation, amongst other cellular behaviours [417], which may contribute 
to different tumour growth rates in vivo.  
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8.2 Targeting the kinase domain of FAK is a valuable anti-cancer strategy 
 
 
Targeting FAK is a promising cancer therapy because it is highly expressed 
amongst cancer cells and is associated with promoting oncogenic signals and 
inactivating tumour suppressive signals [418]. The vast majority of FAK-based 
therapeutics focus on inhibiting the kinase’s catalytic function and not the large 
scaffold it creates that includes may oncogenic and tumour-suppressant proteins 
[418]. Amongst these, is PF-562,271, which demonstrates robust antitumor activity 
in vivo in tumour models [419]. Preliminary clinical trial data shows that FAK 
inhibitors may be best used as combination therapy [420]. The reason for this may 
be to the fact that FAK-inhibition will enhance or synergize with either 
immunotherapy or chemotherapy [421] [422] [423]. FAK is a known regulator of 
chemokine transcription [345], and so it is perhaps unsurprising that in both dual-
therapy strategies, beneficial effects are thought to be, at least in part, chemokine-
dependent [423] [306]. In immunotherapy for instance, small molecular inhibitors 
of FAK alter tumour-cell production of pro-inflammatory and immunosuppressive 
cytokines, which improves the responsiveness of pancreatic cancers to checkpoint 
immunotherapy [423]. Similarly, we show that deleting the kinase domain of FAK 
in the endothelium will reduce their secreting of a number of chemokines after 
induced by doxorubicin.  
 
8.3 Future work 
 
In the short term we would certainly repeat the tumour model experiments we have 
previously completed under different conditions. Primarily, we would ensure that 
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the mice modelled were specifically injected with Tamoxifen only once their 
tumours had reached a volume of 100mm3. We have previously seen that 
abrogating the kinase domain of FAK in the endothelium will reduce B16F0 tumour 
volume without any doxorubicin therapy (appendix 1.0 figure 44). This could be 
due to the fact that there is reduced tumour angiogenesis in those EC-FAKKD mice. 
Similarly, EC-FAK null mice, where tamoxifen was given in tandem to B16F0 
tumour inoculation, resulted in reduced tumour angiogenesis, which led to reduced 
tumour volume itself [305].  
In addition, we would perform further mechanistic assays to determine the effects 
of kinase abrogation with kinase inhibitors on cytokine secretion. In parallel, we 
would perform further MTT-conditioned media (as in figure 41) assays with a 
suboptimal doxorubicin dose, to investigate whether we would see different 
experimental outcomes.  
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CHAPTER 9.0: FINAL STATEMENT 
 
 
The specific objectives of my PhD were to (a) determine the utility of low dose 
Cilengitide in a pressure-overload induced murine model of heart failure and (b) 
investigate whether the kinase domain of FAK is an essential feature of 
endothelial-cell mediated tumour-cell chemosensitisation to DNA-damaging 
doxorubicin therapy. In summary of the work presented in this thesis, I consider 
that I have completed the objectives of the former and have laid some of the 
foundation work that will help complete the latter. In addition, I have established a 
useful connection between two previously unrelated labs that have already began 
to benefit the two.  
The information gathered during my PhD could be useful to direct further therapy 
in the observed fields. Low dose Cilengitide is a novel dual effector of RGD-
integrins in both the cardiac endothelial cells and the cardiomyocytes, whilst 
targeting the kinase domain of FAK in the endothelium with available therapeutics 
may improve the efficacy of existing chemotherapies.    
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APPENDIX 1.0: SUPPLEMENTARY DATA 
 
 
Figure 44: B16F0 tumour survival in EC FAKKD doxorubicin treated and untreated mice as 
compared to EC FAKWT controls. Pdgfb-iCreER;R26FAKKD/KD;FAKfl/fl (n=12) and control mice 
(n=12) were injected subcutaneously with B16 tumour cells (day 0), given tamoxifen (Tam; from 
day 11 for 3 consecutive days) to generate EC FAKKD and EC FAKWT mice, respectively, and 
subsequently treated with either doxorubicin or PBS (Dox/PBS; day 13,15 and 17).  Repeat 
experiment – no effect of doxorubicin between genotypes in a ‘pure’ C57BL6 background. 
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